Combination Cancer Treatment

JP2023550900A5Inactive Publication Date: 2024-11-11ARES TRADING SA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526677
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-02
Filing Date
2021-11-01
Publication Date
2024-11-11
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments, particularly radiation therapy, face significant challenges due to resistance mechanisms involving DNA damage response pathways, immunosuppressive cytokines like TGFβ, and immune checkpoint pathways like PD-L1/PD-1, leading to treatment resistance and limited efficacy.

Method used

A combination therapy using PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors, optionally with radiation therapy, to target and overcome these resistance mechanisms by inhibiting PD-L1/PD-1, TGFβ, and DNA repair pathways in cancer cells.

Benefits of technology

Enhances cancer treatment efficacy by inhibiting tumor growth, progression, and metastasis, and inducing regression, offering improved outcomes compared to individual therapies with potential synergistic effects and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000073_0000
    Figure 00000073_0000
  • Figure 00000073_0001
    Figure 00000073_0001
  • Figure 00000074_0000
    Figure 00000074_0000
Patent Text Reader

Abstract

The present disclosure relates to combination therapies useful in the treatment of cancer. In particular, the present disclosure relates to the combination of a PD-1 inhibitor, a TGFbeta inhibitor, and a PARP inhibitor to treat cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to the treatment of cancer. In particular, this invention relates to a combination of compounds for inhibiting PD-1, TGFβ, and PARP for use in the treatment of cancer. [Background technology]

[0002] While radiotherapy is the standard treatment for many different types of cancer, treatment resistance remains a major concern. The mechanisms of resistance to radiotherapy are diverse and complex. These include alterations in the DNA damage response pathway (DDR), modulation of immune cell function, and increased levels of immunosuppressive cytokines such as transforming growth factor beta (TGFβ). Strategies to combat resistance include combining radiotherapy with therapies that target these mechanisms.

[0003] DDR inhibitors are a promising combination partner for radiotherapy. Radiotherapy kills cancer cells by damaging their DNA, but this also leads to activation of the DDR pathway as cells attempt to repair the damage. While the DDR pathway is unnecessary in normal cells, one or more pathways are often lost during malignant progression, resulting in cancer cells becoming more dependent on the remaining pathways and increasing the likelihood of genetic errors. This makes cancer cells uniquely vulnerable to treatment with DDR inhibitors.

[0004] Poly-ADP-ribose polymerase (PARP) inhibitors are a class of DDR inhibitors, and several PARP inhibitors, including olaparib, lucaparib, niraparib, and talazoparib, are already approved. The PARP enzyme finds single-strand DNA breaks (SSBs) and then recruits other DNA repair enzymes to the SSBs, which complete the DNA repair process. Inhibition of PARP leads to the accumulation of SSBs. These SSBs are converted to double-strand DNA breaks (DSBs) during replication when the replication fork remains on the SSB. Tumors also often lack the DSB repair pathway, so the accumulation of DSBs leads to the death of these cells.

[0005] Therapies targeting immunosuppressive pathways such as TGFβ and programmed death ligand 1 (PD-L1) / PD-1 are also being studied, either alone or in combination with radiotherapy. While the cytokine TGFβ plays a physiological role in maintaining immunological self-tolerance, in cancer it can promote tumor growth and immune evasion through its effects on innate and adaptive immunity. Immune checkpoints mediated by PD-L1 / PD-1 signaling are utilized by cancer to attenuate T cell activity and suppress the anti-tumor T cell response. Radiation induces the expression of both PD-L1 and TGFβ, which can contribute to radioresistance.

[0006] WO2015 / 118175 describes a bifunctional fusion protein consisting of the extracellular domain of tumor growth factor β receptor type II (TGFβRII) to function as a TGF-β "trap" fused to a human IgG1 antibody that blocks PD-L1. Specifically, this protein is a heterotetramer consisting of two heavy chains, each containing two immunoglobulin light chains of an anti-PD-L1 antibody and a heavy chain of an anti-PD-L1 antibody genetically fused via a flexible glycine-serine linker. It binds to the extracellular domain of human TGFβRII (see Figure 1). This fusion molecule is designed to target both the PD-L1 and TGFβ pathways to counter immunosuppression in the tumor microenvironment.

[0007] There remains a need to develop new treatment options for cancer. Furthermore, there is a need for treatments that are more effective than existing therapies. [Overview of the project]

[0008] This invention stems from the discovery that therapeutic effects in cancer treatment can be obtained by combining compounds that inhibit PD-1, TGFβ, and PARP, particularly when combined with radiotherapy.

[0009] Accordingly, in a first aspect, the Disclosure provides PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in a method of treating cancer in a subject, for use in inhibiting the growth or progression of tumors in a subject having malignant tumors, for use in inhibiting the metastasis of malignant cells in a subject, for use in reducing the risk of developing metastases and / or metastatic growth in a subject, or for use in inducing tumor regression in a subject having malignant cells, wherein the use comprises optionally administering the compound to the subject together with radiotherapy.

[0010] The disclosure also provides the use of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for the manufacture of a pharmacopoeia for the treatment of cancer in a subject, for inhibiting the growth or progression of a tumor in a subject having a malignant tumor, for inhibiting the metastasis of malignant cells in a subject, for reducing the risk of developing and / or growing metastases in a subject, or for inducing tumor regression in a subject having malignant cells, wherein the subject is optionally receiving radiotherapy in combination with the pharmacopoeia.

[0011] In another aspect, the Disclosure provides a method for treating cancer in a subject, a method for inhibiting the growth or progression of a tumor in a subject having a malignant tumor, a method for inhibiting the metastasis of malignant cells in a subject, a method for reducing the risk of developing metastases and / or the growth of metastases in a subject, or a method for inducing tumor regression in a subject having malignant cells, comprising optionally administering a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor to the subject together with radiotherapy.

[0012] In a further aspect, the present disclosure is a method for promoting the use of a combination for treating a subject having cancer, such as cancer based on the expression of PD-L1 in a sample, e.g., a tumor sample taken from the subject, with a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, optionally together with radiation therapy, which comprises prompting a reader who is targeted to the use of the combination for treating the subject.

[0013] Also provided herein is a pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and at least a pharmaceutically acceptable excipient or adjuvant. In one embodiment, the PD-1 inhibitor and the TGFβ inhibitor are fused in such a pharmaceutical composition. The PD-1 inhibitor, the TGFβ inhibitor, and the PARP inhibitor are provided in a single or separate unit dosage form.

[0014] In a further embodiment, the present disclosure relates to a kit comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and a package insert containing instructions for the optional use of the compounds in combination with radiotherapy to treat or slow the progression of cancer in a subject. In a further embodiment, the present invention relates to a kit comprising a PD-1 inhibitor and a package insert containing instructions for the optional use of the PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor in combination with radiotherapy to treat or slow the progression of cancer in a subject. In a further embodiment, the present invention relates to a kit comprising a TGFβ inhibitor and a package insert containing instructions for the optional use of the TGFβ inhibitor, a PD-1 inhibitor, and a PARP inhibitor in combination with radiotherapy to treat or slow the progression of cancer in a subject. In a further embodiment, the present invention relates to a kit comprising a PARP inhibitor and a package insert containing instructions for the optional use of the PARP inhibitor, a PD-1 inhibitor, and a TGFβ inhibitor in combination with radiotherapy to treat or slow the progression of cancer in a subject. In a further embodiment, the present invention relates to a kit comprising an anti-PD(L)1:TGFβRII fusion protein and a package insert containing instructions for the optional use of the anti-PD(L)1:TGFβRII fusion protein and a PARP inhibitor in combination with radiotherapy to treat or slow the progression of cancer in a subject. The compounds of the kit may be contained in one or more containers. The instructions may state that the pharmaceutical product is intended for use in the treatment of a subject having cancer that has been tested to be positive for PD-L1 expression by an immunohistochemical (IHC) assay.

[0015] In certain embodiments, a PD-1 inhibitor and a TGFβ inhibitor are fused. In one embodiment, the fusion molecule is an anti-PD(L)1:TGFβRII fusion protein. In one embodiment, the fusion molecule is an anti-PD-L1:TGFβRII fusion protein. In one embodiment, the amino acid sequence of the anti-PD-L1:TGFβRII fusion protein corresponds to the amino acid sequence of vintrafusp alfa. [Brief explanation of the drawing]

[0016] [Figure 1A] Figure 1 shows the amino acid sequence of vintrafusp alpha. (A) SEQ ID NO: 8 represents the heavy chain sequence of vintrafusp alpha. The CDRs having the amino acid sequences of SEQ ID NOs: 1, 2, and 3 are underlined. [Figure 1B] (B) SEQ ID NO: 7 represents the light chain sequence of vintrafusp alpha. The CDRs having the amino acid sequences of SEQ ID NOs: 4, 5, and 6 are underlined. [Figure 2] Figure 2 shows an exemplary structure of the anti-PD-L1:TGFβRII fusion protein. [Figure 3] Vintrafusp alpha + niraparib increased the antitumor effect in the MDA-MB-436 model compared to niraparib monotherapy. MDA-MB-436 cells (10 × 106 cells) were inoculated into the right flank of NOD / SCID mice (-19 days). On day 0 when the average tumor volume reached 100 mm3, the mice were treated with isotype control (400 μg i.v.; BiW × 4), vintrafusp alpha (492 μg i.v.; BiW × 4), niraparib (35 mg / kg p.o.; QD × 28), or vintrafusp alpha (492 μg i.v.; BiW × 4) + niraparib (35 mg / kg p.o.; QD × 28) (n = 8 mice / group). Tumor volume was measured twice a week and presented as mean ± SEM or individual tumor volumes. The p-value was calculated by two-way ANOVA using Tukey or Sidak's post hoc test. The disease progression day was defined as the first day after treatment discontinuation when the tumor volume of an individual mouse became at least 5-fold larger than the standard deviation of the mean tumor volume during treatment (day 0 to day 28). [Figure 4]Vintrafasp alfa plus niraparib increased the antitumor effect in the MDA-MB-231 model compared to niraparib monotherapy. NOD / SCID mice were subcutaneously inoculated with MDA-MB-231 cells (10 × 10⁶ cells) into the right flank (-19 days). On day 0, when the mean tumor volume reached 100 mm³, mice were treated with isotype control (400 μg iv; BiW × 4), vintrafasp alfa (492 μg iv; BiW × 4), niraparib (50 mg / kg po; QD × 28), or vintrafasp alfa (492 μg iv; BiW × 4) + niraparib (50 mg / kg po; QD × 28) (n=8 mice / group). Tumor volume was measured twice weekly and expressed as mean ± SEM or individual tumor volume. The p-value was calculated using a two-way ANOVA with Tukey's post-hoc test. [Figure 5] Vintrafasp alfa plus niraparib tended to increase the antitumor effect in the RENCA model compared to monotherapy. RENCA cells (0.5 × 10⁵ cells) were orthotopically inoculated into the left kidney of BALB / c mice (days 0-6). On day 0, mice were treated with isotype control (400 μg iv; days 0, 2, 5), vintrafasp alfa (492 μg iv; days 0, 2, 5), niraparib (50 mg / kg po; days 0-11, once daily), or vintrafasp alfa (492 μg iv; days 0, 2, 5) + niraparib (50 mg / kg po; days 0-11, once daily) (n=10 mice / group). Mice were euthanized on day 12, and the weight of both kidneys was measured. The mass ratio of the kidneys was calculated by dividing the weight of the left kidney containing the tumor by the weight of both right kidneys. The mass ratios of the individual kidneys were plotted using a line representing the median. [Figure 6]Vintrafasp alfa plus niraparib increased the antitumor effect in the B16F10 model compared to monotherapy. B16F10 cells (0.5 × 10⁶ cells) were subcutaneously inoculated into the flanks of C57BL / 6 mice. On day 0, 5 days after tumor cell transplantation, mice were treated with isotype control (400 μg iv; days 0, 3, 6), vintrafasp alfa (492 μg iv; days 0, 3, 6), niraparib (50 mg / kg po; QD × 14), or vintrafasp alfa (492 μg iv; days 0, 3, 6) + niraparib (50 mg / kg po; QD × 14) (n=10 mice / group). Tumor volume was measured twice weekly and expressed as mean ± SEM or individual tumor volume. p-values ​​were calculated by bidirectional ANOVA using Tukey or Sidak post-hoc tests. [Figure 7] Vintrafasp alfa plus niraparib increased the antitumor effect in the AT-3 model compared to vintrafasp alfa alone and isotype controls. AT3 cells (0.5 × 10⁶ cells) were orthotopically inoculated into the mammary fat pad of C57BL / 6 mice (days 0-11). On day 0, when the mean tumor volume reached approximately 50 mm³, mice were treated with either isotype controls (400 μg iv; days 0, 3, 6), vintrafasp alfa (492 μg iv; days 0, 3, 6), niraparib (50 mg / kg po; days 0-13, once daily), or vintrafasp alfa (492 μg iv; days 0, 3, 6) + niraparib (50 mg / kg po; days 0-13, once daily) (n=10 mice / group). Tumor volume was measured twice weekly. In the lower plot, the individual tumor volumes on day 13 are displayed, along with a line representing the median tumor volume and error bars indicating the 95% confidence interval. Tumors with a volume less than 1σ of the control group volume are shown as responders. p-values ​​were calculated using two-way ANOVA with Tukey's post-hoc test. [Figure 8]Vintrafasp alfa + RT + niraparib increased the antitumor effect in the 4T1 model compared to vintrafasp alfa + RT or isotype controls. 4T1 cells (0.5 × 10⁵ cells) were inoculated into the thigh muscle of BALB / c mice (-7 days). On day 0, when the mean tumor volume reached 75–125 mm³, mice were treated with isotype controls (400 μg iv; days 0, 2, 4), vintrafasp alfa (492 μg iv; days 0, 2, 4) + RT (8 Gy, days 0–3), or vintrafasp alfa (492 μg iv; days 0, 2, 4) + RT (8 Gy, days 0–3) + niraparib (50 mg / kg po; days 0–13, once daily) (n=10 mice / group). Tumor volume was measured twice weekly and expressed as mean ± SEM or individual tumor volume. The p-value was calculated using a two-way ANOVA with Tukey or Sidak post-hoc tests. [Modes for carrying out the invention]

[0017] Each of the embodiments described herein can be combined with any other embodiment described herein that is not inconsistent with the embodiment in which it is combined. Furthermore, unless inconsistent in a given context, where a compound that can be ionized (e.g., protonated or deprotonated) is specified, the definition of such compound includes any pharmaceutically acceptable salt thereof. Thus, the phrase "or a pharmaceutically acceptable salt thereof" is included in the description of all compounds described herein. Embodiments within the embodiments described below can be combined with any other embodiment that is not inconsistent within the same or different embodiments. For example, any embodiment of a therapeutic method of the present invention can be combined with any embodiment of a combined product or pharmaceutical composition of the present invention, and vice versa. Similarly, any detail or feature given to a therapeutic method of the present invention applies to the combined product and pharmaceutical composition of the present invention, and vice versa, where not inconsistent.

[0018] The present invention may be more readily understood by referring to the above and below detailed descriptions of certain preferred embodiments of the invention and the examples included herein. It should be understood that the terms used herein are intended solely to describe certain embodiments and are not intended to limit them. It should be further understood that, unless otherwise specifically defined herein, the terms used herein are given their traditional meanings known in the relevant art. Certain technical and scientific terms are specifically defined below to facilitate the understanding of the invention. Unless otherwise specifically defined elsewhere in this document, all other technical and scientific terms used herein have meanings generally understood by those skilled in the art to which the invention pertains.

[0019] definition "A," "an," and "the" include multiple references unless otherwise specified by the context. Therefore, for example, a reference to an antibody refers to one or more antibodies or at least one antibody. Thus, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein.

[0020] When used to describe modifying a numerically defined parameter, the term "approximately" refers to any minimal change to such a parameter that does not alter the overall effect, for example, the effectiveness of a drug in treating a disease or disorder. In some embodiments, the term "approximately" means that the parameter may vary by 10% above or below the numerical value stated for that parameter.

[0021] "Administering" a drug to a patient, or its "administration" (and its grammatical equivalent), means administering the drug to the patient by a medical professional, or by self-administration, and / or by direct administration, and / or indirect administration (which may be the act of prescribing the drug), for example, by instructing the patient to self-administer the drug or by a physician providing the patient with a prescription for the drug.

[0022] "Amino acid differences" refer to amino acid substitutions, deletions, or insertions.

[0023] An "antibody" is an immunoglobulin (Ig) molecule that can specifically bind to targets such as carbohydrates, polynucleotides, lipids, and polypeptides via at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term "antibody" includes not only intact polyclonal or monoclonal antibodies, but also, unless otherwise specified, any antigen-binding fragment or antibody fragment thereof that competes with an intact antibody for specific binding, as well as any protein containing such antigen-binding fragment or antibody fragment (including fusion proteins (e.g., antibody-drug conjugates, antibodies fused to cytokines, or antibodies fused to cytokine receptors), antibody compositions having polyepitope specificity, and multispecific antibodies (e.g., bispecific antibodies)). A basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. IgM antibodies consist of five basic heterotetrameric units along with an additional polypeptide called a J chain, containing 10 antigen-binding sites. IgA antibodies contain 2 to 5 basic tetrameric units that, in combination with the J chain, can polymerize to form multivalent aggregates. In the case of IgG, a tetrameric unit is generally about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, and two H chains are linked to each other by one or more disulfide bonds depending on the isotype of the H chains. Each H and L chain also has intrachain disulfide crosslinks with regular spacing. Each H chain has a variable domain (V) at its N-terminus. H ), followed by three constant domains (CH) for each of the a and y chains, and four CH domains for the μ and ε isotypes. Each L chain has a variable domain (V) at its N-terminus. L ) has a constant domain on the opposite side. L is V H It is aligned with C Lis aligned with the first constant domain (CH1) of the heavy chain. Certain amino acid residues are thought to form the interface between the light and heavy chain variable domains. V H and V L pairing together form a single antigen binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology, 8 th Edition, Sties et al. (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71, chapter 6. L chains from any vertebrate species can be assigned to one of two distinct types called kappa and lambda based on the amino acid sequence of the constant domain. Depending on the amino acid sequence of the constant domain of the heavy chain (C H ), immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each having a heavy chain called α, δ, ε, γ, and μ, respectively. The γ and α classes are further divided into subclasses based on relatively small differences in the C H sequence and function. For example, humans express the following subclasses: IgG1, IgG2A, IgG2B, IgG3, IgG4, IgGA1, and IgGK1.

[0024] Antibody "antigen-binding fragments" or "antibody fragments" contain intact portions of an antibody that can still bind to an antigen. Antigen-binding fragments include, for example, Fab, Fab', F(ab')2, Fd, and Fv fragments, domain antibodies (dAb, e.g., shark and camel antibodies), fragments containing CDRs, single-chain variable fragment antibodies (scFv), single-chain antibody molecules, multispecific antibodies formed from antibody fragments, maxibodies, nanobodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFv, linear antibodies (see, e.g., U.S. Patent No. 5,641,870, Example 2; Zapata et al. (1995) Protein Eng. 8HO:1057), and polypeptides containing at least a portion of immunoglobulin sufficient to confer specific antigen binding to the polypeptide. Papain digestion of antibodies produces two identical antigen-binding fragments called "Fab" fragments, and the remaining "Fc" fragment, a name reflecting its ability to readily crystallize. The Fab fragment is a variable region domain (V) of the H chain. H ) and the entire L chain together with a first constant domain (CH1) of one heavy chain. Each Fab fragment is monovalent with respect to antigen binding, i.e., has a single antigen-binding site. Pepsin treatment of the antibody yields a single large F(ab')2 fragment, which roughly corresponds to a Fab fragment linked by two disulfides with different antigen-binding activities and can still crosslink antigens. The Fab' fragment differs from the Fab fragment in that it has several additional residues at the carboxyl terminus of the CH1 domain, which contains one or more cysteines from the antibody hinge region. Fab'-SH is the designation used herein for Fab' in which the cysteine ​​residue of the constant domain has a free thiol group. The F(ab')2 antibody fragment was originally produced as a pair of Fab' fragments with a hinge cysteine ​​in between. Other chemical bonds of antibody fragments are also known.

[0025] "Anti-PD-L1 antibody" or "anti-PD-1 antibody" means an antibody or its antigen-binding fragment that specifically binds to PD-L1 or PD-1, respectively, and blocks the binding of PD-L1 to PD-1. In any of the therapeutic methods, pharmaceuticals, and uses of the present invention in which a human subject is treated, the anti-PD-L1 antibody specifically binds to human PD-L1 and blocks the binding of human PD-L1 to human PD-1. In any of the therapeutic methods, pharmaceuticals, and uses of the present invention in which a human subject is treated, the anti-PD-1 antibody specifically binds to human PD-1 and blocks the binding of human PD-L1 to human PD-1. The antibody may be a monoclonal antibody, a human antibody, a humanized antibody, or a chimeric antibody, and may contain a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in some embodiments, the human constant region is IgG1 or IgG4 constant region. In some embodiments, the antigen-binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.

[0026] "Anti-PD(L)1 antibody" refers to either an anti-PD-L1 antibody or an anti-PD-1 antibody.

[0027] Vintrafasp alfa, also known as M7824, is well understood in the relevant field. Vintrafasp alfa is an anti-PD-L1:TGFβRII fusion protein, described by CAS registry number 1918149-01-5. It is also described in WO2015 / 118175 and further refined by Lan et al (Lan et al, “Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β”, Sci. Transl. Med. 10, 2018, pp. 1-15). In particular, vintrafasp alfa is a fully human IgG1 monoclonal antibody against human PD-L1 fused to the extracellular domain of human TGF-β receptor II (TGFβRII). Therefore, vintrafasp alfa is a bifunctional fusion protein that simultaneously blocks both the PD-L1 and TGF-β pathways. In particular, WO2015 / 118175 describes vintrafasp alfa on page 34 in Example 1 as follows (vintrafasp alfa is referred to as "anti-PD-L1 / TGFβ trap" in this section): "The anti-PD-L1 / TGFβ trap is an anti-PD-L1 antibody-TGFβ receptor II fusion protein. The light chain of this molecule is identical to the light chain of the anti-PD-L1 antibody (SEQ ID NO: 1). The heavy chain of this molecule (SEQ ID NO: 3) is a fusion protein containing the heavy chain of the anti-PD-L1 antibody (SEQ ID NO: 2) which is gene-fused to the N-terminus of the soluble TGFβ receptor II (SEQ ID NO: 10) via a mobile (Gly4Ser)4Gly linker (SEQ ID NO: 11). At the fusion junction, the C-terminal lysine residue of the antibody heavy chain is mutated to alanine to reduce proteolytic cleavage."

[0028] "Biomarkers" generally refer to biological molecules that indicate a disease state, as well as their quantitative and qualitative measurements. "Prognostic biomarkers" correlate with disease outcomes independently of treatment. For example, tumor hypoxia is a negative prognostic marker; the higher the tumor hypoxia, the more likely the disease outcome is to be negative. "Predictive biomarkers" indicate whether a patient is likely to respond positively to a particular treatment. For example, HER2 profiling is commonly used in breast cancer patients to determine whether these patients are likely to respond to herceptin (trastuzumab, Genentech). "Response biomarkers" provide a measure of response to treatment and indicate whether the treatment is working. For example, a decrease in prostate-specific antigen levels generally indicates that anticancer therapy is working in prostate cancer patients. When markers are used as a basis for identifying or selecting patients for the treatments described herein, the markers may be measured before and / or during treatment, and the values ​​obtained may be used by the clinician to evaluate any of the following: (a) whether the individual is likely or likely to be suitable for initial treatment, (b) whether the individual is likely or likely to be unsuitable for initial treatment, (c) responsiveness to treatment, (d) whether the individual is likely or likely to be suitable for continuing treatment, (e) whether the individual is likely or likely to be unsuitable for continuing treatment, (f) adjusting the dosage, (g) predicting the probability of clinical benefit, or (h) toxicity. As will be readily apparent to those skilled in the art, the measurement of biomarkers in a clinical setting clearly indicates that this parameter is used as a basis for initiating, continuing, adjusting, and / or discontinuing the administration of the treatments described herein.

[0029] "Cancer" means a collection of cells that grow in an abnormal manner. As used herein, the term "cancer" refers to all types of cancer, neoplasms, malignant or benign tumors found in mammals, including leukemia, carcinomas, and sarcomas. Examples of cancer include breast cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, lung cancer, pancreatic cancer, and glioblastoma. Additional examples include brain cancer, lung cancer, non-small cell lung cancer, melanoma, sarcoma, prostate cancer, cervical cancer, stomach cancer, head and neck cancer, uterine cancer, mesothelioma, metastatic bone cancer, medulloblastoma, Hodgkin's disease, non-Hodgkin lymphoma, multiple myeloma, neuroblastoma, rhabdomyosarcoma, primary thrombocytosis, primary macrobuloidemia, bladder cancer, pre-malignant skin lesions, testicular cancer, lymphoma, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary cancer, malignant hypercalcemia, endometrial cancer, adrenocortical carcinoma, and neoplasms of the endocrine and exocrine pancreas.

[0030] A "CDR" is the complementarity-determining region amino acid sequence of an antibody, antibody fragment, or antigen-binding fragment. These are the hypervariable regions of the heavy and light chains of immunoglobulins. The variable region of an immunoglobulin contains three heavy-chain CDRs and three light-chain CDRs (or CDR regions).

[0031] "Clinical outcome," "clinical parameter," "clinical response," or "clinical endpoint" refers to any clinical observation or measurement of a patient's response to treatment. Non-limiting examples of clinical outcomes include tumor response (TR), overall survival (OS), progression-free survival (PFS), disease-free survival, time to recurrence (TTR), time to progression (TTP), relative risk (RR), toxicity, or adverse events.

[0032] As used herein, “combination” refers to providing a first active modality in addition to one or more further active modalities (the one or more active modalities may be fused). Any regimen of combination modalities or partners (i.e., active compounds, components, drugs, or treatments) such as a combination of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor contained in one or more compounds and compositions is intended within the scope of combinations described herein. It is understood that any modality within a single composition, formulation, or unit dosage form (i.e., a combination of fixed doses) must have the same administration regimen and delivery route. It is not intended to mean that modalities must be formulated to be delivered together (e.g., in the same composition, formulation, or unit dosage form). Combined modalities may be manufactured and / or formulated by the same or different manufacturers. Thus, combination partners may be, for example, completely separate pharmaceutical dosage forms or pharmaceutical compositions marketed independently of each other. In some embodiments, a TGFβ inhibitor is fused with a PD-1 inhibitor and is therefore contained within a single composition, having the same administration regimen and delivery route.

[0033] As used herein, “combination therapy,” “in combination with,” or “in conjunction with” refers to any form of concurrent, parallel, simultaneous, sequential, or intermittent treatment by at least two distinct therapeutic modalities (i.e., compounds, components, targeted agents, therapeutic agents, or therapies). These terms therefore refer to the administration of one therapeutic modality before, during, or after the administration of another therapeutic modality to the target. Modalities in combination may be administered in any order. Therapeutically effective modalities may be administered together (e.g., simultaneously in the same or separate compositions, formulations, or unit dosage forms) or separately (e.g., in appropriate dosage forms for separate compositions, formulations, or unit dosage forms). In accordance with Rotcor, the drugs are administered (on the same day or on different days, in any order) in the form and administration regimen prescribed by a healthcare professional or in accordance with the regulatory authority. Generally, each therapeutic modality is administered in the dose and / or time schedule determined for that therapeutic modality. Optionally, four or more modalities may be used in combination therapy. Furthermore, the combination therapies provided herein may be used in combination with other types of treatment. For example, other anti-cancer treatments may be selected from among other treatments related to the current standard of care for the subject, consisting of chemotherapy, surgery, radiotherapy (radiation), and / or hormone therapy.

[0034] "Complete response" or "complete remission" refers to the disappearance of all signs of cancer in response to treatment. This does not necessarily mean that the cancer has been cured.

[0035] As used herein, “contains” is intended to mean that the compositions and methods described include the elements described but do not exclude other elements. “Essentially consists of” means, when used to define compositions and methods, to exclude any other elements that are essentially important to the composition or method. “Consists of” means that, with respect to the compositions and substantial method steps described in the claims, elements that are more than trace amounts of other components are excluded. Embodiments defined by each of these transitional terms are within the scope of the invention. Accordingly, methods and compositions may include additional steps and components, or may include non-essential steps and compositions, or may intend to consist only of the method steps or compositions described.

[0036] "Dosage" and "Dosage" refer to a specific amount of an activator or therapeutic agent for administration. Such an amount is included in "Dosage Form," which refers to a physically distinct unit suitable as a unit dose for human subjects and other mammals, each unit containing a predetermined amount of activator calculated to produce a desired initiation, tolerability, and therapeutic effect in combination with one or more suitable pharmaceutical excipients, such as a carrier.

[0037] "Fc" is a fragment containing the carboxyl terminus of both H chains linked together by a disulfide. The effector function of an antibody is determined by the sequence of the Fc region, which is also recognized by Fc receptors (FcRs) found in specific types of cells.

[0038] The term “fusion molecule” is well understood in the art, and it will be understood that molecules including fused PD-1 inhibitors and TGFβ inhibitors referred to herein include Ig:TGFβR fusion proteins, e.g., anti-PD-1:TGFβR fusion protein or anti-PD-L1:TGFβR fusion protein. An Ig:TGFβR fusion protein is an antibody (in some embodiments, e.g., a monoclonal antibody in homodimeric form) or its antigen-binding fragment fused to a TGF-β receptor. The naming of anti-PD-L1:TGFβRII fusion protein refers to an anti-PD-L1 antibody or its antigen-binding fragment fused to a fragment of its extracellular domain capable of binding to TGF-β receptor II or TGF-β. The naming of anti-PD-1:TGFβRII fusion protein refers to an anti-PD-1 antibody or its antigen-binding fragment fused to a fragment of its extracellular domain capable of binding to TGF-β receptor II or TGF-β. The naming of anti-PD(L)1:TGFβRII fusion protein refers to an anti-PD-1 antibody or its antigen-binding fragment, or an anti-PD-L1 antibody or its antigen-binding fragment, fused to a fragment of the extracellular domain of the TGF-β receptor II or TGF-β, which can bind to TGF-β.

[0039] "Fv" is the smallest antibody fragment containing a complete antigen recognition site and antigen binding site. This fragment consists of a dimer of one heavy chain variable domain and one light chain variable domain, which are associated by tight non-covalent bonds. The folding of these two domains gives rise to six hypervariable loops (three from the H chain and three from the L chain) that contribute amino acid residues for antigen binding and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of Fv containing only the three antigen-specific HVRs) has the ability to recognize and bind to an antigen, albeit with lower affinity than the entire binding site.

[0040] A “human antibody” is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human, and / or an antibody prepared using any of the techniques for preparing human antibodies disclosed herein. This definition of a human antibody explicitly excludes humanized antibodies containing non-human antigen-binding residues. Human antibodies can be prepared using a variety of techniques known in the art, including phage display libraries (see, e.g., Hoogenboom and Winter (1991), JMB227:381; Marks et al. (1991), JMB222:581). Methods described in Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, page 77; Boerner et al. (1991), J. Immunol 147(l):86; van Dijk and van de Winkel (2001), Curr. Opin. Pharmacol 5:368 may also be used for the preparation of human monoclonal antibodies. Human antibodies can be prepared by administering antigens to transgenic animals, such as immunized xenomous mice, that have been modified to produce such antibodies in response to antigen challenge, but whose endogenous gene locus has been deactivated (see, for example, U.S. Patent No. 6,075,181; and U.S. Patent No. 6,150,584, for xenomous mouse technology). See also, for example, Li et al. (2006) PNAS USA, 103:3557, for human antibodies produced by human B-cell hybridoma technology.

[0041] The “humanized” form of a non-human (e.g., mouse) antibody is a chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. In one embodiment, the humanized antibody is a human immunoglobulin (recipient antibody) in which residues derived from the recipient's HVR are replaced by residues derived from the HVR of a non-human species (donor antibody), such as mouse, rat, rabbit, or non-human primate, having the desired specificity, affinity, and / or capabilities. In some embodiments, framework ("FR") residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may contain residues not found in the recipient antibody or donor antibody. These modifications may be made to further refine antibody performance, such as binding affinity. Generally, the humanized antibody contains substantially all of at least one variable domain, typically two variable domains, corresponding to all or substantially all of a non-human immunoglobulin sequence of hypervariable loops, and all or substantially all of the FR region being a human immunoglobulin sequence, although the FR region may contain one or more individual FR residue substitutions that improve antibody performance, such as binding affinity, isomerization, and immunogenicity. The number of these amino acid substitutions in the FR is typically 6 or less in the H chain and 3 or less in the L chain. Humanized antibodies also optionally contain at least a portion of the immunoglobulin constant region (Fc), typically that of human immunoglobulin. For further details, see, for example, Jones et al. (1986) Nature 321:522; Riechmann et al. (1988) Nature 332:323; Presta (1992) Curr. Op. Struct. Biol. 2:593; Vaswani and Hamilton (1998) Ann. Allergy, Asthma & Immunol. 1:105; Harris (1995) Biochem. Soc. Transactions 23:1035; Hurle and Gross (1994) Curr. Op. Biotech. 5:428; and U.S. Patent Nos. 6,982,321 and 7,087,409.

[0042] "Injection" or "to inject" refers to the introduction of a drug-containing solution into the body via a vein for therapeutic purposes. Generally, this is achieved via an intravenous (IV) bag.

[0043] A "line of treatment" refers to a therapy or combination therapy used to treat a condition in a patient. If the first line of treatment fails, for example, after disease progression or after drug resistance to the current treatment develops, the line of treatment is usually changed. The first line of treatment used to treat a particular condition is called the "first-line treatment." Subsequent lines of treatment are numbered sequentially (second-line, third-line, fourth-line, etc.).

[0044] "Metastatic" cancer refers to cancer that has spread from one part of the body (for example, the lungs) to another part of the body.

[0045] As used herein, “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies; that is, the individual antibodies constituting the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization and amidation) that may be present in small amounts. Monoclonal antibodies are highly specific, specifically against a single antigenic site. Typically, in contrast to polyclonal antibody preparations, which contain different antibodies against different determinants (epitopes), each monoclonal antibody is specific to a single determinant on an antigen. In addition to their specificity, monoclonal antibodies have the advantage that they are synthesized by hybridoma culture and are not contaminated with other immunoglobulins. The modifier “monoclonal” indicates a characteristic of the antibody that it is obtained from a substantially homogeneous population of antibodies, and should not be interpreted as requiring antibody production by any particular method. For example, monoclonal antibodies used in accordance with the present invention are, for example, those produced by hybridoma (e.g., Kohler and Milstein (1975) Nature 256:495; Hongo et al. (1995) Hybridoma 14(3):253; Harlow et al. (1988) Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 2 nded.; Hammerling et al. (1981) In: Monoclonal Antibodies and T-CeIl Hybridomas 563 (Elsevier, NY), recombinant DNA method (see, e.g., U.S. Patent No. 4,816,567), phage display technology (Clackson et al. (1991) Nature 352:624; Marks et al. (1992) JMB 222:581; Sidhu et al. (2004) JMB 338(2):299; Lee et al. (2004) JMB 340(5):1073; Fellouse (2004) PNAS USA 101(34):12467; and Lee et al. (2004) J. Immunol. Methods 284(1-2):119), and techniques for producing human or human-like antibodies in animals having some or all of the human immunoglobulin locus or genes encoding human immunoglobulin sequences (e.g., WO1998 / 24893; WO1996 / 34096; WO1996 / 33735; WO1991 / 10741; Jakobovits et al. (1993) PNAS USA 90:2551; Jakobovits et al. (1993) Nature 362:255; Bruggemann et al. (1993) Year in It can be produced by various techniques, including Immunol.7:33; U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016; Marks et al. (1992) Bio / Technology 10:779; Lonberg et al. (1994) Nature 368:856; Morrison (1994) Nature 368:812; Fishwild et al. (1996) Nature Biotechnol.14:845; Neuberger (1996), Nature Biotechnol.14:826; and Lonberg and Huszar (1995), Intern. Rev. Immunol.13:65-93.The monoclonal antibodies used herein specifically include chimeric antibodies (immunoglobulins) in which, insofar as they exhibit the desired biological activity, a portion of the heavy chain and / or light chain is derived from a particular species or is identical or homologous to the corresponding sequence in an antibody belonging to a particular antibody class or subclass, but the rest of the chain is derived from another species or belongs to another antibody class or subclass, and is identical or homologous to the corresponding sequence in a fragment of such an antibody (see, for example, U.S. Patent No. 4,816,567; Morrison et al. (1984) PNAS USA, 81:6851).

[0046] "Niraparib" is well known to those skilled in the art and refers to the free base form of (3S)-3-[4-{7-(aminocarbonyl)-2H-indazole-2-yl}phenyl]piperidine. Pharmacopoecially acceptable salts of niraparib include, but are not limited to, (3S)-3-{4-[7-(aminocarbonyl)-2H-indazole-2-yl]phenyl}piperidinium 4-methylbenzenesulfonate, or its solvated or hydrated form (e.g., (3S)-3-{4-[7-(aminocarbonyl)-2H-indazole-2-yl]phenyl}piperidinium 4-methylbenzenesulfonate monohydrate). In some embodiments, (3S)-3-{4-[7-(aminocarbonyl)-2H-indazole-2-yl]phenyl}piperidinium 4-methylbenzenesulfonate may be referred to as "niraparib tosylate". In some embodiments, (3S)-3-{4-[7-(aminocarbonyl)-2H-indazole-2-yl]phenyl}piperidinium 4-methylbenzene sulfonate monohydrate may be referred to as "niraparib tosylate monohydrate".

[0047] "Response" refers to a measurable response, including complete response (CR) or partial response (PR).

[0048] A "PARP inhibitor" refers to a compound that inhibits the PARP pathway, such as a compound that inhibits the activity of any one of the proteins in the poly(ADP-ribose) polymerase (PARP) family. This may include inhibitors of any of the more than 15 different enzymes in the PARP family that are involved in various cellular functions, including cell cycle regulation, transcription, and DNA damage repair. PARP inhibitors may function by competitively binding to the NAD+ site of a PARP enzyme such as PARP1 and / or PARP2, thereby inhibiting its catalytic activity, or by immobilizing a PARP enzyme such as PARP1 on damaged DNA. In some embodiments, a PARP inhibitor inhibits the activity of PARP1. In some embodiments, a PARP inhibitor primarily inhibits the activity of PARP1. In some embodiments, a PARP inhibitor inhibits the activity of PARP2. In some embodiments, a PARP inhibitor primarily inhibits the activity of PARP2. In some embodiments, a PARP inhibitor inhibits the activity of PARP1 and / or PARP2. In some embodiments, a PARP inhibitor inhibits the activity of both PARP1 and PARP2. In some embodiments, PARP inhibitors inhibit the activity of PARP1, PARP2, PARP3, and PARP4. PARP inhibitors may be small molecules (e.g., organic or inorganic small molecules), nucleic acids, polypeptides (e.g., antibodies), carbohydrates, lipids, metals, or toxins. In some embodiments, PARP inhibitors are small molecule drugs. In some embodiments, PARP inhibitors are nicotinamide analogs.In some embodiments, the PARP inhibitors are ABT-767, AZD2461, BGP15, CEP8983, CEP9722, DR2313, E7016, E7449, fluzoparib, IMP4297, INO1001, JPI289, JPI547, monoclonal antibody B3-LysPE40 conjugate, MP124, NU1025, NU1064, NU1076, NU1085, and ONO22. 31, PD128763, olaparib, lucaparib, R503, R554, niraparib, SBP101, SC101914, simiparib, talazoparib, veliparib, pamiparib, WW46, 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine-4-ol, nicotinamide, theophylline, and derivatives thereof are selected from the group. In some embodiments, the PARP inhibitor is flusoparib, niraparib, olaparib, lucaparib, talazoparib, or veliparib. In some embodiments, the PARP inhibitor is niraparib. In one embodiment, the PARP inhibitor is flusoparib, niraparib, olaparib, lucaparib, talazoparib, or veliparib, or any combination thereof. In some embodiments, the PARP inhibitor can be prepared as a pharmaceutically acceptable salt. In certain embodiments, the PARP inhibitor is fluzoparib. In certain embodiments, the PARP inhibitor is olaparib. In certain embodiments, the PARP inhibitor is lucaparib. In certain embodiments, the PARP inhibitor is talazoparib. In certain embodiments, the PARP inhibitor is veliparib. In another embodiment, the PARP inhibitor is niraparib. Those skilled in the art will understand that such salt forms may exist as solvated or hydrated polymorphic forms. In one embodiment, the PARP inhibitor is niraparib, niraparib tosylate, or niraparib tosylate monohydrate, or any combination thereof. In one embodiment, the PARP inhibitor is niraparib tosylate monohydrate. In some embodiments, IC for the inhibition of the PARP enzyme by the PARP inhibitor. 50The values ​​are less than 1000 μM, less than 100 μM, less than 1 μM, or less than 100 nM. Expected effects of PARP pathway inhibition include inhibition of tumor growth. Inhibition in this context does not need to be complete or 100%. Instead, inhibition means reducing, decreasing, or inactivating the activity of the PARP pathway or tumor growth, respectively.

[0049] "Partial response" refers to a reduction in the size of one or more tumors or lesions, or the extent of cancer throughout the body, in response to treatment.

[0050] "Patient" and "subject" are used interchangeably herein to refer to mammals requiring treatment for cancer. Generally, a patient is a human being diagnosed with cancer or at risk of developing one or more symptoms of cancer. In certain embodiments, "patient" or "subject" may refer to non-human mammals, such as non-human primates, dogs, cats, rabbits, pigs, mice, or rats, or animals used, for example, in screening, characterization, and evaluation of drugs and therapies.

[0051] As used herein, “PD-1 inhibitor” refers to a molecule that inhibits the PD-1 pathway by inhibiting the interaction of PD-1 axis binding partners, such as between the PD-1 receptor and PD-L1 and / or PD-L2 ligands. Expected effects of such inhibition include the elimination of immunosuppression resulting from signaling on the PD-1 signaling axis. Inhibition in this context does not need to be complete or 100%. Instead, inhibition means reducing, decreasing, or inactivating the binding between PD-1 and one or more of its ligands, and / or reducing, decreasing, or inactivating signaling via the PD-1 receptor. In some embodiments, the PD-1 inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, binds to PD-L1 or PD-1 and inhibits the interaction between these molecules. In some embodiments, the PD-1 inhibitor is a PD-L1 antibody, which may be fused to a TGFβ inhibitor, for example, as an anti-PD-L1:TGFβRII fusion protein.

[0052] As used herein, “PD-L1 expression” means the expression of PD-L1 protein on the cell surface or PD-L1 mRNA within cells or tissues at any detectable level. PD-L1 protein expression may be detected using a diagnostic PD-L1 antibody in an IHC assay of tumor tissue sections or by flow cytometry. Alternatively, PD-L1 protein expression by tumor cells may be detected by PET imaging using a binder (e.g., antibody fragment, aphid, etc.) that specifically binds to PD-L1. Techniques for detecting and measuring PD-L1 mRNA expression include RT-PCR and real-time quantitative RT-PCR.

[0053] "PD-L1-positive" or "high PD-L1" cancers are cancers that include cells on which PD-L1 is present on the cell surface, and / or cancers that produce sufficient levels of PD-L1 on the surface of those cells; therefore, anti-PD-L1 antibodies have a therapeutic effect mediated by the binding of the anti-PD-L1 antibody to PD-L1. For example, methods for detecting biomarkers such as PD-L1 on cancer or tumors are commonplace in the art and are intended herein. Non-limiting examples include immunohistochemistry (IHC), immunofluorescence, and fluorescence-activated cell sorting (FACS). Several approaches for quantifying PD-L1 protein expression in IHC assays of tumor tissue sections have been described. The proportion of PD-L1-positive cells is often expressed as a tumor ratio score (TPS) or composite positivity score (CPS). TPS represents the percentage of surviving tumor cells in partial or complete membrane staining (e.g., staining for PD-L1). CPS is calculated by dividing the number of PD-L1-stained cells (tumor cells, lymphocytes, macrophages) by the total number of surviving tumor cells and multiplying by 100. For example, in some embodiments, "high PD-L1" refers to a tumor proportion score (TPS) of over 80% PD-L1-positive tumor cells as determined by the PD-L1 Dako IHC73-10 assay, or over 50% as determined by the Dako IHC22C3 PharmDx assay. The IHC73-10 and IHC22C3 assays select similar patient populations at their respective cutoffs. In certain embodiments, the Ventana PD-L1 (SP263) assay, which has high agreement with the 22C3 PharmDx assay (see Sughayer et al., Appl Immunohistochem Mol Morphol 2019 Oct;27(9):663-666), can also be used to determine PD-L1 expression levels. Another assay for measuring PD-L1 expression in cancer is the Ventana PD-L1(SP142) assay. In some embodiments, a cancer is counted as PD-L1 positive if at least 1%, at least 5%, at least 25%, at least 50%, at least 75%, or at least 80% of tumor cells express PD-L1.

[0054] The “percentage of sequence identity (%)” for a peptide or polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences to achieve the maximum percentage of sequence identity, without considering conservative substitutions as part of sequence identity, and introducing gaps if necessary. Alignment for determining the percentage of amino acid sequence identity can be achieved in various ways within the scope of the art, for example, using publicly available computer software such as BLAST, BLAST-2, or ALIGN software. A person skilled in the art can determine appropriate parameters for measuring the alignment, including any algorithm necessary to achieve the maximum alignment over the entire length of the sequences being compared.

[0055] "Pharmacologically acceptable" means that a substance or composition must be chemically and / or toxicologically compatible with the other components of the formulation and / or the mammals it treats. "Pharmacologically acceptable carriers" include any physiologically compatible solvents, dispersions, coatings, antimicrobial and antifungal agents, isotonic agents, and absorption retarders. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate-buffered saline, dextrose, glycerol, ethanol, and combinations thereof.

[0056] "Radiotherapy" is a therapy using ionizing radiation. In some embodiments, radiotherapy is selected from the group consisting of whole-body radiotherapy, external beam radiotherapy, image-guided radiotherapy, tomotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, and proton therapy. In some embodiments, radiotherapy includes external beam radiotherapy, internal radiotherapy, or whole-body radiotherapy. In some embodiments, radiotherapy includes external beam radiotherapy, and external beam radiotherapy includes intensity-modulated radiation therapy (IMRT), image-guided radiotherapy (IGRT), tomotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, proton therapy, or other charged particle beams. Internal radiotherapy involves implanting a radiation source, such as beads, wires, pellets, or capsules, inside the body at or near the tumor site. The radiation used is, but is not limited to, derived from radioisotopes such as iodine, strontium, phosphorus, palladium, cesium, iridium, phosphate, or cobalt. Such implants can be removed after treatment or left inactive in the body. Types of internal radiotherapy include, but are not limited to, brachytherapy, interstitial irradiation, and intracavitary irradiation. Less common forms of internal radiotherapy today include radioimmunotherapy, which uses a biological carrier of radioisotopes, where tumor-specific antibodies bound to radioactive material are administered to the patient. The antibodies bind to tumor antigens, thereby effectively delivering a radiation dose to the relevant tissues. In another example, radiation is delivered to the patient from outside the body using gamma rays. Gamma rays are produced by the decomposition of radioisotopes such as cobalt-60. A therapeutic approach called stereotactic body radiotherapy (SBRT) allows for strong focusing of gamma rays to target only tumor tissue, resulting in minimal damage to healthy tissue. SBRT can be used for patients with localized tumors. Meanwhile, X-rays produced by particle accelerators can be used to deliver radiation to wider areas of the body.

[0057] "Recurrent" cancer is cancer that has grown again, either at the original site or in a distant site, after responding to initial treatment such as surgery. Local "recurrent" cancer is cancer that has recurred in the same location as the previously treated cancer after treatment.

[0058] "Reduction" (and its grammatical equivalent) of one or more symptoms refers to reducing the severity or frequency of a symptom, or eliminating the symptom.

[0059] "Single-chain Fv," also abbreviated as "sFv" or "scFv," is a single polypeptide chain to which V is linked. H and V L It is an antibody fragment containing an antibody domain. In some embodiments, the sFv polypeptide is V H Domain and V L The inclusion of a polypeptide linker between the domain and the sFv allows the sFv to form the desired structure for antigen binding. For a review of sFv, see, for example, Pluckthun (1994), In: The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore (eds.), Springer-Verlag, New York, pp. 269.

[0060] "Substantially identical" means (1) the query amino acid sequence is at least 75%, 85%, 90%, 95%, 99%, or 100% identical to the target amino acid sequence, or (2) the query amino acid sequence differs from the target amino acid sequence by 20% or less, 30% or less, 20% or less, 10% or less, 5% or less, 1% or less, or 0% in terms of amino acid position (the difference in amino acid position is either an amino acid substitution, deletion, or insertion).

[0061] "Systemic" therapy is a treatment in which drug substances travel through the bloodstream and reach and affect cells throughout the body.

[0062] As used herein, “TGFβ inhibitor” refers to a molecule that inhibits the TGFβ pathway, for example, by inhibiting the interaction between TGFβ and the TGFβ receptor (TGFβR). Expected effects of such inhibition include the removal of immunosuppression caused by signaling on the TGFβ signaling axis. Inhibition in this context does not need to be complete or 100%. Instead, inhibition means reducing, decreasing, or inactivating the binding between TGF-β and TGFβR, and / or reducing, decreasing, or inactivating signaling via TGFβR. In some embodiments, the TGFβ inhibitor binds to TGFβ or TGFβR to inhibit the interaction between these molecules. In some embodiments, the TGFβ inhibitor comprises the extracellular domain of TGFβRII, or a fragment of TGFβRII capable of binding to TGFβ. In some embodiments, such the TGFβ inhibitor is fused to a PD-1 inhibitor, for example, as an anti-PD(L)1:TGFβRII fusion protein.

[0063] The terms “TGF-β receptor” (TGFβR) and “TGF-β receptor I” (abbreviated as TGFβRI or TGFβR1) or “TGF-β receptor II” (abbreviated as TGFβRII or TGFβR2) are well known in the art. For the purposes of this disclosure, references to such receptors include the complete receptor and fragments capable of binding to TGF-β. In some embodiments, it is the extracellular domain of the receptor or a fragment of the extracellular domain capable of binding to TGF-β. In some embodiments, the fragment of TGFβRII is selected from the group consisting of SEQ ID NOs: 11, 12, and 13.

[0064] In each case of the present invention, the “therapeutic effective dose” of a PD-1 inhibitor, TGFβ inhibitor, PARP inhibitor, or radiotherapy means an effective amount in the required dosage and duration that, when administered to a patient with cancer, produces the intended therapeutic effect, e.g., reduction, improvement, mitigation, or elimination of one or more signs of cancer in the patient, or any other clinical outcome in the course of treatment for the cancer patient. The therapeutic effect does not necessarily occur with a single dose, but may occur only after a series of doses. Therefore, the therapeutic effective dose may be administered in one or more doses. Such a therapeutic effective dose may vary depending on factors such as the individual’s disease state, age, sex, and weight, as well as the ability of the PD-1 inhibitor, TGFβ inhibitor, PARP inhibitor, or radiotherapy to produce the desired response in the individual. The therapeutic effective dose is also the amount in which the therapeutically beneficial effect outweighs any toxic or adverse effects of the PD-1 inhibitor, TGFβ inhibitor, PARP inhibitor, or radiotherapy.

[0065] "Treating" a condition or patient, or "treatment," means taking steps to obtain beneficial or desirable outcomes, including clinical outcomes. For the purposes of this invention, beneficial or desirable clinical outcomes include, but are not limited to, reduction or improvement of one or more symptoms of cancer; reduction of disease severity; delay or stabilization of disease progression; improvement, mitigation, or stabilization of the disease state; or other beneficial outcomes. It should be understood that references to "treating" or "treatment" include prevention and mitigation of established symptoms of the condition. Therefore, “treating” a state, disorder, or condition, or “treating” such a state, disorder, or condition, includes (1) preventing or delaying the onset of the clinical symptoms of a state, disorder, or condition in a subject who is already suffering from or predisposed to the state, disorder, or condition but has not yet experienced or shown any clinical or quasi-clinical symptoms of the state, disorder, or condition; (2) inhibiting the state, disorder, or condition, i.e., preventing, reducing, or delaying the onset or recurrence of the disease (in the case of maintenance treatment) or at least one clinical or quasi-clinical symptom thereof; or (3) alleviating or reducing the disease, i.e., causing regression of the state, disorder, or condition, or at least one clinical or quasi-clinical symptom thereof.

[0066] As used herein, “unit dosage form” refers to a physically distinct unit of a therapeutic formulation suitable for the subject being treated. However, it will be understood that the total daily dose of the compositions of the present invention is to be determined by the attending physician within the bounds of sound medical judgment. A specific effective dose level for any particular subject or organism depends on a variety of factors, including the disorder and its severity being treated; the activity of the specific activator used; the specific composition used; the subject’s age, weight, overall health, sex, and diet; the timing and rate of administration of the specific activator used; the duration of treatment; any drugs and / or additional therapies used in combination with or concurrently with the specific compound used, as well as similar elements well known in the medical field.

[0067] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy chain or light chain of the antibody. The variable domains of the heavy chain and light chain are respectively called "V H " and "V L These domains are sometimes referred to as "antibody domains." These domains are generally the most variable parts of an antibody (compared to other antibodies of the same class) and include the antigen-binding site.

[0068] As used herein, multiple items, structural elements, compositional elements, and / or materials may be presented in common lists for convenience. However, these lists should be interpreted as if each member of the list were individually identified as a separate, unique member.

[0069] Concentration, quantity, and other numerical data may be expressed or presented in range form as herein. Such range forms are used solely for convenience and conciseness, and should therefore be understood to be interpreted flexibly to include all individual numerical values ​​or subranges within their range, as if each numerical value and subrange were explicitly stated, as well as the numerical values ​​explicitly stated as limits of the range. For example, a numerical range of "about 1 to about 5" should be interpreted to include not only the explicitly stated values ​​of about 1 to about 5, but also the individual values ​​and subranges within the indicated range. Thus, this numerical range includes individual values ​​such as 2, 3, and 4, subranges such as 1 to 3, 2 to 4, and 3 to 5, and individually 1, 2, 3, 4, and 5. The same principle applies to ranges that state only one numerical value as the minimum or maximum value. Furthermore, such interpretation should apply regardless of the breadth or characteristics of the stated range.

[0070] Explanatory Embodiment Therapeutic combinations and their methods of use This invention arises, in part, from the remarkable discovery of the benefits of a combination of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors, particularly when combined with radiotherapy. The treatment schedule and dosages were designed to reveal potential synergistic effects.

[0071] Accordingly, in one embodiment, the present invention provides PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in a method for treating cancer in a subject, comprising the administration of the PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in combination with radiotherapy, a method for treating cancer in a subject, comprising the administration of the PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors to the subject in combination with radiotherapy, and a use of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in the manufacture of a pharmaceutical for treating cancer in a subject, wherein the subject is optionally a subject receiving radiotherapy in combination with the pharmaceutical. It should be understood that therapeutically effective doses of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors are applied in each therapeutic method, and in embodiments where the subject receives further radiotherapy, therapeutically effective doses of radiotherapy are applied. In some embodiments, the PD-1 inhibitor is an anti-PD(L)1 antibody, and the TGFβ inhibitor is TGFβRII or an anti-TGFβ antibody. In some embodiments, the PD-1 inhibitor is fused to the TGFβ inhibitor. For example, the PD-1 inhibitor and the TGFβ inhibitor may be contained in an anti-PD(L)1:TGFβRII fusion protein, such as an anti-PD-L1:TGFβRII fusion protein or an anti-PD-1:TGFβRII fusion protein. In some embodiments, the fusion molecule is an anti-PD-L1:TGFβRII fusion protein, such as an anti-PD-L1:TGFβRII fusion protein, where the light chain sequence and heavy chain sequence correspond to SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

[0072] PD-1 inhibitors can inhibit the interaction between PD-1 and at least one of its ligands, such as PD-L1 or PD-L2, thereby inhibiting the PD-1 pathway, for example, the immunosuppressive signaling pathway of PD-1. PD-1 inhibitors can bind to one of its ligands, such as PD-1 or PD-L1. In one embodiment, a PD-1 inhibitor inhibits the interaction between PD-1 and PD-L1. In some embodiments, a PD-1 inhibitor is an anti-PD(L)1 antibody, such as an anti-PD-1 antibody or anti-PD-L1 antibody, that can inhibit the interaction between PD-1 and PD-L1. In some embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is selected from the group consisting of pembrolizumab, nivolumab, avelumab, atezolizumab, durvalumab, spartalizumab, camrelizumab, cintilimab, tislerizumab, tripalimab, semiprimab, and antibodies whose light chain and heavy chain sequences correspond to SEQ ID NOs. 7 and SEQ ID NOs. 16 or SEQ ID NOs. 15 and SEQ ID NOs. 14, respectively, or antibodies that compete for binding with any of the antibodies in this group. In some embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is still capable of binding to PD-1 or PD-L1, and its amino acid sequence is substantially identical to that of one antibody selected from the group consisting of pembrolizumab, nivolumab, avelumab, atezolizumab, durvalumab, spartalizumab, camrelizumab, cintilimab, tislerizumab, tripalimab, semiprimab, and antibodies whose light chain and heavy chain sequences correspond to SEQ ID NOs. 7 and SEQ ID NOs. 16 or SEQ ID NOs. 15 and SEQ ID NOs. 14, for example, having at least 90% sequence identity.

[0073] In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody that can inhibit the interaction between PD-1 and PD-L1. In some embodiments, the anti-PD-L1 antibody comprises a heavy chain containing three CDRs having the amino acid sequences of SEQ ID NO: 19 (CDRH1), SEQ ID NO: 20 (CDRH2), and SEQ ID NO: 21 (CDRH3), and a light chain containing three CDRs having the amino acid sequences of SEQ ID NO: 22 (CDRL1), SEQ ID NO: 23 (CDRL2), and SEQ ID NO: 24 (CDRL3). In some embodiments, the anti-PD-L1 antibody comprises a heavy chain containing three CDRs having the amino acid sequences of SEQ ID NO: 1 (CDRH1), SEQ ID NO: 2 (CDRH2), and SEQ ID NO: 3 (CDRH3), and a light chain containing three CDRs having the amino acid sequences of SEQ ID NO: 4 (CDRL1), SEQ ID NO: 5 (CDRL2), and SEQ ID NO: 6 (CDRL3). In some embodiments, the light chain variable region and heavy chain variable region of the anti-PD-L1 antibody contain SEQ ID NO: 25 and SEQ ID NO: 26, respectively. In some embodiments, the light chain sequence and heavy chain sequence of the anti-PD-L1 antibody correspond to SEQ ID NO: 7 and SEQ ID NO: 16 or SEQ ID NO: 15 and SEQ ID NO: 14, respectively.

[0074] In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody, and each of the light chain and heavy chain sequences has 80% or more sequence identity with the heavy chain and light chain amino acid sequences of the antibody moiety of vintrafasp alfa, for example, 90% or more sequence identity, 95% or more sequence identity, 99% or more sequence identity, or 100% sequence identity, and the PD-1 inhibitor still has the ability to bind to PD-L1. In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody, and each of the light chain and heavy chain sequences has 80% or more sequence identity with the heavy chain and light chain amino acid sequences of the antibody moiety of vintrafasp alfa, for example, 90% or more sequence identity, 95% or more sequence identity, 99% or more sequence identity, or 100% sequence identity, and the CDR is completely identical to the CDR of vintrafasp alfa. In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody having an amino acid sequence that differs from the heavy chain and light chain sequences of the antibody moiety of vintrafasp alfa by 50 or fewer, 40 or fewer, or 25 or fewer amino acid residues, and the PD-1 inhibitor still has the ability to bind to PD-L1. In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody having an amino acid sequence that differs from the heavy chain and light chain sequences of the antibody moiety of vintrafasp alfa by 50 or fewer, 40 or fewer, 25 or fewer, or 10 or fewer amino acid residues, and the CDR is completely identical to the CDR of vintrafasp alfa.

[0075] In some embodiments, a TGFβ inhibitor can inhibit the interaction between TGFβ and the TGFβ receptor, and may be, for example, a TGFβ receptor, a TGFβ ligand or receptor-blocking antibody, a small molecule that inhibits the interaction between TGFβ-binding partners, or an inactive mutant TGFβ ligand that binds to the TGFβ receptor and competes with endogenous TGFβ for binding. In some embodiments, a TGFβ inhibitor is a soluble TGFβ receptor (e.g., soluble TGFβ receptor II or III) or a fragment thereof that can bind to TGFβ. In some embodiments, a TGFβ inhibitor is the extracellular domain of human TGFβ receptor II (TGFβRI) or a fragment thereof that can bind to TGFβ. In some embodiments, TGFβRII corresponds to the wild-type human TGF-β receptor type 2 isoform A sequence (e.g., the amino acid sequence of NCBI reference sequence (RefSeq) accession number NP_001020018 (SEQ ID NO: 9)) or the wild-type human TGF-β receptor type 2 isoform B sequence (e.g., the amino acid sequence of NCBI RefSeq accession number NP_003233 (SEQ ID NO: 10)). In some embodiments, the TGFβ inhibitor includes or consists of the sequence corresponding to SEQ ID NO: 11 or a fragment thereof that can bind to TGFβ. For example, the TGFβ inhibitor may correspond to the full-length sequence of SEQ ID NO: 11. Alternatively, it may have an N-terminal deletion. For example, it may have a deletion of 26 or fewer amino acids at the N-terminus of SEQ ID NO: 11, e.g., 14 to 21 or 14 to 26 N-terminal amino acids. In some embodiments, 14, 19, or 21 amino acids at the N-terminus of SEQ ID NO: 11 are deleted. In some embodiments, the TGFβ inhibitor comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. In some embodiments, the TGFβ inhibitor is a protein that is substantially identical to any one of the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, for example, having at least 90% sequence identity, and capable of binding to TGFβ.In another embodiment, the TGFβ inhibitor is a protein that is substantially identical to the amino acid sequence of SEQ ID NO: 11, for example, having at least 90% sequence identity, and capable of binding to TGFβ. In one embodiment, the TGFβ inhibitor is a protein having an amino acid sequence that is identical to SEQ ID NO: 11 by more than 25 amino acids, and capable of binding to TGFβ.

[0076] In some embodiments, the TGFβ inhibitor is a protein that is substantially identical to the amino acid sequence of bintrafusp alfa's TGFβR, for example, having at least 90% sequence identity and still being able to bind to TGFβ. In some embodiments, the TGFβ inhibitor is a protein that has an amino acid sequence that differs from bintrafusp alfa's TGFβR by 50 or fewer, 40 or fewer, or 25 or fewer amino acid residues, and is still able to bind to TGFβ. In some embodiments, the TGFβ inhibitor has 100 to 160 amino acid residues or 110 to 140 amino acid residues. In some embodiments, the amino acid sequence of the TGFβ inhibitor is selected from the group consisting of sequences corresponding to positions 1 to 136 of bintrafusp alfa's TGFβR, sequences corresponding to positions 20 to 136 of bintrafusp alfa's TGFβR, and sequences corresponding to positions 22 to 136 of bintrafusp alfa's TGFβR.

[0077] In some embodiments, the TGFβ inhibitor is reldelimumab, XPA681, XPA089, LY2382770, LY3022859, 1D11, 2G7, AP11014, A-80-01, LY364947, LY550410, LY580276, LY566578, SB-505124, SD-093, SD-208, SB-431542, ISTH0036, ISTH0047, garnicertib (LY2157299 monohydrate, a small molecule kinase inhibitor of TGF-βRI), LY3200882 (Pei et al. (2017) CANCER RES 77 (13 Suppl): Small molecule kinase inhibitors (TGF-βRI) disclosed in Abstract 955, meterimumab (antibody targeting TGF-β1, see Colak et al. (2017) TRENDS CANCER 3(1):56-71), fresolimmab (GC-1008; antibody targeting TGF-β1 and TGF-β2), XOMA089 (antibody targeting TGF-β1 and TGF-β2, see Mirza et al. (2014) INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 55:1121), AVID200 (TGF-β1 and TGF-β3 trap, see Thwaites et al. (2017) BLOOD 130:2532), Travedersen / AP12009 (TGF-β2 antisense oligonucleotide, see Jaschinski et al. The selection is made from the group consisting of (see al. (2011) CURR PHARM BIOTECHNOL. 12(12):2203-13), Belagen-pumatucel-L (a tumor cell vaccine that targets TGF, see, for example, Giaccone et al. (2015) EUR J CANCER 51(16):2321-9), and TGB-β pathway targeters described in Colak et al. (2017) (including Ki26894, SD208, SM16, IMC-TR1, PF-03446962, TEW-7197, and GW788388).

[0078] In some embodiments, the PD-1 inhibitor and the TGFβ inhibitor are fused, for example, as an anti-PD(L)1:TGFβRII fusion protein. In some embodiments, the fusion molecule is an anti-PD-1:TGFβRII fusion protein or an anti-PD-L1:TGFβRII fusion protein. In some embodiments, the anti-PD(L)1:TGFβRII fusion protein is one of the anti-PD(L)1:TGFβRII fusion proteins disclosed in WO2015 / 118175, WO2018 / 205985, WO2020 / 014285, or WO2020 / 006509. In some embodiments, the N-terminus of the TGFβRII or fragment thereof sequence is fused to the C-terminus of each heavy chain sequence or fragment thereof of the antibody. In some embodiments, the antibody or fragment thereof and the extracellular domain or fragment thereof of TGFβRII are genetically fused via a linker sequence. In some embodiments, the linker sequence is a short, flexible peptide. In one embodiment, the linker array is (G4S)XG, where x is 3 to 6, for example, 4 to 5 or 4.

[0079] An example of an anti-PD-L1:TGFβRII fusion protein is shown in Figure 2. The depicted heterotetramer consists of two sequences, each containing two light chain sequences of an anti-PD-L1 antibody and a heavy chain sequence of an anti-PD-L1 antibody, the C-terminus of which is genetically fused to the N-terminus of the extracellular domain or fragment thereof of TGFβRII via a linker sequence.

[0080] In one embodiment, the extracellular domain of TGFβRII of the anti-PD(L)1:TGFβRII fusion protein or a fragment thereof has an amino acid sequence that is not different from SEQ ID NO: 11 by more than 25 amino acids and can bind to TGFβ. In some embodiments, the anti-PD-L1:TGFβRII fusion protein is one of the anti-PD-L1:TGFβRII fusion proteins disclosed in WO2015 / 118175, WO2018 / 205985, or WO2020 / 006509. For example, the anti-PD-L1:TGFβRII fusion protein may contain the light chain sequence and heavy chain sequence of SEQ ID NO: 1 and SEQ ID NO: 3 of WO2015 / 118175, respectively. In another embodiment, the anti-PD-L1:TGFβRII fusion protein is one of the constructs listed in Table 2 of WO2018 / 205985, for example, construct 9 or 15. In other embodiments, an antibody having the heavy chain sequence of SEQ ID NO: 11 and the light chain sequence of SEQ ID NO: 12 of International Publication No. 2018 / 205985 is fused to the TGFβRII extracellular domain sequence of SEQ ID NO: 14 (where x is 4 to 5) or SEQ ID NO: 15 (where x is 5) of WO2018 / 205985 via a linking sequence (G4S)xG (where x is 4 to 5). In another embodiment, the anti-PD-L1:TGFβRII fusion protein is SHR1701. In a further embodiment, the anti-PD-L1:TGFβRII fusion protein is one of the fusion molecules disclosed in WO2020 / 006509. In one embodiment, the anti-PD-L1:TGFβRII fusion protein is Bi-PLB-1, Bi-PLB-2, or Bi-PLB-1.2 disclosed in WO2020 / 006509. In one embodiment, the anti-PD-L1:TGFβRII fusion protein is Bi-PLB-1.2 disclosed in WO2020 / 006509. In one embodiment, the anti-PD-L1:TGFβRII fusion protein includes SEQ ID NOs. 128 and 95 disclosed in WO2020 / 006509.In some embodiments, the amino acid sequences of the light chain and heavy chain of the anti-PD-L1:TGFβRII fusion protein correspond to light chain and heavy chain sequences selected from the group consisting of (1) SEQ ID NOs. 7 and 8, (2) SEQ ID NOs. 15 and 17, (3) SEQ ID NOs. 15 and 18 of this disclosure, and (4) SEQ ID NOs. 128 and 95 disclosed in International Publication No. 2020 / 006509, respectively. In some embodiments, the anti-PD-L1:TGFβRII fusion protein can still bind to PD-L1 and TGFβ, and the amino acid sequences of its light chain and heavy chain are substantially sequence-identical, for example, at least 90%, to the light chain and heavy chain sequences selected from the group consisting of (1) SEQ ID NOs. 7 and 8, (2) SEQ ID NOs. 15 and 17, (3) SEQ ID NOs. 15 and 18 of this disclosure, and (4) SEQ ID NOs. 128 and 95 disclosed in WO2020 / 006509, respectively. In some embodiments, the amino acid sequences of the light chain and heavy chain of the PD-1 inhibitor of the anti-PD-L1:TGFβRII fusion protein differ from the light chain and heavy chain sequences of the antibody portion of vintrafusp alfa by 50 or fewer, 40 or fewer, 25 or fewer, or 10 or fewer amino acid residues, respectively, and the CDR is completely identical to that of vintrafusp alfa, and / or the PD-1 inhibitor can still bind to PD-L1. In some embodiments, the amino acid sequence of the anti-PD-L1:TGFβRII fusion protein is substantially identical to that of vintrafusp alfa, for example, having at least 90% sequence identity, and can bind to PD-L1 and TGF-p. In some embodiments, the amino acid sequence of the anti-PD-L1:TGFβRII fusion protein corresponds to the amino acid sequence of vintrafusp alfa. In some embodiments, the anti-PD-L1:TGFβRII fusion protein is vintrafusp alfa.

[0081] In certain embodiments, the anti-PD-1:TGFβRII fusion protein is one of the fusion molecules disclosed in WO2020 / 014285, for example, shown in Figure 4 therein, or described in Example 1 (including those specified in Tables 2-9), as specified in Table 16 therein, which bind to both PD-1 and TGF-β, and in particular, a fusion protein comprising a sequence that binds to both PD-1 and TGF-β and is substantially identical to SEQ ID NO: 15 or SEQ ID NO: 296, for example, having at least 90% sequence identity, and a sequence that is substantially identical to SEQ ID NO: 16, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 294, or SEQ ID NO: 295, for example, having at least 90% sequence identity. In one embodiment, the anti-PD-1:TGFβRII fusion protein comprises SEQ ID NO: 15 and SEQ ID NO: 16 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 15 and 143 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 15 and 144 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 15 and 145 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 15 and 294 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 15 and 295 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 296 and 16 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 296 and 143 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 296 and 144 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 296 and 145 of WO2020 / 014285.In one embodiment, the anti-PD-1:TGFβRII fusion protein comprises SEQ ID NOs. 296 and 294 of WO2020 / 014285. In one embodiment, the anti-PD-1:TGFβRII fusion protein comprises SEQ ID NOs. 296 and 295 of WO2020 / 014285. In a further embodiment, the anti-PD-1:TGFβRII fusion protein is one of the fusion molecules disclosed in WO2020 / 006509. In one embodiment, the anti-PD-1:TGFβRII fusion protein is Bi-PB-1, Bi-PB-2, or Bi-PB-1.2 disclosed in WO2020 / 006509. In one embodiment, the anti-PD-1:TGFβRII fusion protein is Bi-PB-1.2 disclosed in WO2020 / 006509. In one embodiment, the anti-PD-1:TGFβRII fusion protein includes SEQ ID NOs. 108 and 93 disclosed in WO2020 / 006509.

[0082] In some embodiments, the PARP inhibitor competitively binds to a site on the NAD+PARP enzyme and / or immobilizes the PARP enzyme on damaged DNA. In some embodiments, the PARP inhibitor inhibits PARP1 and / or PARP2. In some embodiments, the PARP inhibitor inhibits PARP1. In some embodiments, the PARP inhibitor is a nicotinamide analog. In some embodiments, the PARP inhibitor is ABT-767, AZD2461, BGP15, CEP8983, CEP9722, DR2313, E7016, E7449, fluzoparib, IMP4297, INO1001, JPI289, JPI547, monoclonal antibody B3-LysPE40 conjugate, MP124, NU1025, NU1064, NU1076, NU1085, O The group consists of NO2231, PD128763, olaparib, rucaparib, R503, R554, niraparib, SBP101, SC101914, simiparib, thalazoparib, beriparib, pamiparib, WW46, 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine-4-ol, nicotinamide, and theophylline. In some embodiments, the PARP inhibitor is selected from the group consisting of the compounds and their derivatives. In some embodiments, the PARP inhibitor is selected from the group consisting of olaparib, rucaparib, niraparib, thalazoparib, beriparib, pamiparib, nicotinamide, and theophylline. In some embodiments, the PARP inhibitor is selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, veliparib, and pamiparib. In some embodiments, the PARP inhibitor is niraparib.

[0083] Niraparib, which is (3S)-3-[4-{7-(aminocarbonyl)-2H-indazole-2-yl}phenyl]piperidine, is an orally available, potent poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP)-1 and -2 inhibitor. The structure of niraparib is as follows: [ka]

[0084] The empirical molecular formula for niraparib is C 26 H 30 It is N4O5S with a molecular weight of 510.61. The drug substance, niraparib tosylate monohydrate, is a white to off-white, non-hygroscopic crystalline solid. The solubility of niraparib is pH-independent below pKa 9.95, and the solubility in free base aqueous solution is 0.7 mg / mL to 1.1 mg / mL across the entire physiological pH range. Niraparib is a potent and selective PARP-1 and PARP-2 inhibitor, with inhibitory concentrations of 50% (IC) of the control, respectively. 50 Niraparib has IC50s of approximately 3.8 nM and 2.1 nM, and is at least 100 times more selective than other PARP family members. In various cell lines, niraparib stimulates PARP activity as a result of DNA damage induced by the addition of hydrogen peroxide to approximately 4 nM and 50 nM IC50s of the control. 50 and 90% inhibitory concentration (IC 90 ) inhibits each of them.

[0085] In some embodiments, niraparib can be prepared as a pharmaceutically acceptable salt. Those skilled in the art will understand that such salt forms may exist as solvated or hydrated polymorphs. In one embodiment, niraparib is prepared in the form of a hydrate.

[0086] In some embodiments, niraparib is prepared in the form of a tosylate. In one embodiment, niraparib is prepared in the form of a tosylate monohydrate.

[0087] Niraparib crystalline tosylate monohydrate is being developed as a monotherapy for tumors with defects in the homologous recombination (HR) deoxyribonucleic acid (DNA) repair pathway, as well as as a sensitizer in combination with cytotoxic agents and radiotherapy.

[0088] Pharmaceutically acceptable salts include, in particular, those listed in Berge, J. Pharm. Sci., 1977, 66, 1-19, or those enumerated in PH Stahl and CG Wermuth, editors, Handbook of Pharmaceutical Salts; Properties, Selection and Use, Second Edition Stahl / Wermuth: Wiley-VCH / VHCA, 2011. Preferred pharmaceutically acceptable salts may include acid or base addition salts.

[0089] Representative pharmaceutically acceptable acid addition salts include 4-acetamidebenzoate, acetate, adipine, alginate, ascorbate, aspartate, benzenesulfonate (besilate), benzoate, bisulfate, tartrate, butyrate, calcium edetate, camphorate, camphor sulfonate (cansilate), caprate (decanoate), caproate (hexanoate), caprylate (octanoate), cinnamate, citrate, cyclamate, digluconate, 2,5-dihydroxybenzoate, disuccinate, and dodecyl sulfate (estolate). Salts (estolate), edetate (ethylenediaminetetraacetate), estolate (lauryl sulfate), ethane-1,2-disulfonate (edisylate), ethanesulfonate (esylate), formate, fumarate, galactarate (mucinate), gentisinate (2,5-dihydroxybenzoate), glucoheptonate (gluceptate), gluconate, glucuronate, glutamate, glutarate, glycerophosphate, glycolate, hexylresorcinate, hippurate, hydravamin (N,N'-di(dehydroabiethyl) Telydiamine), hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate (mesylate), methylsulfate, mucinate, naphthalene-1,5-disulfonate (napadisylate), naphthalene-2-sulfonate (napsylate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminosalicylate, pamoate (embonate), pantothenic acid This includes, but is not limited to, salts, pectinates, persulfates, phenylacetates, phenylethyl barbiturates, phosphates, polygalacturonic acid salts, propionates, p-toluenesulfonates (tosate), pyroglutamates, pyruvates, salicylates, sebacinates, stearates, acetates, succinates, sulfamates, sulfates, tannates, tartrates, theoclates (8-chlorotheophylline), thiocyans, triethiodides, undecanoates, undecylenates, and valersates.

[0090] Typical pharmaceutically acceptable base addition salts include aluminum, 2-amino-2-(hydroxymethyl)-1,3-propanediol (TRIS), arginine, benetamine (N-benzylphenethylamine), benzathine (N,N'-dibenzylethylenediamine), bis-(2-hydroxyethyl)amine, bismuth, calcium, chloroprocaine, choline, cremisole (1-p-chlorobenzyl-2-pyrroridine-1'-ylmethylbenzimidazole), cyclohexylamine, and dibenzylethylenediamine. This includes, but is not limited to, amines, diethylamine, diethyltriamine, dimethylamine, dimethylethanolamine, dopamine, ethanolamine, ethylenediamine, L-histidine, iron, isoquinoline, lepidine, lithium, lysine, magnesium, meglumine (N-methylglucamine), piperazine, piperidine, potassium, procaine, quinine, quinoline, sodium, strontium, t-butylamine, tromethamine (tris(hydroxymethyl)aminomethane), and zinc.

[0091] In one embodiment, the therapeutic combination of the present invention is used for the treatment of human subjects. The main benefit expected from treatment with the therapeutic combination is an improvement in the risk / benefit ratio of these human patients. Administration of the combination of the present invention may be more advantageous than individual administration of a single therapeutic agent in that the combination may provide one or more of the following improved characteristics: i) greater anticancer effect than the most active single agent, ii) synergistic or highly synergistic anticancer activity, iii) administration protocols that result in enhanced anticancer activity while reducing the side effect profile, iv) reduced toxicity profile, v) increased therapeutic concentration range, and / or vi) increased bioavailability of one or both therapeutic agents.

[0092] In certain embodiments, the present invention provides treatments for diseases, disorders, and conditions characterized by excessive or abnormal cell proliferation. Such diseases include proliferative or hyperproliferative disorders. Examples of proliferative and hyperproliferative disorders include cancer and myeloproliferative disorders.

[0093] In another embodiment, cancer is selected from carcinomas, lymphomas, leukemias, blastomas, and sarcomas. More specific examples of such cancers include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer, glioma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, liver cancer, breast cancer, colon cancer, biliary tract cancer, and head and neck cancer. The disease or medical disorder of interest may be selected from any of those disclosed in WO2015118175, WO2018029367, WO2018208720, PCT / US18 / 12604, PCT / US19 / 47734, PCT / US19 / 40129, PCT / US19 / 36725, PCT / US19 / 732271, PCT / US19 / 38600, or PCT / EP2019 / 061558.

[0094] In various embodiments, the methods of the present invention are used as first-line, second-line, third-line, or further treatment options. Treatment options refer to the sequence of treatments with different drugs or other therapies received by the patient. A first-line therapy regimen is the first treatment performed, while a second-line or third-line therapy is performed after the first-line or second-line therapy, respectively. Thus, a first-line therapy is the initial treatment for a disease or condition. In cancer patients, a first-line therapy, also called primary therapy or primary treatment, may be surgery, chemotherapy, radiation therapy, or a combination of these therapies. Typically, a patient receives a subsequent chemotherapy regimen (second or third-line therapy) because they have not shown a positive clinical outcome, have only shown a quasi-clinical response to a first-line or second-line therapy, or have shown a positive clinical response but later experience relapse and occasionally have a disease that is resistant to the initial treatment that showed an initial positive response.

[0095] In some embodiments, the therapeutic combinations of the present invention are applicable to subsequent treatment options, particularly second-line and subsequent cancer treatments. There is no limit to the number of previous treatments, as long as the subject has received at least one round of previous cancer treatment. A round of previous cancer treatment refers to a defined schedule / period for treating the subject with, for example, one or more chemotherapy agents, radiotherapy, or chemoradiotherapy, and the subject has failed in such previous treatment, and the treatment has either been completed or terminated earlier than scheduled. One reason may be that the cancer was resistant to or became resistant to the previous treatment. Current standards of care (SoCs) for treating cancer patients often involve the administration of toxic, older chemotherapy regimens. Such SoCs are associated with a high risk of severe adverse events (such as secondary cancers) that can impair quality of life. In one embodiment, a combination of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor may be as effective as a SoC in cancer patients, but with better tolerability. Since PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors have different mechanisms of action, it is considered unlikely that administration of the therapeutic treatment of the present invention will lead to an exacerbation of immune-related adverse events (irAEs).

[0096] In one embodiment, PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors are administered as second-line or subsequent treatment for cancers selected from the group of previously treated recurrent metastatic NSCLC, unresectable locally advanced NSCLC, previously treated SCLC ED, SCLC unsuitable for systemic treatment, previously treated relapsing (recurrent) or metastatic SCCHN, recurrent SCCHN eligible for re-irradiation, and previously treated low-frequency microsatellite-unstable (MSI-L) or microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). SCLC and SCCHN are particularly systemically pre-treated. MSI-L / MSS mCRC occurs in 85% of all mCRCs.

[0097] In some embodiments, the cancer has a defect in homologous recombination repair (HRR). In some embodiments, the cancer has a defect in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, PTEN, Rad51, ATM, ATR, CtIP, and MRE11, which causes the HRR defect. In some embodiments, the cancer has a defect in the BRCA1 and / or BRCA2 genes, which causes the HRR defect.

[0098] In one embodiment, cancer exhibits microsatellite instability (MSI). Microsatellite instability ("MSI") is, or includes, a change in the DNA of a particular cell (such as a tumor cell) where the number of microsatellites (short repeat sequences of DNA) differs from the number of repeats present in the inherited DNA. Microsatellite instability results from a failure of the DNA mismatch repair (MMR) system to repair replication-related errors. This failure allows mismatch mutations to persist throughout the genome, but particularly in regions of repeating DNA known as microsatellites, leading to an increased mutational load. At least some tumors characterized by MSI-H have been shown to improve their response to certain anti-PD-1 agents (Le et al. (2015) N.Engl.J.Med. 372(26):2509-2520; Westdorp et al. (2016) Cancer Immunol.Immunother. 65(10):1249-1259).

[0099] In some embodiments, cancer has a microsatellite instability state with high frequency of microsatellite instability (e.g., MSI-H state). In some embodiments, cancer has a microsatellite instability state with low frequency of microsatellite instability (e.g., MSI-L state). In some embodiments, cancer has a microsatellite instability state with microsatellite stability (e.g., MSS state). In some embodiments, the microsatellite instability state is evaluated by next-generation sequencing (NGS) based assays, immunohistochemistry (IHC) based assays, and / or PCR-based assays. In some embodiments, microsatellite instability is detected by NGS. In some embodiments, microsatellite instability is detected by IHC. In some embodiments, microsatellite instability is detected by PCR.

[0100] In some embodiments, cancer is associated with a high tumor mutational load (TMB). In some embodiments, cancer is associated with high TMB and MSI-H. In some embodiments, cancer is associated with high TMB and MSI-L or MSS. In some embodiments, cancer is endometrial cancer associated with high TMB. In some related embodiments, endometrial cancer is associated with high TMB and MSI-H. In some related embodiments, endometrial cancer is associated with high TMB and MSI-L or MSS.

[0101] In some embodiments, the cancer is a mismatch repair deficiency (dMMR) cancer. Microsatellite instability can result from a failure of the DNA mismatch repair (MMR) system to repair replication-related errors. This failure allows for the persistence of mismatch mutations throughout the genome, but particularly in regions of repeating DNA known as microsatellites, leading to increased mutational loads that can improve responses to certain therapeutic agents.

[0102] In some embodiments, the cancer is a hypermutated cancer. In some embodiments, the cancer has a mutation in polymerase epsilon (POLE). In some embodiments, the cancer has a mutation in polymerase delta (POLD).

[0103] In some embodiments, the cancer is endometrial cancer (e.g., MSI-H or MSS / MSI-L endometrial cancer). In some embodiments, the cancer is MSI-H cancer with a mutation in POLE or POLD (e.g., MSI-H non-endometrial cancer with a mutation in POLE or POLD).

[0104] In some embodiments, the cancer is advanced cancer. In some embodiments, the cancer is metastatic cancer. In some embodiments, the cancer is recurrent cancer (e.g., recurrent gynecological cancer, e.g., recurrent epithelial ovarian cancer, recurrent ovarian cancer, fallopian tube cancer, recurrent primary peritoneal cancer, or recurrent endometrial cancer). In one embodiment, the cancer is recurrent or advanced.

[0105] In one embodiment, cancer is selected from appendiceal cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer (especially esophageal squamous cell carcinoma), fallopian tube cancer, gastric cancer, glioma (especially diffuse pontine glioma), head and neck cancer (especially head and neck squamous cell carcinoma and oropharyngeal cancer), leukemia (especially acute lymphoblastic leukemia and acute myeloid leukemia), lung cancer (especially non-small cell lung cancer), lymphoma (especially Hodgkin lymphoma and non-Hodgkin lymphoma), melanoma, mesothelioma (especially malignant pleural mesothelioma), Merkel cell carcinoma, neuroblastoma, oral cancer, osteosarcoma, ovarian cancer, prostate cancer, kidney cancer, salivary gland tumors, sarcomas (especially Ewing's sarcoma or rhabdomyosarcoma), squamous cell carcinoma, soft tissue sarcoma, thymoma, thyroid cancer, urothelial carcinoma, uterine cancer, vaginal cancer, vulvar cancer, or Wilms' tumor. In further embodiments, cancer is selected from appendiceal cancer, bladder cancer, cervical cancer, colorectal cancer, esophageal cancer, head and neck cancer, melanoma, mesothelioma, non-small cell lung cancer, prostate cancer, and urothelial carcinoma. In further embodiments, cancer is selected from cervical cancer, endometrial cancer, head and neck cancer (particularly head and neck squamous cell carcinoma and oropharyngeal cancer), lung cancer (particularly non-small cell lung cancer), lymphoma (particularly non-Hodgkin lymphoma), melanoma, oral cancer, thyroid cancer, urothelial carcinoma, or uterine cancer. In another embodiment, cancer is selected from head and neck cancer (particularly head and neck squamous cell carcinoma and oropharyngeal cancer), lung cancer (particularly non-small cell lung cancer), urothelial carcinoma, melanoma, or cervical cancer.

[0106] In one embodiment, the human has a solid tumor. In one embodiment, the solid tumor is a progressive solid tumor. In one embodiment, the cancer is selected from head and neck cancer, head and neck squamous cell carcinoma (SCCHN or HNSCC), gastric cancer, melanoma, renal cell carcinoma (RCC), esophageal cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer, and pancreatic cancer. In one embodiment, the cancer is selected from the group consisting of colorectal cancer, cervical cancer, bladder cancer, urothelial carcinoma, head and neck cancer, melanoma, mesothelioma, non-small cell lung cancer, prostate cancer, esophageal cancer, and esophageal squamous cell carcinoma. In one embodiment, the human has one or more of SCCHN, colorectal cancer, esophageal cancer, cervical cancer, bladder cancer, breast cancer, head and neck cancer, ovarian cancer, melanoma, renal cell carcinoma (RCC), esophageal squamous cell carcinoma, non-small cell lung cancer, mesothelioma (e.g., pleural malignant mesothelioma), and prostate cancer.

[0107] In another embodiment, a human being may have a liquid tumor, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic lymphoblastic leukemia, follicular lymphoma, acute myeloid leukemia, and chronic myeloid leukemia.

[0108] In one embodiment, the cancer is head and neck cancer. In one embodiment, the cancer is HNSCC. Squamous cell carcinoma is a cancer that arises from specific cells called squamous epithelial cells. Squamous epithelial cells are found in the outer layers of the skin and mucous membranes. Mucous membranes are moist tissues that form the inside of body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) occurs in the mucous membranes of the mouth, nose, and throat. HNSCC is also known as SCCHN and squamous cell carcinoma of the head and neck.

[0109] HNSCC can occur in the mouth (oral cavity), the middle of the throat near the mouth (oropharynx), the space behind the nose (nasal cavity and sinuses), the upper part of the throat near the nasal cavity (nasopharynx), the voice box (larynx), or the lower part of the throat near the larynx (hypopharynx). Depending on the location, the cancer may cause abnormal spots or sores (open sores) (ulcers) in the mouth and throat, abnormal bleeding or pain in the mouth, persistent nasal congestion, sore throat, ear pain, pain or difficulty swallowing, hoarseness, difficulty breathing, or enlarged lymph nodes.

[0110] HNSCC can metastasize to other parts of the body, such as the lymph nodes, lungs, or liver.

[0111] Tobacco use and alcohol consumption are the two most important risk factors for developing HNSCC, and their contribution to risk is synergistic. Furthermore, human papillomavirus (HPV), particularly HPV-16, is now an established independent risk factor. Patients with HNSCC have a relatively poor prognosis. Relapsed / metastatic (R / M) HNSCC is particularly difficult to manage, regardless of the HPV status, and there are currently few effective treatment options available in the field. In HPV-negative HNSCC, the local relapse rate is 19–35% and the distant metastasis rate is 14–22% after standard treatment, compared to 9–18% and 5–12%, respectively, in HPV-positive HNSCC. The median overall survival for patients with R / M disease is 10–13 months in the first-line chemotherapy setting and 6 months in the second-line setting. The current standard treatment is platinum-based doublet chemotherapy with or without cetuximab. Second-line standard treatment options include cetuximab, methotrexate, and taxanes. All of these chemotherapy agents are associated with serious side effects, and only 10-13% of patients respond to treatment. Regression of HNSCC with existing systemic therapies is transient, life expectancy is not significantly extended, and virtually all patients die from the malignancy.

[0112] In one embodiment, the cancer is head and neck cancer. In one embodiment, the cancer is head and neck squamous cell carcinoma (HNSCC). In one embodiment, the cancer is recurrent / metastatic (R / M) HNSCC. In one embodiment, the cancer is recurrent / refractory (R / R) HNSCC. In one embodiment, the cancer is HPV-negative or HPV-positive HNSCC. In one embodiment, the cancer is locally advanced HNSCC. In one embodiment, the cancer is HNSCC such as (R / M) HNSCC in PD-L1-positive patients with ≥1% CPS or ≥50% TPS. CPS or TPS is determined by an FDA or EMA-approved test such as the Dako IHC22C3 PharmDx assay. In one embodiment, the cancer is HNSCC in patients with or without PD-1 inhibitor experience. In one embodiment, the cancer is HNSCC in patients with or without PD-1 inhibitor experience.

[0113] In one embodiment, head and neck cancer is oropharyngeal cancer. In one embodiment, head and neck cancer is oral cancer (i.e., cancer of the mouth).

[0114] In one embodiment, the cancer is lung cancer. In some embodiments, the lung cancer is squamous cell carcinoma of the lung. In some embodiments, the lung cancer is small cell lung cancer (SCLC). In some embodiments, the lung cancer is non-small cell lung cancer (NSCLC), such as squamous NSCLC. In some embodiments, the lung cancer is ALK translocation lung cancer (e.g., ALK translocation NSCLC). In some embodiments, the cancer is NSCLC with an identified ALK translocation. In some embodiments, the lung cancer is EGFR mutation lung cancer (e.g., EGFR mutation NSCLC). In some embodiments, the cancer is NSCLC with an identified EGFR mutation. In one embodiment, the cancer is NSCLC in a PD-L1-positive patient with a TPS of 1% or more or 50% or more. TPS is determined by an FDA or EMA-approved test such as the Dako IHC 22C3 PharmDx assay or the VENTANA PD-L1(SP263) assay.

[0115] In one embodiment, the cancer is melanoma. In some embodiments, the melanoma is progressive melanoma. In some embodiments, the melanoma is metastatic melanoma. In some embodiments, the melanoma is MSI-H melanoma. In some embodiments, the melanoma is MSS melanoma. In some embodiments, the melanoma is POLE mutation melanoma. In some embodiments, the melanoma is POLD mutation melanoma. In some embodiments, the melanoma is high TMB melanoma.

[0116] In one embodiment, the cancer is colorectal cancer. In some embodiments, the colorectal cancer is advanced colorectal cancer. In some embodiments, the colorectal cancer is metastatic colorectal cancer. In some embodiments, the colorectal cancer is MSI-H colorectal cancer. In some embodiments, the colorectal cancer is MSS colorectal cancer. In some embodiments, the colorectal cancer is POLE mutation colorectal cancer. In some embodiments, the colorectal cancer is POLD mutation colorectal cancer. In some embodiments, the colorectal cancer is high TMB colorectal cancer.

[0117] In some embodiments, cancer is gynecological cancer (i.e., cancer of the female reproductive system, such as ovarian cancer, fallopian tube cancer, cervical cancer, vaginal cancer, vulvar cancer, uterine cancer, or primary peritoneal cancer, or breast cancer). In some embodiments, cancer of the female reproductive system includes, but is not limited to, ovarian cancer, fallopian tube cancer, peritoneal cancer, and breast cancer.

[0118] In some embodiments, the cancer is ovarian cancer (e.g., serous or clear cell ovarian cancer). In some embodiments, the cancer is fallopian tube cancer (e.g., serous or clear cell fallopian tube cancer). In some embodiments, the cancer is primary peritoneal cancer (e.g., serous or clear cell primary peritoneal cancer).

[0119] In some embodiments, ovarian cancer is epithelial cancer. Epithelial cancers make up 85% to 90% of ovarian cancers. Historically, it was thought to begin on the surface of the ovary, but new evidence suggests that at least some ovarian cancers begin in specific cells in a part of the fallopian tube. The fallopian tubes are small tubes that connect a woman's ovaries to the uterus, which is part of the female reproductive system. A normal female reproductive system has two fallopian tubes, one on each side of the uterus. Cancer cells that develop in the fallopian tubes can reach the surface of the ovary at an early stage. The term “ovarian cancer” is often used to describe epithelial cancers that arise from the ovaries, fallopian tubes, and the inner lining of the abdominal cavity called the peritoneum. In some embodiments, the cancer is or includes germ cell tumors. Germ cell tumors are a type of ovarian cancer that develops in the egg-producing cells of the ovary. In some embodiments, the cancer is or includes stromal tumors. Stromal tumors develop in the connective tissue cells that hold the ovaries together, and these connective tissue cells may also be the tissue that produces the female hormone called estrogen. In some embodiments, the cancer is or includes a granulosa cell tumor. Granulosa cell tumors secrete estrogen and present with abnormal vaginal bleeding at diagnosis. In some embodiments, the gynecological cancer is associated with homologous recombination repair deficiency / homologous repair deficiency (HRD) and / or BRCA1 / 2 mutations. In some embodiments, the gynecological cancer is platinum-sensitive. In some embodiments, the gynecological cancer responds to platinum-based treatment. In some embodiments, the gynecological cancer has developed resistance to platinum-based treatment. In some embodiments, the gynecological cancer has previously (at one time) shown partial or complete response to platinum-based therapy (e.g., partial or complete response to the last or second-to-last platinum-based therapy). In some embodiments, the gynecological cancer is currently resistant to platinum-based treatment.

[0120] In some embodiments, cancer is breast cancer. Typically, breast cancer arises in the cells or ducts of the mammary gland, known as lobules. Less frequently, breast cancer can arise in the stromal tissue. These include the fatty connective tissue and fibrous connective tissue of the breast. Over time, breast cancer cells can invade nearby tissues, such as the lymph nodes in the armpit or the lungs, in a process known as metastasis. The stage of breast cancer, the size of the tumor, and its growth rate are all factors that determine the type of treatment offered. Treatment options include surgical removal of the tumor, drug therapy including chemotherapy and hormone therapy, radiation therapy, and immunotherapy. Prognosis and survival rates vary considerably, with the 5-year relative survival rate ranging from 98% to 23% depending on the type of breast cancer that develops. Breast cancer is the second most common cancer in the world, with approximately 1.7 million new cases in 2012, and is the fifth leading cause of cancer death, with approximately 521,000 deaths. Of these cases, approximately 15% are triple-negative, meaning they do not express estrogen receptor, progesterone receptor (PR), or HER2. In some embodiments, triple-negative breast cancer (TNBC) is characterized as breast cancer cells that are estrogen receptor negative (less than 1% of cells), progesterone receptor negative (less than 1% of cells), and HER2 negative. In one embodiment, the cancer is a TNBC in a PD-L1-positive patient with 1% or more PD-L1-expressing tumor-infiltrating immune cells (ICs). ICs are determined by FDA or EMA-approved tests such as the Ventana PD-L1 (SP142) assay.

[0121] In some embodiments, the cancer is estrogen receptor (ER) positive breast cancer, ER negative breast cancer, PR positive breast cancer, PR negative breast cancer, HER2 positive breast cancer, HER2 negative breast cancer, BRCA1 / 2 positive breast cancer, BRCA1 / 2 negative breast cancer, or TNBC. In some embodiments, the breast cancer is metastatic breast cancer. In some embodiments, the breast cancer is cancer of the advanced breast. In some embodiments, the cancer is stage II, stage III, or stage IV breast cancer. In some embodiments, the cancer is stage IV breast cancer. In some embodiments, the breast cancer is triple-negative breast cancer.

[0122] In one embodiment, the cancer is endometrial cancer. Endometrial cancer is the most common cancer of the female reproductive organs, accounting for 10-20 cases per 100,000 people per year. The estimated annual number of new cases of endometrial cancer (EC) worldwide is approximately 325,000. Furthermore, EC is the cancer that most frequently occurs in postmenopausal women. Approximately 53% of endometrial cancers occur in developed countries. In 2015, approximately 55,000 cases of EC were diagnosed in the United States, and there are currently no targeted therapies approved for use in EC. Drugs and regimens are needed to improve survival rates for advanced and recurrent EC in 1L and 2L situations. In the United States, approximately 10,170 deaths from EC were projected in 2016. The most common histological form is endometrioid adenocarcinoma, accounting for approximately 75-80% of diagnosed cases. Other histological morphologies include uterine papillary serous (less than 10%), clear cell (4%), mucinous (1%), squamous (less than 1%), and mixed (approximately 10%).

[0123] From a pathogenic standpoint, EC is classified into two distinct types, so-called type I and type II. Type I tumors are low-grade estrogen-associated endometrioid carcinomas (EEC), while type II tumors are non-endometrioid carcinomas (NEEC) (primarily serous and clear cell) carcinomas. The World Health Organization has updated its pathological classification of EC and recognizes nine distinct subtypes, although EEC and serous carcinoma (SC) account for the majority of cases. EEC is an estrogen-associated carcinoma that occurs in perimenopause patients and is preceded by a precursor lesion (endometrial hyperplasia / endometrioid intraepithelial neoplasia). Microscopically, low-grade EEC (EEC1-2) contains tubular glands, somewhat resembles proliferative endometrium, and has a complex structure with glandular fusion and cribriform structures. High-grade EEC shows a solid growth pattern. In contrast, SC occurs in postmenopausal patients without hyperestrogenism. Microscopically, SCs present with thick, fibrous or edematous papillae and marked lamination of undifferentiated cells with tumor cells, cell budding, and large eosinophilic cytoplasm. The majority of EECs are low-grade tumors (grades 1 and 2) and, when limited to the uterus, have a good prognosis. Grade 3 EECs (EEC3) are aggressive tumors with an increased frequency of lymph node metastasis. SCs are highly aggressive, independent of estrogen stimulation, and occur mainly in older women. EEC3 and SCs are considered high-grade tumors. SCs and EEC3s have been compared using data from the Surveillance, Epidemiology, and Final Outcomes (SEER) program from 1988 to 2001. They accounted for 10% and 15% of ECs, respectively, but accounted for 39% and 27% of cancer-related deaths, respectively. Endometrial cancer can also be classified into the following four molecular subgroups: (1) ultramutated / POLE mutation, (2) hypermutated MSI+ (e.g., MSI-H or MSI-L); (3) low copy number / microsatellite stable (MSS); and (4) high copy number / serous-like. Approximately 28% of cases are high-frequency MSI (Murali, Lancet Oncol. (2014)). In some embodiments, the patient has a mismatch repair deficiency subset of 2L endometrial cancer. In some embodiments, the endometrial cancer is metastatic endometrial cancer. In some embodiments, the patient has MSS endometrial cancer.In some embodiments, the patient has MSI-H endometrial cancer.

[0124] In one embodiment, the cancer is cervical cancer. In some embodiments, the cervical cancer is advanced cervical cancer. In some embodiments, the cervical cancer is metastatic cervical cancer. In some embodiments, the cervical cancer is MSI-H cervical cancer. In some embodiments, the cervical cancer is MSS cervical cancer. In some embodiments, the cervical cancer is POLE mutation cervical cancer. In some embodiments, the cervical cancer is POLD mutation cervical cancer. In some embodiments, the cervical cancer is high TMB cervical cancer. In one embodiment, the cancer is cervical cancer in PD-L1-positive patients with 1% or more CPS. CPS is determined by an FDA or EMA-approved test such as the DakoI HC22C3 PharmDx assay.

[0125] In one embodiment, the cancer is uterine cancer. In some embodiments, the uterine cancer is advanced uterine cancer. In some embodiments, the uterine cancer is metastatic uterine cancer. In some embodiments, the uterine cancer is MSI-H uterine cancer. In some embodiments, the uterine cancer is MSS uterine cancer. In some embodiments, the uterine cancer is POLE mutation uterine cancer. In some embodiments, the uterine cancer is POLD mutation uterine cancer. In some embodiments, the uterine cancer is high TMB uterine cancer.

[0126] In one embodiment, the cancer is urothelial carcinoma. In some embodiments, the urothelial carcinoma is advanced urothelial carcinoma. In some embodiments, the urothelial carcinoma is metastatic urothelial carcinoma. In some embodiments, the urothelial carcinoma is MSI-H urothelial carcinoma. In some embodiments, the urothelial carcinoma is MSS urothelial carcinoma. In some embodiments, the urothelial carcinoma is POLE-mutated urothelial carcinoma. In some embodiments, the urothelial carcinoma is POLD-mutated urothelial carcinoma. In some embodiments, the urothelial carcinoma is high-TMB urothelial carcinoma. In one embodiment, the cancer is urothelial carcinoma in a PD-L1-positive patient with ≥10% CPS. CPS is determined by an FDA or EMA-approved test such as the Dako IHC22C3 PharmDx assay. In one embodiment, the cancer is urothelial carcinoma in a PD-L1-positive patient with ≥5% PD-L1-expressing tumor-infiltrating immune cells (ICs). IC is determined by FDA or EMA-approved tests such as the Ventana PD-L1 (SP142) assay.

[0127] In one embodiment, the cancer is thyroid cancer. In some embodiments, the thyroid cancer is advanced thyroid cancer. In some embodiments, the thyroid cancer is metastatic thyroid cancer. In some embodiments, the thyroid cancer is MSI-H thyroid cancer. In some embodiments, the thyroid cancer is MSS thyroid cancer. In some embodiments, the thyroid cancer is POLE mutation thyroid cancer. In some embodiments, the thyroid cancer is POLD mutation thyroid cancer. In some embodiments, the thyroid cancer is high TMB thyroid cancer.

[0128] Tumors may be hematopoietic (or hematologic, hematological, or blood-related) cancers, sometimes referred to as “liquid tumors,” such as cancers originating from blood cells or immune cells. Specific examples of clinical conditions based on hematological malignancies include leukemias, e.g., chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia; plasma cell malignancies, e.g., multiple myeloma, undetermined (or unknown or unknown) monoclonal immunoglobulinemia (MGLIS), and Waldenström macroglobulinemia; and lymphomas, e.g., non-Hodgkin lymphoma, Hodgkin lymphoma, etc.

[0129] In one embodiment, the cancer is gastric cancer (GC) or gastroesophageal junction cancer (GEJ). In one embodiment, the cancer is GC or GEJ in PD-L1-positive patients with 1% or more CPS. CPS is determined by an FDA or EMA-approved test such as the Dako IHC22C3 PharmDx assay.

[0130] In one embodiment, the cancer is esophageal squamous cell carcinoma (ESCC). In one embodiment, the cancer is ESCC in PD-L1-positive patients with 10% CPS. CPS is determined by an FDA or EMA-approved test such as the Dako IHC22C3 PharmDx assay.

[0131] Cancer can be any cancer diagnosed as a hematological malignancy, including both lymphoid and myelogenic malignancies, or characterized by the presence of an abnormal number of blast cells or undesirable cell proliferation. Myelogenic malignancies include, but are not limited to, acute myeloid (or myeloid, myelogenous, or myeloblastic) leukemia (undifferentiated or differentiated), acute promyeloid (or promyelocytic, promyelogenous, or promyeloblastic) leukemia, acute myelomonocytic (or myeloblastic) leukemia, acute monocytic (or monoblastic) leukemia, erythroleukemia, and megakaryocytic (or megakaryoblastic) leukemia. These leukemias are sometimes collectively referred to as acute myeloid (or myeloid, or myelogenous) leukemia. Myelogenic malignancies include, but are not limited to, chronic myelogenous (or myeloid or myeloid) leukemia (CML), chronic myelomonocytic leukemia (CMML), essential thrombocythemia (or thrombocytosis), and polycythemia vera (PCV), as well as myeloproliferative disorders (MPD). Myelogenic malignancies also include myelodysplasia (or myelodysplastic syndromes or MDS), sometimes referred to as refractory anemia (RA), refractory anemia with blast cell proliferation (RAEB), and refractory anemia with transitional blast cell proliferation (RAEBT), as well as myelofibrosis (MFS) with or without idiopathic myeloid metaplasia.

[0132] In one embodiment, the cancer is non-Hodgkin lymphoma. Hematopoietic cancers also include lymphoid malignancies that may affect the lymph nodes, spleen, bone marrow, peripheral blood, and / or extranodal sites. Lymphoid cancers include, but are not limited to, B-cell non-Hodgkin lymphoma (B-NHL). B-NHL may be indolent (or low-grade), intermediate-grade (or aggressive), or high-grade (very aggressive). Indolent B-cell lymphomas include follicular lymphoma (FL); small lymphocytic lymphoma (SLL); marginal zone lymphoma (MZL) (including nodal MZL, extranodal MZL, splenic MZL, and splenic MZL with choriolymphocytes); lymphoplasmacytic lymphoma (LPL); and mucosa-associated lymphoid tissue (MALT or extranodal marginal zone) lymphoma. Intermediate-grade B-NHL includes mantle cell lymphoma (MCL) with or without leukemia, diffuse large B-cell lymphoma (DLBCL), follicular large B-cell (or grade 3 or grade 3B) lymphoma, and primary mediastinal lymphoma (PML). High-grade B-NHL includes Burkitt lymphoma (BL), Burkitt-like lymphoma, small non-incisional nuclear cell lymphoma (SNCCL), and lymphoblastic lymphoma. Other B-NHLs include immunoblastic lymphoma (or immunocytoma), primary exudative lymphoma, HIV-associated (or AIDS-associated) lymphoma, and post-transplant lymphoproliferative disorder (PTLD) or lymphoma. B-cell malignancies also include, but are not limited to, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), Waldenström macroglobulinemia (WM), hairy cell leukemia (HCL), large granular lymphocyte (LGL) leukemia, acute lymphoblastic leukemia (or lymphocytic or lymphoblastic) leukemia, and Castleman disease. NHLs may also include, but are not limited to, T-cell non-Hodgkin lymphoma (T-NHL), peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma disorder (AILD), nasal natural killer (NK) cell / T-cell lymphoma, gamma / delta lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, and Sézary syndrome.

[0133] Hematopoietic cancers also include Hodgkin lymphomas (or diseases), including classical Hodgkin lymphoma, nodular sclerosing Hodgkin lymphoma, mixed cell type Hodgkin lymphoma, lymphocyte-predominant (LP) Hodgkin lymphoma, nodular LP Hodgkin lymphoma, and lymphopenic Hodgkin lymphoma. Hematopoietic cancers also include cancers such as plasma cell diseases or multiple myeloma (MM), such as smoldering MM, undetermined (or unknown or unclear) monoclonal immunoglobulinemia (MGLIS), plasmacytoma (bone, extramedullary), lymphoplasmacytic lymphoma (LPL), Waldenström macroglobulinemia, plasma cell leukemia, and primary amyloidosis (AL). Hematopoietic cancers may also include other cancers of additional hematopoietic cells, including polymorphonuclear leukocytes (or neutrophils), basophils, eosinophils, dendritic cells, platelets, erythrocytes, and natural killer cells. Tissues containing hematopoietic cells, referred to herein as “hematopoietic cell tissue,” include bone marrow, peripheral blood; thymus; spleen, and lymph nodes; peripheral lymphoid tissues, such as the spleen, lymph nodes, mucosal lymphoid tissues (such as intestinal lymphoid tissue), tonsils, Peyer’s patches, and appendix, as well as other mucosal lymphoid tissues, such as the lining of the bronchi.

[0134] In one embodiment, the treatment is a first-line or second-line treatment for HNSCC. In one embodiment, the treatment is a first-line or second-line treatment for relapsed / metastatic HNSCC. In one embodiment, the treatment is a first-line treatment for relapsed / metastatic (1LR / M) HNSCC. In one embodiment, the treatment is a first-line treatment for PD-L1-positive 1LR / MHNSCC. In one embodiment, the treatment is a second-line treatment for relapsed / metastatic (2LR / M) HNSCC.

[0135] In one embodiment, the treatment is a first-line, second-line, third-line, fourth-line, or fifth-line treatment for HNSCC that has not experienced PD-1 / PD-L1. In another embodiment, the first-line, second-line, third-line, fourth-line, or fifth-line treatment for PD-1 / PD-L1 is for patients who have experienced HNSCC.

[0136] In some embodiments, the cancer treatment is a first-line treatment for cancer. In one embodiment, the cancer treatment is a second-line treatment for cancer. In some embodiments, the treatment is a third-line treatment for cancer. In some embodiments, the treatment is a fourth-line treatment for cancer. In some embodiments, the treatment is a fifth-line treatment for cancer. In some embodiments, the prior treatment for the above second-line, third-line, fourth-line, or fifth-line treatment for cancer includes one or more of the following: radiotherapy, chemotherapy, surgery, or chemoradiotherapy.

[0137] In one embodiment, previous treatments include, for example, diterpenoids such as paclitaxel, nab-paclitaxel, or docetaxel; vinca alkaloids such as vinblastine, vincristine, or vinorelbine; platinum-coordinated complexes such as cisplatin or carboplatin; nitrogen mustards such as cyclophosphamide, melphalan, or chlorambucil; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; triazenes such as dacarbazine; actinomycins such as dactinomycin; anthrocyclines such as daunorubicin or doxorubicin; bleomycin; and epipodophilotoxins such as etoposide or teniposide. Treatment includes antimetabolite antineoplastic agents such as fluorouracil, methotrexate, cytarabine, mecaptopurine, thioguanine, or gemcitabine; methotrexate; camptothecin such as irinotecan or topotecan; rituximab; ofatumumab; trastuzumab; cetuximab; bexarotene; sorafenib; erbB inhibitors such as lapatinib, erlotinib, or gefitinib; pertuzumab; ipilimumab; nivolumab; FOLFOX; capecitabine; FOLFIRI; bevacizumab; atezolizumab; sericrelumab; obinotuzumab, or any combination thereof. In one embodiment, the prior treatment for the above-mentioned second-line, third-line, fourth-line, or fifth-line treatment of cancer includes ipilimumab and nivolumab. In one embodiment, the prior treatment for the above-mentioned second-line, third-line, fourth-line, or fifth-line treatment of cancer includes FOLFOX, capecitabine, FOLFIRI / bevacizumab, and atezolizumab / sericrelumab. In one embodiment, the prior treatment for the above-mentioned second-line, third-line, fourth-line, or fifth-line treatment of cancer includes carboplatin / nab-paclitaxel. In one embodiment, the prior treatment for the above-mentioned second-line, third-line, fourth-line, or fifth-line treatment of cancer includes nivolumab and electrochemotherapy. In one embodiment, the prior treatment for the above-mentioned second-line, third-line, fourth-line, or fifth-line treatment of cancer includes radiotherapy, cisplatin, and carboplatin / paclitaxel.

[0138] In one embodiment, the treatment is a first-line or second-line treatment for head and neck cancer (particularly head and neck squamous cell carcinoma and oropharyngeal cancer). In one embodiment, the treatment is a first-line or second-line treatment for recurrent / metastatic HNSCC. In one embodiment, the treatment is a first-line treatment for recurrent / metastatic (1LR / M) HNSCC. In one embodiment, the treatment is a first-line treatment for PD-L1-positive 1LR / MHNSCC. In one embodiment, the treatment is a second-line treatment for recurrent / metastatic (2LR / M) HNSCC.

[0139] In one embodiment, the treatment is a first-line, second-line, third-line, fourth-line, or fifth-line treatment for HNSCC that has not experienced PD-1 / PD-L1. In another embodiment, the treatment is a first-line, second-line, third-line, fourth-line, or fifth-line treatment for PD-1 / PD-L1 that has experienced HNSCC.

[0140] In some embodiments, the treatment results in one or more of the following compared to pre-treatment levels (e.g., baseline levels): an increase in tumor-infiltrating lymphocytes, including cytotoxic T cells, helper T cells, and NK cells; an increase in T cells; an increase in granzyme B+ cells; a decrease in proliferating tumor cells; and an increase in activated T cells. Activated T cells may be observed by greater expression of OX40 and human leukocyte antigen DR. In some embodiments, the treatment results in upregulation of PD-1 and / or PD-L1 compared to pre-treatment levels (e.g., baseline levels).

[0141] In one embodiment, the method of the present invention further comprises administering at least one neoplastic agent or cancer adjuvant to the human being. The method of the present invention may also be used in conjunction with other treatment methods for cancer.

[0142] Typically, any antineoplastic agent or adjuvant cancer agent that is active against tumors, such as susceptible tumors to be treated, may be co-administered in the treatment of cancer according to the present invention. Examples of such agents can be found in Cancer Principles and Practice of Oncology by VTDevita, TS Lawrence, and SA Rosenberg (editors), 10th edition (December 5, 2014), Lippincott Williams & Wilkins Publishers.

[0143] In one embodiment, a person has been previously treated with one or more different cancer treatment modalities. In some embodiments, at least a portion of patients in a cancer patient population have been previously treated with one or more therapies, such as surgery, radiotherapy, chemotherapy, or immunotherapy. In some embodiments, at least a portion of patients in a cancer patient population have been previously treated with chemotherapy (e.g., platinum-based chemotherapy). For example, a patient who has received two-choice cancer treatments can be identified as a 2L cancer patient (e.g., a 2L NSCLC patient). In some embodiments, a patient has received a second-line or subsequent-choice cancer treatment (e.g., a 2L+ cancer patient, such as a 2L+ endometrial cancer patient). In some embodiments, a patient has never been previously treated with antibody therapy, such as anti-PD-1 therapy. In some embodiments, a patient has previously received at least one choice of cancer treatment (e.g., a patient has previously received at least one choice of cancer treatment or at least two choices of cancer treatment). In some embodiments, a patient has previously received at least one choice of treatment for metastatic cancer (e.g., a patient has previously received one or two choices of treatment for metastatic cancer). In some embodiments, the subjects are resistant to treatment with PD-1 inhibitors. In some embodiments, the subjects are resistant to treatment with PD-1 inhibitors. In some embodiments, the method described herein sensitizes the subjects to treatment with PD-1 inhibitors.

[0144] In certain embodiments, the cancer to be treated is PD-L1 positive. For example, in certain embodiments, the cancer to be treated exhibits PD-L1+ expression (e.g., high PD-L1 expression). Methods for detecting biomarkers such as PD-L1 on cancer or tumors are commonplace in the art and are intended herein. Non-limiting examples include immunohistochemistry, immunofluorescence, and fluorescence-activated cell sorting (FACS). In some embodiments, subjects or patients with high PD-L1 cancer are treated by intravenous administration of anti-PD(L)1:TGFβRII fusion protein at a dose of approximately 1200 mg over Q2W. In some embodiments, subjects or patients with high PD-L1 cancer are treated by intravenous administration of anti-PD(L)1:TGFβRII fusion protein at a dose of approximately 1800 mg over Q3W. In some embodiments, subjects or patients with high PD-L1 cancer are treated by intravenous administration of anti-PD(L)1:TGFβRII fusion protein at a dose of approximately 2100 mg over Q3W. In some embodiments, subjects or patients with high PD-L1 cancer are treated by intravenous administration of anti-PD(L)1:TGFβRII fusion protein at a dose of approximately 2400 mg over Q3W. In some embodiments, subjects or patients with high PD-L1 cancer are treated by intravenous administration of anti-PD(L)1:TGFβRII fusion protein at a dose of approximately 15 mg / kg over Q3W.

[0145] In certain embodiments, the administration regimen includes one or more PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in doses of approximately 0.01 to 3000 mg (for example, approximately 0.01 mg; approximately 0.08 mg; approximately 0.1 mg; approximately 0.24 mg; approximately 0.8 mg; approximately 1 mg; approximately 2.4 mg; approximately 8 mg; approximately 10 mg; approximately 20 mg; approximately 24 mg; approximately 30 mg; approximately 40 mg; approximately 48 mg; approximately 50 mg; approximately 60 mg; approximately 70 mg; approximately 80 mg; approximately 90 mg; approximately 100 mg; approximately 160 mg; approximately 200 mg; approximately 240 mg; approximately 300 mg; approximately 4 This includes administering the drug in doses of 00 mg; approximately 500 mg; approximately 600 mg; approximately 700 mg; approximately 800 mg; approximately 900 mg; approximately 1000 mg; approximately 1100 mg; approximately 1200 mg; approximately 1300 mg; approximately 1400 mg; approximately 1500 mg; approximately 1600 mg; approximately 1700 mg; approximately 1800 mg; approximately 1900 mg; approximately 2000 mg; approximately 2100 mg; approximately 2200 mg; approximately 2300 mg; approximately 2400 mg; approximately 2500 mg; approximately 2600 mg; approximately 2700 mg; approximately 2800 mg; approximately 2900 mg; or approximately 3000 mg. In some embodiments, the dose of one or more of the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor is about 0.001 to 100 mg / kg (for example, a dose of about 0.001 mg / kg; a dose of about 0.003 mg / kg; a dose of about 0.01 mg / kg; a dose of about 0.03 mg / kg; a dose of about 0.1 mg / kg; a dose of about 0.3 mg / kg; a dose of about 1 mg / kg; a dose of about 2 mg / kg; a dose of about 3 mg / kg; a dose of about 10 mg / kg; a dose of about 15 mg / kg; or a dose of about 30 mg / kg).

[0146] In certain embodiments, the administration regimen is an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, in doses of approximately 0.01 to 3000 mg (e.g., approximately 0.01 mg; approximately 0.08 mg; approximately 0.1 mg; approximately 0.24 mg; approximately 0.8 mg; approximately 1 mg; approximately 2.4 mg; approximately 8 mg; approximately 10 mg; approximately 20 mg; approximately 24 mg; approximately 30 mg; approximately 40 mg; approximately 48 mg; approximately 50 mg; approximately 60 mg; approximately 70 mg; approximately 80 mg; approximately 90 mg; approximately 100 mg; approximately 160 mg; approximately 200 mg; approximately 240 mg; approximately 3 00mg dose; approximately 400mg dose; approximately 500mg dose; approximately 600mg dose; approximately 700mg dose; approximately 800mg dose; approximately 900mg dose; approximately 1000mg dose; approximately 1100mg dose; approximately 1200mg dose; approximately 1300mg dose; approximately 1400mg dose; approximately 1500mg dose; approximately 1600mg dose; approximately 1700mg dose; This includes administering the drug in doses of approximately 1800 mg; approximately 1900 mg; approximately 2000 mg; approximately 2100 mg; approximately 2200 mg; approximately 2300 mg; approximately 2400 mg; approximately 2500 mg; approximately 2600 mg; approximately 2700 mg; approximately 2800 mg; approximately 2900 mg; or approximately 3000 mg. In some embodiments, the dose is approximately 500 mg. In some embodiments, the dose is approximately 1200 mg. In some embodiments, the dose is approximately 2400 mg. In some embodiments, the dose of an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is about 0.001 to 100 mg / kg (e.g., a dose of about 0.001 mg / kg; a dose of about 0.003 mg / kg; a dose of about 0.01 mg / kg; a dose of about 0.03 mg / kg; a dose of about 0.1 mg / kg; a dose of about 0.3 mg / kg; a dose of about 1 mg / kg; a dose of about 2 mg / kg; a dose of about 3 mg / kg; a dose of about 10 mg / kg; a dose of about 15 mg / kg; or a dose of about 30 mg / kg).

[0147] All fixed doses disclosed herein are considered equivalent to body weight administration based on a reference body weight of 80 kg. Therefore, where a fixed dose of 2400 mg is referred to, a dose of 30 mg / kg body weight is disclosed alongside it.

[0148] In some embodiments, the light and heavy chain sequences of the anti-PD(L)1:TGFβRII fusion protein correspond to SEQ ID NO: 15 and SEQ ID NO: 17 or SEQ ID NO: 15 and SEQ ID NO: 18, respectively, and the dose of the anti-PD(L)1:TGFβRII fusion protein is 30 mg / kg.

[0149] In one embodiment, one or more of the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered once every 2 to 6 weeks (e.g., 2, 3, or 4 weeks, particularly 3 weeks). In one embodiment, one or more of the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered once every 2 weeks ("Q2W"). In one embodiment, one or more of the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered once every 3 weeks ("Q3W"). In one embodiment, one or more of the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered once every 6 weeks ("Q6W"). In one embodiment, one or more of the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered at Q3W over 2 to 6 administration cycles (e.g., the first 3, 4, or 5 administration cycles, particularly the first 4 administration cycles).

[0150] In one embodiment, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered once every 2 to 6 weeks (e.g., 2, 3, or 4 weeks, particularly 3 weeks). In one embodiment, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered in Q2W. In one embodiment, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered in Q3W. In one embodiment, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered in Q6W. In one embodiment, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered in Q3W over 2 to 6 administration cycles (e.g., the first 3, 4, or 5 administration cycles, particularly the first 4 administration cycles).

[0151] In some embodiments, the light and heavy chain sequences of the anti-PD(L)1:TGFβRII fusion protein correspond to SEQ ID NOs. 15 and 17 or SEQ ID NOs. 15 and 18, respectively, and the anti-PD(L)1:TGFβRII fusion protein is administered during Q3W.

[0152] In certain embodiments, approximately 1200 mg of anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered to the subject at Q2W. In certain embodiments, approximately 2400 mg of anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered to the subject at Q3W.

[0153] In some embodiments, the light and heavy chain sequences of the anti-PD(L)1:TGFβRII fusion protein correspond to SEQ ID NOs. 15 and 17 or SEQ ID NOs. 15 and 18, respectively, and the anti-PD(L)1:TGFβRII fusion protein is administered at a dose of 30 mg / kg during Q3W.

[0154] In some embodiments, the administration regimen involves a dose of PARP inhibitor ranging from approximately 0.01 to 5000 mg (for example, approximately 0.01 mg; approximately 0.08 mg; approximately 0.1 mg; approximately 0.24 mg; approximately 0.8 mg; approximately 1 mg; approximately 2.4 mg; approximately 8 mg; approximately 10 mg; approximately 20 mg; approximately 24 mg; approximately 30 mg; approximately 40 mg; approximately 48 mg; approximately 50 mg; approximately 60 mg; approximately Dosages of 70 mg; approximately 80 mg; approximately 90 mg; approximately 100 mg; approximately 160 mg; approximately 200 mg; approximately 240 mg; approximately 300 mg; approximately 400 mg; approximately 500 mg; approximately 600 mg; approximately 700 mg; approximately 800 mg; approximately 900 mg; approximately 1000 mg; approximately 1100 mg; approximately 1200 mg; approximately 1300 mg; approximately 1400 mg; approximately 1500 mg Dosage; approximately 1600 mg; approximately 1700 mg; approximately 1800 mg; approximately 1900 mg; approximately 2000 mg; approximately 2100 mg; approximately 2200 mg; approximately 2300 mg; approximately 2400 mg; approximately 2500 mg; approximately 2600 mg; approximately 2700 mg; approximately 2800 mg; approximately 2900 mg; approximately 3000 mg; approximately 3100 mg; approximately 3200 mg; approximately 3300 mg; This includes administering the drug in doses of approximately 3400 mg; approximately 3500 mg; approximately 3600 mg; approximately 3700 mg; approximately 3800 mg; approximately 3900 mg; approximately 4000 mg; approximately 4100 mg; approximately 4200 mg; approximately 4300 mg; approximately 4400 mg; approximately 4500 mg; approximately 4600 mg; approximately 4700 mg; approximately 4800 mg; approximately 4900 mg; or approximately 5000 mg.In some embodiments, the dose of the PARP inhibitor is about 0.001 to 100 mg / kg (for example, a dose of about 0.001 mg / kg; a dose of about 0.003 mg / kg; a dose of about 0.01 mg / kg; a dose of about 0.03 mg / kg; a dose of about 0.1 mg / kg; a dose of about 0.3 mg / kg; a dose of about 1 mg / kg; a dose of about 2 mg / kg; a dose of about 3 mg / kg; a dose of about 10 mg / kg; a dose of about 15 mg / kg; or a dose of about 30 mg / kg). In one embodiment, such a dose of the PARP inhibitor is administered orally.

[0155] In some embodiments, the therapeutically effective dose of the PARP inhibitor is determined according to baseline body weight. In some embodiments, if the baseline body weight is 77 kg or greater, the therapeutically effective dose of the PARP inhibitor is approximately 300 mg. In some embodiments, if the baseline body weight is less than 77 kg, the therapeutically effective dose of the PARP inhibitor is approximately 200 mg.

[0156] In some embodiments, the therapeutically effective dose of the PARP inhibitor is determined according to the baseline platelet count. In some embodiments, if the baseline platelet count is 150,000 / μL or higher, the therapeutically effective dose of the PARP inhibitor is approximately 300 mg. In some embodiments, if the baseline platelet count is less than 150,000 / μL, the therapeutically effective dose of the PARP inhibitor is approximately 200 mg.

[0157] In some embodiments, the effective therapeutic dose of the PARP inhibitor is 300 mg when the baseline body weight is 77 kg or more and / or the baseline platelet count is 150,000 / μL or more. In some embodiments, the effective therapeutic dose of the PARP inhibitor is 200 mg when the baseline body weight is less than 77 kg and / or the baseline platelet count is less than 150,000 / μL.

[0158] In some embodiments, the therapeutic effective dose of a PARP inhibitor may be reduced due to adverse reactions. In some embodiments, the therapeutic effective dose of a PARP inhibitor may be reduced due to hematological adverse reactions. In some embodiments, the therapeutic effective dose of a PARP inhibitor is reduced if the platelet count is less than 100,000 / pL. In some embodiments, the therapeutic effective dose of a PARP inhibitor is reduced if the platelet count is less than 75,000 / μL. In some embodiments, the therapeutic effective dose of a PARP inhibitor may undergo a first dose reduction. In some embodiments, the therapeutic effective dose of a PARP inhibitor may undergo a second dose reduction. In some embodiments, the therapeutic effective dose of a PARP inhibitor is reduced from about 200 mg to about 100 mg. In some embodiments, the therapeutic effective dose of a PARP inhibitor is reduced from about 300 mg to about 200 mg. In some embodiments, the therapeutic effective dose of a PARP inhibitor is reduced from about 300 mg to about 200 mg (first reduction), and then reduced from about 200 mg to about 100 mg (second reduction).

[0159] In one embodiment, the PARP inhibitor is administered once, twice, three, or four times a day. In one embodiment, the PARP inhibitor is administered once a day ("QD"), particularly sequentially. In one embodiment, the PARP inhibitor is administered twice a day ("BID"), particularly sequentially. In one embodiment, the PARP inhibitor is administered three times a day ("TID"), particularly sequentially. In one embodiment, the PARP inhibitor is administered four times a day ("QID"), particularly sequentially.

[0160] In one embodiment, olaparib is administered in a dose of 200 or 300 mg. In one embodiment, olaparib is administered in a BID (Biochemical Intake) dose. In one embodiment, olaparib is administered in a BID dose of 200 or 300 mg. In one embodiment, rucaparib is administered in a dose of 600 mg. In one embodiment, rucaparib is administered in a BID (Biochemical Intake). In one embodiment, rucaparib is administered in a BID dose of 600 mg. In one embodiment, niraparib is administered in a dose of 200 or 300 mg. In one embodiment, niraparib is administered in a QD (Quadruple Intake) dose. In one embodiment, niraparib is administered in a QD dose of 200 or 300 mg. In one embodiment, talazoparib is administered in a dose of 0.75 or 1 mg. In one embodiment, talazoparib is administered in a QD (Quadruple Intake). In one embodiment, talazoparib is administered in a dose of 0.75 or 1 mg via QD. In one embodiment, veliparib is administered in a dose of 150 mg, 240 mg, or 400 mg. In one embodiment, veliparib is administered via BID. In one embodiment, veliparib is administered via BID in a dose of 150 mg, 240 mg, or 400 mg. In one embodiment, pamiparib is administered in a dose of 60 mg. In one embodiment, pamiparib is administered via BID. In one embodiment, pamiparib is administered via BID in a dose of 60 mg.

[0161] In one embodiment, niraparib is administered in a dose of 200 mg or 300 mg, and vintrafusp alfa is administered in a dose of 1200 mg or 2400 mg. In one embodiment, niraparib is administered at QD, and vintrafusp alfa is administered at Q2W or Q3W. In one embodiment, niraparib is administered at QD with a dose of 200 mg or 300 mg, and vintrafusp alfa is administered at Q2W with a dose of 1200 mg or at Q3W with a dose of 2400 mg.

[0162] In addition to treatment with PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors, further combination therapies deemed necessary for the patient's health may be given at the discretion of the attending physician. In some embodiments, the present invention provides a method for treating, stabilizing, or mitigating the severity or progression of one or more diseases or disorders described herein, comprising administering PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in combination with additional therapies such as chemotherapy, radiotherapy, or chemoradiotherapy to a patient in need. In some embodiments, the present invention provides a method for treating, stabilizing, or mitigating the severity or progression of one or more diseases or disorders described herein, comprising administering PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in combination with radiotherapy to a patient in need.

[0163] In one embodiment, radiotherapy is further administered in combination with PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors. In some embodiments, the radiation dose is divided for maximum target cell exposure and reduced toxicity. In some embodiments, the total radiation dose is divided and administered over several days. Thus, the daily radiation dose can include approximately 1–50 Gy / day, for example, at least 1, at least 2, at least 3, 1–4, 1–10, 1–20, 1–50, 2–4, 2–10, 2–20, 2–25, 2–50, 3–4, 3–10, 3–20, 3–25, and 3–50 Gy / day. The daily dose can be administered as a single dose or as a “micro-fractionated” dose administered in two or more doses per day. For example, when an internal radiation source is used in brachytherapy or radioimmunotherapy, the irradiation time typically increases and the radiation intensity decreases accordingly.

[0164] In certain embodiments, radiotherapy involves approximately 35–70 Gy / 20–35 fractions. In some embodiments, radiotherapy is administered five days a week in standard fractions of 1.8–2 Gy per day, giving a total dose of up to 50–70 Gy. Other fraction schedules can also be considered, for example, with a lower dose per fraction but administered twice a day. Higher daily doses can also be administered over shorter periods. In one embodiment, stereotactic radiotherapy and gamma knife are used. In palliative situations, other fraction schedules are also widely used, for example, 25 Gy divided into 5 fractions or 30 Gy divided into 10 fractions.

[0165] In some embodiments, radiation is administered concurrently with a radiosensitizer that enhances tumor cell death or a radioprotective agent (e.g., IL-1 or IL-6) that protects healthy tissue from the harmful effects of radiation. In some embodiments, radiation is administered concurrently with the application of heat, i.e., hyperthermia, or chemotherapy can sensitize tissue to radiation.

[0166] In one embodiment, chemotherapy is further administered in combination with a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor. In one embodiment, chemotherapy is further administered in combination with a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor to patients who have not previously received a PD-1 inhibitor.

[0167] In one embodiment, PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors are administered to PD-L1-positive patients in optional combination with radiotherapy.

[0168] In one embodiment, there are no further treatments in addition to treatment with PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors. In one embodiment, there are no further treatments in addition to treatment with PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and radiotherapy. In one embodiment, in such a selection of treatments, there are no further treatments in addition to treatment with PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors. In one embodiment, in such a selection of treatments, there are no further treatments in addition to treatment with PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and radiotherapy.

[0169] PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and optionally radiotherapy are administered in any amount and via any route of administration that is effective in treating or mitigating the severity of the disorders described above. The exact required dose may vary from patient to patient, depending on the species, age, and general condition of the patient, the severity of the infection, the specific drug, and its mode of administration.

[0170] In some embodiments, PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and optionally radiotherapy are administered simultaneously, separately, sequentially, or in any order. The PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors are administered to the patient in any order (i.e., simultaneously or sequentially), and the compounds may be in separate compositions, formulations, or unit dosage forms, or together in a single composition, formulation, or unit dosage form. In one embodiment, the PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and optionally radiotherapy are administered together in a therapeutically effective amount (e.g., a synergistically effective amount), simultaneously or sequentially, in any order, for example, in a daily dose or intermittent dose corresponding to the amounts described herein. The individual combination partners of PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and optionally radiotherapy may be administered separately or simultaneously at different points in time during the course of treatment. Typically, in such combination therapies, the individual compounds are formulated into separate pharmaceutical compositions or pharmaceuticals. When compounds are formulated separately, the individual compounds can be administered simultaneously, sequentially, or optionally via different routes. Optionally, each treatment regimen of a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and optionally radiotherapy may have different but overlapping delivery regimens (e.g., daily, twice daily, single doses, or weekly). In certain embodiments, the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered simultaneously in the same composition containing the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor, or optionally, simultaneously, separately, or sequentially, in any order, along with radiotherapy. In certain embodiments, the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered simultaneously in separate compositions, i.e., the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor are administered simultaneously in separate unit dosage forms, or optionally, simultaneously, separately, or sequentially, in any order, along with radiotherapy.In some embodiments, the PD-1 inhibitor and the TGFβ inhibitor are fused and administered in separate unit dosage forms from the PARP inhibitor, and the PD-1 inhibitor and the TGFβ inhibitor are administered simultaneously or sequentially, in any order, together with the PARP inhibitor and optionally with radiotherapy. It is understood that the PD-1 inhibitor, TGFβ inhibitor, PARP inhibitor, and optionally with radiotherapy are administered on the same day or on different days, in any order, according to an appropriate administration protocol. Therefore, the present invention should be understood to encompass all such regimens of simultaneous or alternating treatment, and the term “administer” should be interpreted accordingly. In one embodiment, the PD-1 inhibitor and the TGFβ inhibitor are administered at Q2W or Q3W, and the PARP inhibitor is administered at QD or BID.

[0171] In some embodiments, the anti-PD(L)1:TGFβRII fusion protein, PARP inhibitor, and optionally radiotherapy are administered simultaneously, separately, or sequentially, in any order. The anti-PD(L)1:TGFβRII fusion protein and PARP inhibitor are administered to the patient in any order (i.e., simultaneously or sequentially) as separate compositions, formulations, or unit dosage forms, or together in a single composition, formulation, or unit dosage form. In one embodiment, the anti-PD(L)1:TGFβRII fusion protein, PARP inhibitor, and optionally radiotherapy are administered simultaneously or sequentially, in any order, in a therapeutically effective amount (e.g., a synergistically effective amount), for example, in a daily dose or intermittent dose corresponding to the amounts described herein. The individual combination partners of the anti-PD(L)1:TGFβRII fusion protein, PARP inhibitor, and optionally radiotherapy may be administered separately or simultaneously at different points in time during the course of treatment. Typically, in such combination therapies, the individual compounds are formulated into separate pharmaceutical compositions or pharmaceuticals. When formulated separately, the individual compounds can be administered simultaneously or sequentially, or optionally, via different routes. Optionally, each treatment regimen of anti-PD(L)1:TGFβRII fusion, PARP inhibitor, and optionally radiotherapy may have different but overlapping delivery regimens (e.g., daily, twice daily, versus single dose, or weekly). The anti-PD(L)1:TGFβRII fusion protein may be delivered before, substantially simultaneously with, or after the PARP inhibitor and optionally radiotherapy. In certain embodiments, the anti-PD(L)1:TGFβRII fusion protein is administered simultaneously in the same composition containing the anti-PD(L)1:TGFβRII fusion protein and the PARP inhibitor, or optionally simultaneously with radiotherapy. In certain embodiments, the anti-PD(L)1:TGFβRII fusion protein and the PARP inhibitor are administered simultaneously in separate compositions, i.e., the anti-PD(L)1:TGFβRII fusion protein and the PARP inhibitor are administered simultaneously in separate unit dosage forms, and are optionally administered concurrently with radiotherapy.It is understood that anti-PD(L)1:TGFβRII fusion protein, PARP inhibitors, and optionally radiotherapy are administered on the same day or on different days, in any order, according to an appropriate administration protocol. In one embodiment, the anti-PD(L)1:TGFβRII fusion protein is administered, for example, by intravenous infusion or injection, at Q2W or Q3W, and the PARP inhibitor is administered orally at QD or BID. In another embodiment, the anti-PD(L)1:TGFβRII fusion protein is administered, for example, by intravenous infusion or injection, at 1200 mg Q2W or 2400 mg Q3W, and the PARP inhibitor is administered orally at QD or BID in one of the doses indicated for the PARP inhibitor above.

[0172] In some embodiments, one or more of PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and optionally radiotherapy are administered to a patient in need of treatment in a first dose at a first interval over a first period, and in a second dose at a second interval over a second period. Such first and second periods may be the pre-treatment and maintenance periods. In combination of one or more of PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and optionally radiotherapy, there may be a rest period between the first and second periods during which the drug is not administered to the patient. In some embodiments, there is a rest period between the first and second periods. In some embodiments, the rest period is 1 to 30 days. In some embodiments, the rest period is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days. In some embodiments, the rest period is 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, or 15 weeks.

[0173] In some embodiments, the first dose and the second dose are the same. In some embodiments, the first dose and the second dose are different.

[0174] In some embodiments, the first and second doses of the anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, are about 1200 mg. In some embodiments, the first and second doses of the anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, are about 2400 mg. In some embodiments, the first dose of the anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is about 1200 mg, and the second dose is about 2400 mg. In some embodiments, the first dose of the anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is about 2400 mg, and the second dose is about 1200 mg.

[0175] In some embodiments, the first and second intervals are the same. In some embodiments, the first and second intervals are Q2W. In some embodiments, the first and second intervals are Q3W. In some embodiments, the first and second intervals are Q6W. In some embodiments, the first and second intervals are different. In some embodiments, the first interval is Q2W and the second interval is Q3W. In some embodiments, the first interval is Q3W and the second interval is Q6W.

[0176] In some embodiments, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered at a first dose of 1200 mg for Q2W over the first period of 2 to 6 administration cycles (e.g., the first 3, 4, or 5 administration cycles, especially the first 4 administration cycles), and then at a second dose of 2400 mg for Q3W until treatment is discontinued (e.g., due to disease progression, adverse events, or at the physician's discretion). In some embodiments, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered at a first dose of 1200 mg for Q2W over the first 3 administration cycles, and then at a second dose of 2400 mg for Q3W or longer until treatment is discontinued (e.g., due to disease progression, adverse events, or at the physician's discretion). In some embodiments, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered at a first dose of 1200 mg at Q2W for the first four administration cycles, and then at a second dose of 2400 mg at Q3W or later until treatment is discontinued (e.g., due to disease progression, adverse events, or at the physician's discretion). In some embodiments, an anti-PD(L)1:TGFβRII fusion protein, for example having the amino acid sequence of vintrafusp alfa, is administered at a first dose of 1200 mg at Q2W for the first five administration cycles, and then at a second dose of 2400 mg at Q3W or later until treatment is discontinued (e.g., due to disease progression, adverse events, or at the physician's discretion).

[0177] It is understood that there may be an initial treatment consisting of a PARP inhibitor, PD-1 inhibitor, TGFβ inhibitor, and optionally all of the radiotherapy, followed by treatment with a PARP inhibitor, PD-1 inhibitor, TGFβ inhibitor, and optionally all of the radiotherapy. A no-treatment or no-administration period may be provided between the initial administration of a PARP inhibitor, PD-1 inhibitor, TGFβ inhibitor, or a fused PD-1 inhibitor and TGFβ inhibitor to a patient and the administration of a PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor as a combination therapy described herein, for example, over a defined number of cycles. For example, after the initial administration of monotherapy, the patient may not be treated for one or two cycles of 3 weeks, 6 weeks, or 12 weeks before administering the combination therapy described herein. Therefore, in one embodiment, the patient is first administered a PARP inhibitor as monotherapy as described herein, and then the patient is given no treatment for one or two cycles of 3, 6, or 12 weeks before being administered the PARP inhibitor together with a PD-1 inhibitor and a TGFβ inhibitor as combination therapy as described herein. In one embodiment, the patient is first administered a PD-1 inhibitor and / or a TGFβ inhibitor as monotherapy as described herein, and then the patient is given no treatment for one or two cycles of 3, 6, or 12 weeks before being administered the PD-1 inhibitor and a TGFβ inhibitor together with a PARP inhibitor as combination therapy as described herein.

[0178] The compositions of the present invention are administered orally, parenterally, or by inhalation spray, topically, rectally, nasally, orally, vaginally, or via an implanted reservoir. As used herein, the term “parenteral” includes subcutaneous, intravenous, intramuscular, intra-articular, synovial, intrasternal, intrathecal, intrahepatic, intrafocal, and intracranial injection or infusion techniques. In some embodiments, the compositions are administered orally, intraperitoneally, subcutaneously, or intravenously. In one embodiment, the compositions are administered by intravenous infusion or injection. In another embodiment, the compositions are administered by intramuscular or subcutaneous injection. In one embodiment, the anti-PD(L)1:TGFβRII fusion protein is administered by intravenous infusion or injection. In another embodiment, the anti-PD(L)1:TGFβRII fusion protein is administered by intramuscular or subcutaneous injection. In one embodiment, the PARP inhibitor is administered orally. In one embodiment, the anti-PD(L)1:TGFβRII fusion protein is administered by intravenous infusion or injection, and the PARP inhibitor is administered orally.

[0179] In some embodiments, anti-PD(L)1:TGFβRII fusion proteins, such as those having the amino acid sequence of vintrafusp alfa, are administered intravenously (e.g., as intravenous infusion) or subcutaneously. In some embodiments, anti-PD(L)1:TGFβRII fusion proteins, such as those having the amino acid sequence of vintrafusp alfa, are administered as intravenous infusion. In some embodiments, anti-PD(L)1:TGFβRII fusion proteins, such as those having the amino acid sequence of vintrafusp alfa, are administered intravenously in doses of approximately 1200 mg or approximately 2400 mg. In some embodiments, anti-PD(L)1:TGFβRII fusion proteins, such as those having the amino acid sequence of vintrafusp alfa, are administered intravenously in doses of approximately 1200 mg at Q2W. In some embodiments, anti-PD(L)1:TGFβRII fusion proteins, such as those having the amino acid sequence of vintrafusp alfa, are administered intravenously in doses of approximately 2400 mg at Q3W. In some embodiments, an anti-PD(L)1:TGFβRII fusion protein, such as one having the amino acid sequence of vintrafusp alfa, is administered intravenously at a dose of approximately 15 mg / kg during Q3W.

[0180] In some embodiments, the PARP inhibitor is administered orally in a QD or BID at one of the above doses.

[0181] In some embodiments, the patient is first administered a monotherapy regimen of approximately 1200 mg of anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, followed by a combination therapy in which approximately 1200 mg of anti-PD(L)1:TGFβRII fusion protein is administered together with a PARP inhibitor and optionally radiotherapy. In some embodiments, the patient is first administered a monotherapy regimen of approximately 2400 mg of anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, followed by a combination therapy in which approximately 2400 mg of anti-PD(L)1:TGFβRII fusion protein is administered together with a PARP inhibitor and optionally radiotherapy. In some embodiments, the patient is first administered a PARP inhibitor as a monotherapy regimen, and then, as a combination therapy regimen, the PARP inhibitor is administered in a dose of approximately 1200 mg of an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, and optionally with radiotherapy. In some embodiments, the patient is first administered a PARP inhibitor as a monotherapy regimen, and then, as a combination therapy regimen, the PARP inhibitor is administered in a dose of approximately 2400 mg of an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, and optionally with radiotherapy.

[0182] In some embodiments, the combination regimen includes (a) the step of the subject receiving a PD-1 inhibitor and a TGFβ inhibitor before first receiving a PARP inhibitor under the direction or supervision of a physician, and (b) the step of the subject receiving a PARP inhibitor under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving a PARP inhibitor before first receiving a PD-1 inhibitor and a TGFβ inhibitor under the direction or supervision of a physician, and (b) the step of the subject receiving a PD-1 inhibitor and a TGFβ inhibitor under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving a PD-1 inhibitor before first receiving a TGFβ inhibitor and a PARP inhibitor under the direction or supervision of a physician, and (b) the step of the subject receiving a TGFβ inhibitor and a PARP inhibitor under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving a TGFβ inhibitor and a PARP inhibitor before first receiving a PD-1 inhibitor, under the direction or supervision of a physician, and (b) the step of the subject receiving a PD-1 inhibitor, under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving a TGFβ inhibitor before first receiving a PD-1 inhibitor and a PARP inhibitor, under the direction or supervision of a physician, and (b) the step of the subject receiving a PD-1 inhibitor and a PARP inhibitor, under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving a PD-1 inhibitor and a PARP inhibitor before first receiving a TGFβ inhibitor, under the direction or supervision of a physician, and (b) the step of the subject receiving a TGFβ inhibitor, under the direction or supervision of a physician.

[0183] In some embodiments, the combination regimen includes (a) the step of the subject receiving an anti-PD(L)1 antibody and TGFβRII or anti-TGFβ antibody before first receiving a PARP inhibitor, under the direction or supervision of a physician, and (b) the step of the subject receiving a PARP inhibitor, under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving a PARP inhibitor before first receiving an anti-PD(L)1 antibody and TGFβRII or anti-TGFβ antibody, under the direction or supervision of a physician, and (b) the step of the subject receiving an anti-PD(L)1 antibody and TGFβRII or anti-TGFβ antibody, under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving an anti-PD(L)1 antibody before first receiving TGFβRII or anti-TGFβ antibody and PARP inhibitor, under the direction or supervision of a physician, and (b) the step of the subject receiving TGFβRII or anti-TGFβ antibody and PARP inhibitor, under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of receiving TGFβRII or an anti-TGFβ antibody and a PARP inhibitor before first receiving an anti-PD(L)1 antibody under the direction or supervision of a physician, and (b) the step of the subject receiving an anti-PD(L)1 antibody under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of receiving TGFβRII or an anti-TGFβ antibody before first receiving an anti-PD(L)1 antibody and a PARP inhibitor under the direction or supervision of a physician, and (b) the step of the subject receiving an anti-PD(L)1 antibody and a PARP inhibitor under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of receiving an anti-PD(L)1 antibody and a PARP inhibitor before first receiving TGFβRII or an anti-TGFβ antibody under the direction or supervision of a physician, and (b) the step of the subject receiving TGFβRII or an anti-TGFβ antibody under the direction or supervision of a physician.

[0184] In some embodiments, the combination regimen includes (a) the step of the subject receiving an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa, under the direction or supervision of a physician, before receiving a PARP inhibitor first, and (b) the step of the subject receiving a PARP inhibitor under the direction or supervision of a physician. In some embodiments, the combination regimen includes (a) the step of the subject receiving an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa, under the direction or supervision of a physician, before receiving a PARP inhibitor first, and (b) the step of the subject receiving a PARP inhibitor under the direction or supervision of a physician.

[0185] In some embodiments, the combined regimen includes (a) the step of the subject receiving, under the direction or supervision of a physician, an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa and a PARP inhibitor before receiving radiotherapy for the first time, and (b) the step of the subject receiving, under the direction or supervision of a physician, radiotherapy. In some embodiments, the combination regimen includes (a) the step of the subject receiving, under the direction or supervision of a physician, an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa and radiotherapy before first receiving a PARP inhibitor, and (b) the step of the subject receiving, under the direction or supervision of a physician, a PARP inhibitor. In some embodiments, the combined regimen includes (a) the step of the subject receiving a PARP inhibitor and radiotherapy under the direction or supervision of a physician before first receiving an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa, and (b) the step of the subject receiving an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa, under the direction or supervision of a physician.In some embodiments, the combination regimen includes (a) the step of the subject receiving an anti-PD(L)1:TGFβRII fusion protein having, for example, the amino acid sequence of vintrafusp alfa, before first receiving a PARP inhibitor and radiotherapy, under the direction or supervision of a physician, and (b) the step of the subject receiving a PARP inhibitor and radiotherapy, under the direction or supervision of a physician.

[0186] Combinations including a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor are also provided. Combinations including an anti-PD(L)1 antibody, TGFβRII or an anti-TGFβ antibody, and a PARP inhibitor are also provided. Combinations including a PARP inhibitor and a fused PD-1 inhibitor and a TGFβ inhibitor are also provided. Combinations including an anti-PD(L)1:TGFβRII fusion protein and a PARP inhibitor are also provided. In some embodiments, any of the above combinations are intended for use as a pharmaceutical or for use in the treatment of cancer.

[0187] In the various embodiments described above, it should be understood that the PD-1 inhibitor and the TGFβ inhibitor may be fused as, for example, an anti-PD-L1:TGFβRII fusion protein or an anti-PD-1:TGFβRII fusion protein.

[0188] Pharmaceutical preparations and kits The PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors described herein may be in the form of pharmaceutical formulations or kits.

[0189] In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising a PD-1 inhibitor. In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising a TGFβ inhibitor. In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising a fused PD-1 inhibitor and a TGFβ inhibitor. In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising an anti-PD(L)1:TGFβRII fusion protein. In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising an anti-PD(L)1:TGFβRII fusion protein having the amino acid sequence of vintrafusp alfa. In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising a PARP inhibitor. In some embodiments, the present invention provides a pharmaceutically acceptable composition of a chemotherapeutic agent. In some embodiments, the present invention provides a pharmaceutical composition comprising a PD-1 inhibitor and a TGFβ inhibitor. In some embodiments, the present invention provides a pharmaceutical composition comprising a TGFβ inhibitor and a PARP inhibitor. In some embodiments, the present invention provides a pharmaceutical composition comprising a PD-1 inhibitor and a PARP inhibitor. In some embodiments, the present invention provides a pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor. In some embodiments, the present invention provides a pharmaceutical composition comprising a PARP inhibitor and a fused PD-1 inhibitor and a TGFβ inhibitor. In some embodiments, the present invention provides a pharmaceutical composition comprising an anti-PD(L)1:TGFβRII fusion protein and a PARP inhibitor. In some embodiments, the present invention provides a pharmaceutical composition comprising an anti-PD(L)1:TGFβRII fusion protein having the amino acid sequence of vintrafusp alfa and a PARP inhibitor. A pharmaceutically acceptable composition may include at least a further pharmaceutically acceptable excipient or adjuvant, such as a pharmaceutically acceptable carrier.

[0190] In some embodiments, a composition containing a fused PD-1 inhibitor and a TGFβ inhibitor, such as an anti-PD(L)1:TGFβRII fusion protein, is separate from a composition containing a PARP inhibitor. In some embodiments, the PD-1 inhibitor and the TGFβ inhibitor are fused, for example, as an anti-PD(L)1:TGFβRII fusion protein and are present together with the PARP inhibitor in the same composition.

[0191] Examples of such pharmaceutically acceptable compositions are further described below herein.

[0192] The compositions of the present invention may be in various forms. These include liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable solutions and injectable solutions), dispersions or suspensions, tablets, pills, powders, liposomes, and suppositories.

[0193] pharmaceutically acceptable carriers, auxiliaries, or vehicles used in the compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffers such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin fat.

[0194] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. Liquid dosage forms may further include inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as mixtures thereof. In addition to inert diluents, oral compositions may also include auxiliaries, such as wetting agents, emulsifiers and suspensions, sweeteners, flavoring agents, and fragrances.

[0195] Preparations for injection, such as sterile aqueous or oily suspensions for injection, can be formulated according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions, suspensions, or emulsions in non-toxic, parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solution. Furthermore, sterile fixed oils have conventionally been used as solvents or suspension media. For this purpose, any brand fixed oil containing synthetic monoglycerides or diglycerides can be used. In addition, fatty acids such as oleic acid are used in the preparation of injectable preparations.

[0196] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium before use.

[0197] To extend the effects of the compounds of the present invention, it is often desirable to delay absorption from subcutaneous or intramuscular injection. This may be achieved by using a liquid suspension of crystalline or amorphous material with low solubility in water. The absorption rate depends on the dissolution rate, which may then depend on the crystal size and crystal form. Alternatively, delaying the absorption of parenterally administered PD-1 inhibitors, TGFβ inhibitors, and / or PARP inhibitors is achieved by dissolving or suspending the compounds in an oil vehicle. Depot formulations for injection are prepared by forming a microencapsulation matrix of PD-1 inhibitors, TGFβ inhibitors, and / or PARP inhibitors in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the properties of the specific polymer used, the release rate of the compound can be controlled. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydrous). Depot injection formulations are also prepared by encapsulating the compounds in liposomes or microemulsions that are compatible with body tissues.

[0198] The composition for rectal or vaginal administration may be a suppository, which can be prepared by mixing the compound of the present invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or suppository wax, which is solid at ambient temperature but liquid at body temperature and therefore dissolves in the rectal or vaginal cavity to release the active compound.

[0199] Dosage forms for oral administration include capsules, tablets, pills, powders, granules, aqueous suspensions, or solutions. In solid dosage forms, the active compound is mixed with at least one inert and pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or bulking agents such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) dissolution retarders such as paraffin; f) absorption enhancers such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may include a buffering agent.

[0200] Similar solid compositions may also be used as fillers for soft and hard gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules can be prepared using coatings and shells, such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. They may optionally contain opaque agents and may be compositions that release the active ingredient in a delayed manner, either only in specific parts of the intestinal tract or preferentially in specific parts of the intestinal tract. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0201] PD-1 inhibitors, TGFβ inhibitors, and / or PARP inhibitors may also be in microencapsulated form with one or more of the above excipients. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules may be prepared using coatings and shells such as enteric coatings, controlled-release coatings, and other coatings known in the field of pharmaceutical formulation technology. In such solid dosage forms, PD-1 inhibitors, TGFβ inhibitors, and / or PARP inhibitors may be mixed with at least one inert diluent, e.g., sucrose, lactose, or starch. Such dosage forms may also contain additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids, e.g., magnesium stearate and microcrystalline cellulose, as is common practice. In the case of capsules, tablets, and pills, the dosage forms may also contain buffers. These may optionally contain opacifiers and may be compositions that selectively release the active ingredient in a delayed manner, either only in specific parts of the intestinal tract or preferentially in specific parts of the intestinal tract. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0202] Dosage forms for topical or transdermal administration of PD-1 inhibitors, TGFβ inhibitors, and / or PARP inhibitors include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier and any preservatives or buffers as needed. Exemplary carriers for topical administration of this compound are mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes, and water. Alternatively, the provided pharmaceutically acceptable compositions can be formulated into suitable lotions or creams containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester waxes, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water. Ophthalmic formulations, ear drops, and eye drops are also considered to be within the scope of the present invention. Furthermore, the present invention intends to use transdermal patches, which have the additional advantage of providing controlled delivery of compounds to the body. Such dosage forms can be made by dissolving or distributing the compound in a suitable medium. Absorption enhancers can also be used to increase the flow of the compound through the skin. The rate can be controlled by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or gel.

[0203] The pharmaceutically acceptable compositions of the present invention are administered optionally by nasal aerosol or inhalation. Such compositions are prepared according to well-known techniques in the field of pharmaceutical formulations and are prepared as solutions in physiological saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizers or dispersants.

[0204] In a further embodiment, the present invention relates to a kit comprising a PD-1 inhibitor and a package insert containing instructions for the use of the PD-1 inhibitor in combination with a PARP inhibitor and a TGFβ inhibitor and optionally radiotherapy to treat or slow the progression of cancer in a subject. A kit is also provided comprising a PARP inhibitor and a package insert containing instructions for the use of the PARP inhibitor in combination with a PD-1 inhibitor and a TGFβ inhibitor and optionally radiotherapy to treat or slow the progression of cancer in a subject. A kit is also provided comprising a TGFβ inhibitor and a package insert containing instructions for the use of the TGFβ inhibitor in combination with a PD-1 inhibitor and a PARP inhibitor and optionally radiotherapy to treat or slow the progression of cancer in a subject. A kit is also provided comprising an anti-PD-L1 antibody and a package insert containing instructions for the use of the anti-PD-L1 antibody in combination with a PARP inhibitor and a TGFβRII or anti-TGFβ antibody and optionally radiotherapy to treat or slow the progression of cancer in a subject. Kits are also provided, comprising a PARP inhibitor and a package insert containing instructions for the use of the PARP inhibitor in combination with an anti-PD-L1 antibody and a TGFβRII or anti-TGFβ antibody, and optionally radiotherapy, to treat or slow the progression of cancer in a subject. Kits are also provided, comprising a TGFβRII or anti-TGFβ antibody and a package insert containing instructions for the use of the PTGFβRII or anti-TGFβ antibody in combination with an anti-PD-L1 antibody and a PARP inhibitor, and optionally radiotherapy, to treat or slow the progression of cancer in a subject. Kits are also provided, comprising a PD-1 inhibitor and a TGFβ inhibitor and a package insert containing instructions for the use of the PD-1 inhibitor and TGFβ inhibitor in combination with a PARP inhibitor and optionally radiotherapy, to treat or slow the progression of cancer in a subject.A kit is also provided, comprising an anti-PD-L1 antibody and a TGFβRII or anti-TGFβ antibody, and a package insert containing instructions for using the anti-PD-L1 antibody and TGFβRII or anti-TGFβ antibody in combination with PARP and optional radiotherapy to treat or delay the progression of cancer in a subject. A kit is also provided, comprising an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, and a package insert containing instructions for using the anti-PD(L)1:TGFβRII fusion protein in combination with a PARP inhibitor and optional radiotherapy to treat or delay the progression of cancer in a subject.

[0205] Kits are also provided, comprising PD-1 inhibitors and PARP inhibitors, and a package insert containing instructions for the use of the PD-1 inhibitors and PARP inhibitors in combination with a TGFβ inhibitor and optionally radiotherapy to treat or slow the progression of cancer in a subject. Kits are also provided, comprising TGFβ inhibitors and PARP inhibitors, and a package insert containing instructions for the use of the TGFβ inhibitors and PARP inhibitors in combination with a PD-1 inhibitor and optionally radiotherapy to treat or slow the progression of cancer in a subject. Kits are also provided, comprising anti-PD-L1 antibodies and PARP inhibitors, and a package insert containing instructions for the use of the anti-PD-L1 antibodies and PARP inhibitors in combination with TGFβRII or anti-TGFβ antibodies and optionally radiotherapy to treat or slow the progression of cancer in a subject. Kits are also provided, comprising TGFβRII or an anti-TGFβ antibody and a PARP inhibitor, and a package insert containing instructions for using TGFβRII or an anti-TGFβ antibody and a PARP inhibitor in combination with an anti-PD-L1 antibody and optionally radiotherapy to treat or delay the progression of cancer in a subject. Kits are also provided, comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and a package insert containing instructions for using the PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor in combination with optionally radiotherapy to treat or delay the progression of cancer in a subject. Kits are also provided, comprising an anti-PD-L1 antibody, TGFβRII or an anti-TGFβ antibody, and a PARP inhibitor, and a package insert containing instructions for using the anti-PD-L1 antibody, a TGFβRII or an anti-TGFβ antibody, and PARP in combination with optionally radiotherapy to treat or delay the progression of cancer in a subject. A kit is also provided which includes an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, and a PARP inhibitor, and a package insert which includes instructions for use in combination with the anti-PD(L)1:TGFβRII fusion protein and the PARP inhibitor, and optionally with radiotherapy, to treat or delay the progression of cancer in a subject.The kit may include a first container, a second container, a third container, and an instruction manual, wherein the first container contains at least one dose of a PD-1 inhibitor, the second container contains at least one dose of a PARP inhibitor, and the third container contains at least one dose of a TGFβ inhibitor, and the instruction manual includes instructions for treating a subject for cancer using the three compounds optionally in conjunction with radiotherapy. In some embodiments, the kit includes a first container, a second container, and an instruction manual, wherein the first container contains at least one dose of an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafasp alfa, the second container contains at least one dose of a PARP inhibitor, and the instruction manual includes instructions for treating a subject for cancer using the two compounds optionally in conjunction with radiotherapy. The first, second, and third containers may be the same or different shapes (e.g., vials, syringes, and bottles) and / or materials (e.g., plastic or glass). The kit may further include other materials that may be useful for administering the drug, such as diluents, filters, IV bags and lines, needles and syringes. The instructions may state that the drug is intended for use in the treatment of subjects with cancer that has been tested for PD-L1 positivity, for example, by immunohistochemistry (IHC) assay, FACS, or LC / MS / MS.

[0206] Further diagnosis, prediction, prognosis, and / or treatment methods This disclosure further provides diagnostic, predictive, prognostic, and / or therapeutic methods that optionally use PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in combination with radiotherapy. Such methods are at least partially based on determining the identity of the expression levels of markers of interest. In particular, the amount of human PD-L1 in a cancer patient sample can be used to predict whether the patient is likely to respond favorably to cancer treatment utilizing the therapeutic combination of the present invention.

[0207] Any suitable sample can be used for the method. Non-limiting examples of such samples include one or more of serum samples, plasma samples, whole blood, pancreatic juice samples, tissue samples, tumor lysates, or tumor samples, which can be isolated from needle biopsies, core biopsies, and needle aspirates. For example, tissue, plasma, or serum samples are collected from the patient before treatment and optionally collected in treatment with the therapeutic combination of the present invention. The expression levels obtained in treatment are compared to the values ​​obtained before the patient started treatment. The information obtained may be prognostic in that it can indicate whether the patient responded favorably or unfavorably to cancer treatment.

[0208] It should be understood that the information obtained using the diagnostic assays described herein may be used alone or in combination with other information, such as, but not limited to, gene expression levels, clinical chemical parameters, histopathological parameters, or the subject's age, sex, and weight. When used alone, the information obtained using the diagnostic assays described herein is useful in determining or identifying the clinical outcome of treatment, selecting patients for treatment, or treating patients. On the other hand, when used in combination with other information, the information obtained using the diagnostic assays described herein is useful in assisting in determining or identifying the clinical outcome of treatment, assisting in selecting patients for treatment, or assisting in treating patients. In certain embodiments, expression levels may be used in a diagnostic panel that contributes to the final diagnosis, prognosis, or treatment selected for a patient, respectively.

[0209] Any suitable method can be used to measure PD-L1 protein, DNA, RNA, or other suitable readings of PD-L1 levels, examples of which are described herein and / or are well known to those skilled in the art.

[0210] In some embodiments, determining PD-L1 levels includes determining PD-L1 expression. In some embodiments, PD-L1 levels are determined by the concentration of PD-L1 protein in a patient sample using a PD-L1-specific ligand, such as an antibody or a specific binding partner. Binding events can be detected by competitive or non-competitive methods, including, for example, the use of a labeled competing moiety containing a labeled ligand or PD-L1-specific moiety that competes with the marker protein for binding events, such as an antibody or a labeled PD-L1 standard. If the marker-specific ligand can form a complex with PD-L1, the complex formation indicates PD-L1 expression in the sample. In various embodiments, biomarker protein levels are determined by methods including quantitative Western blotting, multiple immunoassay formats, ELISA, immunohistochemistry, histochemistry, or FACS analysis of tumor lysates, immunofluorescence staining, bead-based suspension immunoassays, Luminex technology, or proximity ligation assays. In one embodiment, PD-L1 expression is determined by immunohistochemistry using one or more primary anti-PD-L1 antibodies.

[0211] In another embodiment, the biomarker RNA level is determined by a method including a microarray chip, RT-PCR, qRT-PCR, multiplex qPCR, or in-situ hybridization. In one embodiment of the present invention, the DNA or RNA array includes an arrangement of polynucleotides presented by or hybridizing to the PD-L1 gene immobilized on a solid surface. For example, to the extent necessary to determine the PD-L1 mRNA, appropriate sample preparation steps may be taken, if necessary, such as isolating the mRNA from the sample after tissue homogenization and hybridizing it with a marker-specific probe or a PCR-based detection method, such as a primer for PCR extension labeling using a probe specific to a portion of the marker mRNA, particularly on a microarray platform, with or without amplification.

[0212] Several approaches have been described for quantifying PD-L1 protein expression in IHC assays of tumor tissue sections (Thompson et al. (2004) PNAS 101 (49): 17174; Thompson et al. (2006) Cancer Res. 66: 3381; Gadiot et al. (2012) Cancer 117: 2192; Taube et al. (2012) Sci Transl Med 4, 127ra37; and Toplian et al. (2012) New Eng. J Med. 366 (26): 2443). One approach uses a simple binary endpoint, positive or negative, for PD-L1 expression, where a positive result is defined as the percentage of tumor cells showing histological evidence of cell surface membrane staining. The level of PD-L1 mRNA expression may be compared to the mRNA expression levels of one or more reference genes frequently used in quantitative RT-PCR, such as ubiquitin C. In some embodiments, the level of PD-L1 expression (protein and / or mRNA) by malignant cells and / or infiltrating immune cells within a tumor is determined to be “overexpressed” or “elevated” based on a comparison with the level of PD-L1 expression (protein and / or mRNA) by a suitable control. For example, the control PD-L1 protein or mRNA expression level may be a level quantified in non-malignant cells of the same type or in sections from corresponding normal tissue.

[0213] In one embodiment, the efficacy of the therapeutic combination of the present invention is predicted by PD-L1 expression in tumor samples.

[0214] This disclosure also provides a kit for determining whether a combination of the present invention is suitable for therapeutic treatment of a cancer patient, comprising means for determining the protein level of PD-L1 or the expression level of its RNA in a sample isolated from a cancer patient, and instructions for use. In another embodiment, the kit further comprises a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor for treatment. In one embodiment of the present invention, the determination of a high PD-L1 level indicates an increase in PFS or OS when the patient is treated with the therapeutic combination of the present invention. In one embodiment of the kit, the means for determining the PD-L1 protein level is an antibody that specifically binds to PD-L1.

[0215] In yet another aspect, the present invention provides a method for promoting a PD-1 inhibitor, comprising encouraging a targeted reader to use the PD-1 inhibitor in combination with a TGFβ inhibitor, a PARP inhibitor, and optionally radiotherapy to treat a subject having cancer based on PD-L1 expression in a sample randomly taken from the subject. In yet another aspect, the present invention provides a method for promoting a PARP inhibitor, comprising encouraging a targeted reader to use the PARP inhibitor in combination with a fused PD-1 inhibitor and a TGFβ inhibitor, and optionally radiotherapy, to treat a subject having cancer based on PD-L1 expression in a sample randomly taken from the subject. In yet another aspect, the present invention provides a method for promoting a TGFβ inhibitor, comprising encouraging a targeted reader to use the TGFβ inhibitor in combination with a PD-1 inhibitor, a PARP inhibitor, and optionally radiotherapy to treat a subject having cancer based on PD-L1 expression in a sample randomly taken from the subject. In yet another aspect, the present invention provides a method for promoting an anti-PD(L)1:TGFβRII fusion protein, for example, having the amino acid sequence of vintrafusp alfa, comprising encouraging a targeted reader to use the anti-PD(L)1:TGFβRII fusion protein in combination with a PARP inhibitor and optionally radiotherapy to treat subjects having cancer based on PD-L1 expression in a sample randomly taken from a subject. In yet another aspect, the present invention provides a method for promoting a combination comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, comprising encouraging a targeted reader to use the combination in combination with optionally radiotherapy to treat subjects having cancer based on PD-L1 expression in a sample randomly taken from a subject. The encouragement may be made by any available means. In some embodiments, the encouragement is made by a package insert accompanying a commercial formulation of the therapeutic combination of the present invention.Prompt may also be provided by the accompanying documentation for a commercial formulation of a PD-1 inhibitor, TGFβ inhibitor, PARP inhibitor, or another pharmaceutical (where the treatment is treatment with the therapeutic combination of the present invention and further pharmaceuticals). In some embodiments, promptt is provided by documentation that provides instructions for treatment with the therapeutic combination of the present invention, and in some embodiments, treatment in combination with another pharmaceutical, after measuring PD-L1 expression levels. In some embodiments, following promptt, the patient is treated with the therapeutic combination in optional combination with radiotherapy. In some embodiments, the documentation indicates that the therapeutic combination is used to treat the patient when the patient's cancer sample is characterized by high PD-L1 biomarker levels. In some embodiments, the documentation indicates that the therapeutic combination should not be used to treat the patient when the patient's cancer sample expresses low PD-L1 biomarker levels. In some embodiments, high PD-L1 biomarker levels mean measured PD-L1 levels that correlate with the potential for increased PFS and / or OS if the patient is treated with the therapeutic combination, and vice versa. In some embodiments, PFS and / or OS are reduced by the therapeutic combination compared to untreated patients. In some embodiments, the facilitation is provided by the package insert, which provides instructions for treatment with an anti-PD(L)1:TGFβRII fusion protein in combination with a PARP inhibitor and optionally radiotherapy after first measuring PD-L1 expression levels. In some embodiments, the patient is treated with an anti-PD(L)1:TGFβRII fusion protein in combination with a PARP inhibitor and optionally radiotherapy following the facilitation.

[0216] All references cited herein are incorporated by reference into the disclosure of the present invention.

[0217] Methods and materials similar to or equivalent to those described herein may be used in carrying out or testing the present invention, but preferred examples are described below. In the examples, standard reagents and buffers that do not contaminate (whenever carried out) are used. The examples are to be interpreted as not being limited in particular to combinations of express features, but the illustrated features may be combined again non-limitingly, insofar as the technical problem of the invention is solved. Similarly, any feature of any claim may be combined with one or more features of other claims. The present invention, described in summary and in detail, is illustrative and not limited by the following examples. [Examples]

[0218] Example 1: Combination therapy with PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors in a mouse tumor model Combinations of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors were tested in various mouse tumor models.

[0219] result MDA-MB-436 Breast Cancer Model Human MDA-MB-436 human breast cancer cell line was injected into NOD / SCID mice. In this model, niraparib monotherapy significantly inhibited tumor growth compared to isotype controls (p<0.0001, day 41) or vintrafusp alfa (p<0.0001, day 41). However, vintrafusp alfa plus niraparib combination therapy further inhibited tumor growth compared to niraparib monotherapy (p<0.0001, day 69) and isotype controls (p<0.0001, day 41). Vintrafusp alfa plus niraparib combination therapy also significantly delayed the median time to disease progression after discontinuation to 51 days compared to niraparib monotherapy (median time to progression 42.5 days, p=0.026) (Figure 3).

[0220] MDA-MB-231 Breast Cancer Model In subcutaneous MDA-MB-231 human breast cancer, monotherapy with vintrafusp alfa (p<0.0001, day 41) and niraparib (p<0.0001, day 41) significantly reduced tumor growth compared to isotype controls. However, the combination therapy of vintrafusp alfa plus niraparib further reduced tumor growth compared to monotherapy with vintrafusp alfa (p=0.0336, day 41) or niraparib (p<0.0001, day 41), or compared to isotype controls (p<0.0001, day 41) (Figure 4).

[0221] Renal cell carcinoma model In the orthotopic renal cell carcinoma (RENCA) model, the combination of vintrafusp alfa and niraparib reduced relative renal tumor volume, which is defined as the ratio of the mass of the tumorous kidney to the mass of both normal kidneys (median = 2.12) compared to monotherapy with vintrafusp alfa (median = 3.74) or niraparib (median = 7.63), or to isotype controls (median = 5.91). Although there was no significant difference in mass ratio between treatment groups, the combination therapy of vintrafusp alfa and niraparib tended to reduce the mass ratio compared to niraparib (p=0.0578) or vintrafusp alfa (p=0.3156) monotherapy or isotype controls (p=0.0959) (Figure 5).

[0222] B16F10 Melanoma Model In a subcutaneous B16F10 melanoma model, neither vintrafusp alfa nor niraparib monotherapy significantly reduced tumor growth compared to isotype controls. However, the vintrafusp alfa + niraparib combination therapy significantly reduced tumor growth compared to vintrafusp alfa (p=0.0131, day 19) or niraparib (p=0.0045, day 15) monotherapy, or compared to isotype controls (p=0.0011, day 15) (Figure 6).

[0223] AT-3 Breast Cancer Model In an orthotopic AT-3 breast cancer model, vintrafasp alfa monotherapy did not significantly reduce tumor growth compared to isotype controls (p=0.8574, day 13). However, the vintrafasp alfa + niraparib combination therapy reduced tumor growth compared to vintrafasp alfa monotherapy (p<0.0001, day 13) and isotype controls (p<0.0001, day 13). While the vintrafasp alfa + niraparib combination therapy did not significantly reduce tumor growth compared to niraparib monotherapy (p=0.5406, day 13), the combination therapy induced more responders (mice with tumor volume less than 1σ of the control mean) at day 13 after the start of treatment than niraparib (5 / 10 mice) or vintrafasp alfa (1 / 10 mice) monotherapy (8 / 10 mice) (Figure 7). The combination therapy of vintrafusp alfa plus niraparib also significantly extended survival (median survival -15 days) compared to the isotype control (13 days, p=0.0118), but vintrafusp alfa (13 days) or niraparib (13 days) monotherapy did not extend survival compared to the isotype control.

[0224] 4T1 breast cancer model In an intramuscular (im) 4T1 breast cancer model, vintrafasp alfa + RT combination therapy significantly reduced tumor growth compared to isotype controls (p<0.0001, day 13). However, the combination of vintrafasp alfa + RT with niraparib further reduced tumor growth compared to vintrafasp alfa + RT combination therapy (p<0.0001, day 20) or isotype controls (p<0.0001, day 13) (Figure 8).

[0225] Materials and methods cell line MDA-MB-436 (BRCA1-mut) cells were obtained from the American Type Culture Collection (ATCC® HTB-130®) and cultured in RPMI-1640 containing 10% heat-inactivated fetal bovine serum, 100 U / ml penicillin, and 100 μg / ml streptomycin at 37°C in an atmosphere of 5% CO2 in air. MDA-MB-231 (BRCA-wt) cells were obtained from ATCC (ATCC® HTB-26®) and cultured in Leibowitz L-15 medium supplemented with 15% heat-inactivated fetal bovine serum, 100 U / ml penicillin, and 100 μg / ml streptomycin at 37°C in an atmosphere of 5% CO2 in air. RENCA cells were obtained from ATCC (ATCC® CRL-2947®) and cultured in RPMI-1640 containing 10% heat-inactivated fetal bovine serum and 0.1 mM non-essential amino acids. B16F10 cells were obtained from ATCC and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). AT-3 cells were obtained from Sigma and cultured in DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM non-essential amino acids, 15 mM HEPES, and 1× β-mercaptoethanol. 4T1 cells were obtained from ATCC and cultured in RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg / L glucose, and 1500 mg / L sodium bicarbonate. Cells were cultured under sterile conditions and incubated at 37°C with 5% CO2. Cells were passaged before in vivo transplantation, and adherent cells were harvested using TrypLE Express.

[0226] mouse NOD / SCID mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. BALB / c and C57BL / 6 mice were obtained from Charles River Laboratories. All mice used in the experiments were female, 6–12 weeks old. The mice were housed in a pathogen-free facility with free access to food and water. All procedures were followed in accordance with facility protocols approved by the Institutional Animal Care and Use Committee (IACUC).

[0227] Mouse tumor model MDA-MB-436 tumor model For efficacy studies, 10 × 10 6 On day 19, individual MDA-MB-436 tumor cells were inoculated into the right flank of NOD / SCID mice in 0.2 ml of PBS (1:1) containing Matrigel. The average tumor volume was 100 mm². 3 Treatment was started on day 0, when the tumor volume reached 2500 mm³. 3 When this was reached, the mouse was sacrificed to death.

[0228] MDA-MB-231 tumor model For efficacy studies, 10 × 10 6 On day 19, individual MDA-MB-231 tumor cells were inoculated into the right flank of NOD / SCID mice in 0.2 ml of PBS (1:1) containing Matrigel. The average tumor volume was 100 mm². 3 Treatment was started on day 0, when the tumor volume reached 2500 mm³. 3 When this was reached, the mouse was sacrificed to death.

[0229] RENCA tumor model For efficacy studies, 0.5 × 10 5 RENCA cells were orthotopically inoculated into the left kidney of BALB / c mice on day -6. Treatment was initiated on day 0, and the mice were sacrificially killed on day 12.

[0230] B16F10 Tumor Model For efficacy studies, 0.5 × 10 6 B16F10 cells were subcutaneously (sc) inoculated into the right flank of C57BL / 6 mice on day 5. Treatment was initiated on day 0, five days after tumor cell inoculation. The tumor volume was approximately 2000 mm³. 3 When this was reached, the mouse was sacrificed to death.

[0231] AT-3 tumor model For efficacy studies, 0.5 × 10 6 On day 11, individual AT-3 cells were orthotopically inoculated into the right lower mammary gland of C57BL / 6 mice. The average tumor volume was approximately 50 mm². 3 Treatment was started on day 0, when the tumor volume reached approximately 1000 mm³. 3 When this was reached, the mouse was sacrificed to death.

[0232] 4T1 tumor model For efficacy studies, 0.5 × 10 5 Four T1 cells were intramuscularly (im) inoculated into the right thigh of BALB / c mice on day 7. The average tumor volume was approximately 75–125 mm². 3 Treatment was started on day 0, when the tumor volume reached approximately 2000 mm³. 3 When this was reached, the mouse was sacrificed to death.

[0233] treatment Mice were randomly divided into treatment groups according to their tumor volume on the day treatment began (day 0). The exact dosage and treatment schedule for each experiment are described in the legend of the figure.

[0234] Vintrafasp alfa is a bifunctional fusion protein consisting of the extracellular domain of the TGF-βRII receptor, which functions as a TGF-β "trap," fused to a human IgG1 antibody that blocks PD-L1. The isotype control is an anti-PD-L1 mutant form that completely lacks PD-L1 binding. In mice with tumors, vintrafasp alfa (492 pg) or the isotype control (400 pg) was administered intravenously (iv) in 0.2 mL of PBS.

[0235] Niraparib, a selective small molecule PARP1 and PARP2 inhibitor, was administered orally (po) once daily at a dose of 35 or 50 mg / kg (10 μL / g) for 12, 14, 21, or 28 consecutive days. 0.5% Methocel in water (the vehicle for niraparib) was administered once daily at a dose of po (10 μL / g) for 12, 14, 21, or 28 consecutive days. Radiotherapy (RT) was delivered at a dose of 8 Gray (Gy) on days 0-3.

[0236] Tumor growth and survival rate Tumor size was measured twice a week using a digital caliper and automatically recorded using WinWedge software. Tumor volume was calculated using the following formula: Tumor volume (mm²) 3 ) = Tumor length × width × height × 0.5236. Tumor growth inhibition (TGI) was calculated using the following formula: TGI (%) = [1 - (Ti - T0) / (Vi - V0)] × 100 (wherein Ti is the mean tumor volume (mm) of the treatment group on a given day. 3 (where TO is the mean tumor volume of the treatment group on the first day of treatment, Vi is the mean tumor volume of the vehicle control group on the same day as Ti, and V0 is the mean tumor volume of the vehicle control group on the first day of treatment). Kaplan-Meier survival curves were constructed to compare survival rates between different treatment groups. Body weight was measured twice a week, and tumor volume was 2,500 mm for subcutaneous injection + intramuscular tumors. 3 When it exceeds 1,000 mm, and in the case of orthotopic mammary tumors, 1,000 mm 3When the threshold was exceeded, the mice were euthanized. The endpoint for the RENCA orthotopic tumor model was empirically established in previous studies. The net tumor weight of the inoculated left kidney was measured by calculating the difference in weight between the right and left kidneys.

[0237] statistical analysis Statistical analysis was performed using GraphPad Prism Software version 8.0.1. Tumor volume data is displayed graphically as mean ± standard error of the mean (SEM) indicated by symbols, or as individual mice indicated by lines. Two-way analysis of variance (ANOVA) was performed to evaluate the difference in tumor volume between treatment groups, followed by Tukey or Sidak multiple comparison tests. Kaplan-Meier plots were created to show survival rates for each treatment group, and significance was assessed by the log-rank (Mantel-Cox) test.

[0238] The weight of the left kidney with the tumor was divided by the weight of the reference right kidney to calculate the kidney mass ratio. The mass ratios of individual kidneys were plotted, and a line representing the median was used. Unpaired t-tests and Welch correction were used to compare kidney mass ratios between treatment groups.

[0239] Further embodiments of this disclosure: 1. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor to the subject.

[0240] 2. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in a method of treating cancer in a subject, wherein the method comprises administering a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and radiotherapy to the subject.

[0241] 3. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in methods of treating cancer in the subject, The method includes administering PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors to the target population. PD-1 inhibitors are anti-PD(L)1 antibodies, TGFβ inhibitors are TGFβRII or anti-TGFβ antibodies, and PARP inhibitors are small molecules. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors.

[0242] 4. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in methods of treating cancer in the subject, The method includes administering PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and radiotherapy, PD-1 inhibitors are anti-PD(L)1 antibodies, TGFβ inhibitors are TGFβRII or anti-TGFβ antibodies, and PARP inhibitors are small molecules. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors.

[0243] 5. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in methods of treating cancer in the subject, The method includes administering PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors to the target population. PD-1 inhibitors and TGFβ inhibitors are fused as anti-PD(L)1:TGFβRII fusion proteins, and PARP inhibitors are nicotinamide analogs. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors.

[0244] 6. PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for use in methods of treating cancer in the subject, The method includes administering PD-1 inhibitors, TGFβ inhibitors, PARP inhibitors, and radiotherapy, A PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor are fused as an anti-PD(L)1:TGFβRII fusion protein, and the PARP inhibitor is a nicotinamide analog.

[0245] 7. A PD-1 inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor to the subject in combination with a TGFβ inhibitor and a PARP inhibitor.

[0246] 8. A PD-1 inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor to the subject in combination with a TGFβ inhibitor, a PARP inhibitor, and radiotherapy.

[0247] 9. A TGFβ inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the TGFβ inhibitor to the subject in combination with a PD-1 inhibitor and a PARP inhibitor.

[0248] 10. A TGFβ inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the TGFβ inhibitor to the subject in combination with a PD-1 inhibitor, a PARP inhibitor, and radiotherapy.

[0249] 11. A PARP inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor and a TGFβ inhibitor.

[0250] 12. A PARP inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor, a TGFβ inhibitor, and radiotherapy.

[0251] 13. PD-1 inhibitors and TGFβ inhibitors for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor. It is a fusion of a PD-1 inhibitor and a TGFβ inhibitor. PD-1 inhibitors and TGFβ inhibitors.

[0252] 14. PD-1 inhibitors and TGFβ inhibitors for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor and radiotherapy, It is a fusion of a PD-1 inhibitor and a TGFβ inhibitor. PD-1 inhibitors and TGFβ inhibitors.

[0253] 15. A method for treating cancer in a subject, comprising administering a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor to the subject.

[0254] 16. A method for treating cancer in a subject, comprising administering a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and radiotherapy to the subject.

[0255] 17. A method for treating cancer in a subject, comprising administering a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor to the subject, wherein the PD-1 inhibitor is an anti-PD(L)1 antibody, the TGFβ inhibitor is TGFβRII or an anti-TGFβ antibody, and the PARP inhibitor is a small molecule.

[0256] 18. A method for treating cancer in a subject, comprising administering a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and radiotherapy to the subject, wherein the PD-1 inhibitor is an anti-PD(L)1 antibody, the TGFβ inhibitor is TGFβRII or an anti-TGFβ antibody, and the PARP inhibitor is a small molecule.

[0257] 19. A method of treating cancer in a subject, comprising administering to the subject a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, wherein the PD-1 inhibitor and the TGFβ inhibitor are fused as an anti-PD(L)1:TGFβRII fusion protein, and the PARP inhibitor is a nicotinamide analog.

[0258] 20. A method of treating cancer in a subject, comprising administering to the subject a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and radiation therapy, wherein the PD-1 inhibitor and the TGFβ inhibitor are fused as an anti-PD(L)1:TGFβRII fusion protein, and the PARP inhibitor is a nicotinamide analog.

[0259] 21. Use of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor for manufacturing a medicament for treating cancer in a subject.

[0260] 22. Use of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor for manufacturing a medicament for treating cancer in a subject in combination with radiation therapy.

[0261] 23. Use of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor for manufacturing a medicament for a method of treating cancer in a subject, wherein the PD-1 inhibitor is an anti-PD(L)1 antibody, the GFβ inhibitor is TGFβRII or an anti-TGFβ antibody, and the PARP inhibitor is a small molecule.

[0262] 24. Use of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor for manufacturing a medicament for a method of treating cancer in a subject in combination with radiation therapy, wherein the PD-1 inhibitor is an anti-PD(L) inhibitor, the TGFβ inhibitor is TGFβRII or an anti-TGFβ antibody, and the PARP inhibitor is a small molecule.

[0263] 25. Use of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for manufacturing pharmaceuticals for methods of treating cancer in subjects, PD-1 inhibitors and TGFβ inhibitors are fused as anti-PD(L)1:TGFβRII fusion proteins, and PARP inhibitors are nicotinamide analogs, used for this purpose.

[0264] 26. Use of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for manufacturing pharmaceuticals for methods of treating cancer in a subject in combination with radiotherapy, PD-1 inhibitors and TGFβ inhibitors are fused as anti-PD(L)1:TGFβRII fusion proteins, and PARP inhibitors are nicotinamide analogs, used for this purpose.

[0265] 27. Use of a PD-1 inhibitor for manufacturing a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor to the subject in combination with a TGFβ inhibitor and a PARP inhibitor.

[0266] 28. Use of a PD-1 inhibitor for manufacturing a pharmaceutical product for a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor to the subject in combination with a TGFβ inhibitor, a PARP inhibitor, and radiotherapy.

[0267] 29. Use of a TGFβ inhibitor for manufacturing a medicament for a method of treating cancer in a subject, wherein the method comprises administering the TGFβ inhibitor to the subject in combination with a PD-1 inhibitor and a PARP inhibitor.

[0268] 30. Use of a TGFβ inhibitor for manufacturing a medicament for a method of treating cancer in a subject, wherein the method comprises administering the TGFβ inhibitor to the subject in combination with a PD-1 inhibitor, a PARP inhibitor, and radiotherapy.

[0269] 31. Use of a PARP inhibitor for manufacturing a medicament for a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor and a TGFβ inhibitor.

[0270] 32. Use of a PARP inhibitor for manufacturing a medicament for a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor, a TGFβ inhibitor, and radiotherapy.

[0271] 33. Use of a PD-1 inhibitor and a TGFβ inhibitor for manufacturing a medicament for a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and the TGFβ inhibitor to the subject in combination with a PARP inhibitor, wherein the PD-1 inhibitor and the TGFβ inhibitor are fused.

[0272] 34. Use of PD-1 inhibitors and TGFβ inhibitors for manufacturing a pharmacopoeia for a method of treating cancer in a subject, comprising administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor and radiotherapy, wherein the PD-1 inhibitor and TGFβ inhibitor are fused.

[0273] 35. A compound, therapeutic method, or use described in any one of items 1 to 34, in which a PD-1 inhibitor can inhibit the interaction between PD-1 and PD-L1.

[0274] 36. The PD-1 inhibitor is an anti-PD(L)1 antibody, a compound for use, a therapeutic method, or use as described in item 35.

[0275] 37. PD-1 inhibitors are anti-PD-L1 antibodies, compounds for use, therapeutic methods, or uses as described in item 36.

[0276] 38. The use according to item 37, a compound, or a treatment method, wherein the anti-PD-L1 antibody comprises a heavy chain sequence containing CDRH1 having the sequence of SEQ ID NO: 1, CDRH2 having the sequence of SEQ ID NO: 2, and CDRH3 having the sequence of SEQ ID NO: 3, and a light chain sequence containing CDRL1 having the sequence of SEQ ID NO: 4, CDRL2 having the sequence of SEQ ID NO: 5, and CDRL3 having the sequence of SEQ ID NO: 6.

[0277] 39. The use according to any one of items 1 to 38, a compound, or a treatment method, wherein the TGFβ inhibitor is capable of inhibiting the interaction between TGFβ and the TGFβ receptor.

[0278] <确定的 40. The use according to any one of items 1 to 39, a compound, or a treatment method, wherein the TGFβ inhibitor is a fragment thereof capable of binding to the TGFβ receptor or TGFβ.

[0279] 41. The use according to item 40, a compound, or a treatment method, wherein the TGFβ receptor is a fragment thereof capable of binding to TGFβ receptor II or TGFβ.

[0280] 42. The use according to item 41, a compound, or a treatment method, wherein the TGFβ receptor is the extracellular domain of TGFβ receptor II or a fragment thereof capable of binding to TGFβ.

[0281] 43. The use according to any one of items 1 to 42, a compound, or a treatment method, wherein the TGFβ inhibitor has at least 80%, 90%, 95%, or 100% sequence identity to any one of the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13 and is capable of binding to TGFβ.

[0282] 44. The use according to any one of items 1 to 43, a compound, or a treatment method, wherein the TGFβ inhibitor has at least 80%, 90%, or 95% sequence identity to the amino acid sequence of SEQ ID NO: 11 and is capable of binding to TGFβ.

[0283] 45. A compound, therapeutic method, or use for use described in any one of items 1 to 42, wherein the TGFβ inhibitor comprises one sequence of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13.

[0284] 46. ​​A TGFβ inhibitor comprising the sequence of SEQ ID NO: 11, a compound for use, a therapeutic method, or a use as described in item 45.

[0285] 47. A compound for use, method of treatment, or use described in any one of items 1 to 46, comprising a fusion of a PD-1 inhibitor and a TGFβ inhibitor.

[0286] 48. Compounds, therapeutic methods, or uses for use according to any one of items 1 to 47, wherein a PD-1 inhibitor and a TGFβ inhibitor are fused in a molecule comprising (a) an antibody or fragment thereof capable of binding to PD-L1 or PD-1 and inhibiting the interaction between PD-1 and PD-L1, and (b) a fragment thereof capable of binding to the extracellular domain of TGFβRII or TGFβ and inhibiting the interaction between TGFβ and the TGFβ receptor.

[0287] 49. A compound for use, therapeutic method, or use described in item 48, wherein the fusion molecule is one of the respective fusion molecules disclosed in WO2015 / 118175 or WO2018 / 205985.

[0288] 50. A compound, therapeutic method, or use described in item 48, wherein the extracellular domain of TGFβRII or a fragment thereof is fused to each heavy chain sequence of the antibody or fragment thereof.

[0289] 51. Compounds, therapeutic methods, or uses described in item 50, wherein the fusion between the extracellular domain or fragment thereof of TGFβRII and the heavy chain sequence of the antibody or fragment thereof occurs via a linker sequence.

[0290] 52. Compounds for use, therapeutic methods, or uses described in item 51, wherein the amino acid sequence of the light chain sequence, and the sequence containing the heavy chain sequence and the extracellular domain or fragment thereof of TGFβRII, respectively, correspond to sequences selected from the group consisting of (1) SEQ ID NOs. 7 and SEQ ID NOs. 8, (2) SEQ ID NOs. 15 and SEQ ID NOs. 17, and (3) SEQ ID NOs. 15 and SEQ ID NOs. 18.

[0291] 53. A compound, therapeutic method, or use described in any one of items 1 to 52, comprising a fusion of a PD-1 inhibitor and a TGFβ inhibitor, wherein the fusion protein has at least 80%, 90%, 95%, or 100% sequence identity with the amino acid sequence of vintrafasp alfa.

[0292] 54. A compound, therapeutic method, or use described in any one of items 1 to 52, comprising a fusion of a PD-1 inhibitor and a TGFβ inhibitor, wherein the fusion protein is vintrafusp alfa.

[0293] 55. A compound, method of treatment, or use for which a PARP inhibitor is a small molecule, as described in any one of items 1 to 54.

[0294] 56. A compound, therapeutic method, or use for which a PARP inhibitor is a nicotinamide analog, as described in item 55.

[0295] 57. A compound, method of treatment, or use for use as described in item 55, wherein the PARP inhibitor is selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline.

[0296] 58. A PARP inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor and a TGFβ inhibitor. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. A PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline.

[0297] 59. A PARP inhibitor for use in a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor, a TGFβ inhibitor, and radiotherapy. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. A PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline.

[0298] 60. PD-1 inhibitors and TGFβ inhibitors for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. PD-1 inhibitors and TGFβ inhibitors, wherein the PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, veliparib, pamiparib, nicotinamide, and theophylline.

[0299] 61. PD-1 inhibitors and TGFβ inhibitors for use in a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor and radiotherapy, PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. PD-1 inhibitors and TGFβ inhibitors, wherein the PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, veliparib, pamiparib, nicotinamide, and theophylline.

[0300] 62. A method for treating cancer in a subject, comprising administering a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor to the subject. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. A method wherein the PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline.

[0301] 63. A method for treating cancer in a subject, comprising administering a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and radiotherapy to the subject. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. A method wherein the PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline.

[0302] 64. Use of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for manufacturing a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor to the subject. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. The PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline, and is used.

[0303] 65. Use of PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors for the manufacture of a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering a PD-1 inhibitor, a TGFβ inhibitor, a PARP inhibitor, and radiotherapy to the subject. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. The PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline, and is used.

[0304] 66. Use of a PARP inhibitor for manufacturing a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor and a TGFβ inhibitor. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. The PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline, and is used.

[0305] 67. Use of a PARP inhibitor for manufacturing a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering the PARP inhibitor to the subject in combination with a PD-1 inhibitor, a TGFβ inhibitor, and radiotherapy. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. The PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline, and is used.

[0306] 68. Use of PD-1 inhibitors and TGFβ inhibitors for manufacturing a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. The PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline, and is used.

[0307] 69. Use of PD-1 inhibitors and TGFβ inhibitors for manufacturing a pharmacopoeia for a method of treating cancer in a subject, wherein the method comprises administering the PD-1 inhibitor and TGFβ inhibitor to the subject in combination with a PARP inhibitor and radiotherapy. PD-1 and a TGFβ inhibitor are fused together, and the amino acid sequence of the fusion molecule corresponds to the amino acid sequence of vintrafusp alfa. The PARP inhibitor is a compound selected from the group consisting of olaparib, lucaparib, niraparib, talazoparib, beriparib, pamiparib, nicotinamide, and theophylline, and is used.

[0308] 70. A compound, therapeutic method, or use described in any one of items 1 to 69, wherein cancer is selected from the group consisting of carcinoma, lymphoma, leukemia, blastoma, and sarcoma.

[0309] 71. A compound, method of treatment, or use described in any one of items 1 to 70, selected from the group consisting of squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer, glioma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma, cervical cancer, brain cancer, gastric cancer, bladder cancer, liver cancer, breast cancer, colon cancer, biliary tract cancer, and head and neck cancer.

[0310] 72. A compound, method of treatment, or use described in any one of items 1 to 72 for use in cancer having a defect in homologous recombination repair.

[0311] 73. Compounds, therapeutic methods, or uses described in item 72, wherein the homologous recombination repair defect is caused by a defect in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, PTEN, Rad51, ATM, ATR, CtIP, and MRE11.

[0312] 74. Compounds, therapeutic methods, or uses described in any one of items 1 to 73, in which PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors are administered optionally in combination with radiotherapy as a first-line treatment for cancer.

[0313] 75. A compound, treatment method, or use described in any one of items 1 to 73 for use in which the subject has received at least one round of prior cancer treatment.

[0314] 76. The compound, treatment method, or use described in item 75 for use in cancer that is resistant to or has become resistant to previous treatment.

[0315] 77. Compounds, therapeutic methods, or uses described in any one of items 1 to 73, in which PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors are administered optionally in combination with radiotherapy as a second-line or subsequent treatment for cancer.

[0316] 78. Compounds, therapeutic methods, or uses for use as described in item 77, selected from the group consisting of cancer selected from previously treated recurrent metastatic NSCLC, unresectable locally advanced NSCLC, previously treated SCLCED, SCLC unsuitable for systemic treatment, previously treated recurrent or metastatic SCCHN, recurrent SCCHN eligible for re-irradiation, and previously treated low-frequency microsatellite-unstable (MSI-L) or microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

[0317] 79. A compound, method of treatment, or use described in any one of items 1 to 78, comprising a condensation of a PD-L1 inhibitor and a TGFβ inhibitor, administered by intravenous infusion.

[0318] 80. A compound, method of treatment, or use described in any one of items 1 to 79, comprising a condensate of a PD-L1 inhibitor and a TGFβ inhibitor, administered in doses of approximately 1200 mg or approximately 2400 mg.

[0319] 81. A compound, therapeutic method, or use described in any one of items 1 to 80, comprising a PD-L1 inhibitor and a TGFβ inhibitor, administered at a dose of approximately 1200 mg in Q2W or at a dose of approximately 2400 mg in Q3W.

[0320] 82. A compound, method of treatment, or use described in any one of items 1 to 81, in which a PARP inhibitor is administered orally.

[0321] 83. A compound, method of treatment, or use described in any one of items 1 to 82, in which a PARP inhibitor is administered in a dose of approximately 50 to 5000 mg.

[0322] 84. A compound, therapeutic method, or use described in any one of items 1 to 83, in which a PARP inhibitor is administered in a QD or BID.

[0323] 85. A compound, therapeutic method, or use described in any one of items 1 to 84, wherein the method includes a pre-treatment phase, and optionally, a maintenance phase follows the completion of the pre-treatment phase.

[0324] 86. Compounds, therapeutic methods, or uses for use as described in item 85, in which the compounds are administered simultaneously in either the pre-treatment phase or the maintenance phase, and optionally, non-simultaneously in other stages, or the compounds are administered non-simultaneously in the pre-treatment and maintenance phases, or two of the compounds are administered simultaneously, and the other compounds are administered non-simultaneously in the pre-treatment and maintenance phases.

[0325] 87. Compounds, therapeutic methods, or uses described in item 86, in which simultaneous administration is performed sequentially or substantially simultaneously in any order.

[0326] 88. A compound, method of treatment, or use for use as described in any one of items 85 to 87, wherein a PD-1 inhibitor and a TGFβ inhibitor are fused, and the maintenance phase comprises administering the fused PD-1 inhibitor and TGFβ inhibitor alone or concurrently with a PARP inhibitor, or optionally with radiotherapy.

[0327] 89. Compounds, therapeutic methods, or uses for use as described in any one of items 85-88, wherein the preceding phase includes the simultaneous administration of a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and optionally co-administration with radiotherapy.

[0328] 90. A compound, therapeutic method, or use described in any one of items 1 to 89, selected based on the expression of PD-L1 in a sample taken from a subject.

[0329] 91. A pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and at least a pharmaceutically acceptable excipient or adjuvant.

[0330] 92. A pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and at least a pharmaceutically acceptable excipient or adjuvant, A pharmaceutical composition in which the PD-1 inhibitor is an anti-PD(L)1 antibody, the TGFβ inhibitor is TGFβRII or an anti-TGFβ antibody, and the PARP inhibitor is a small molecule.

[0331] 93. A pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and at least a pharmaceutically acceptable excipient or adjuvant, A pharmaceutical composition in which a PD-1 inhibitor and a TGFβ inhibitor are fused as an anti-PD(L)1:TGFβRII fusion protein, and the PARP inhibitor is a nicotinamide analog.

[0332] 94. A pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor, and at least a pharmaceutically acceptable excipient or adjuvant, A pharmaceutical composition comprising a PD-1 inhibitor and a TGFβ inhibitor fused as an anti-PD(L)1:TGFβRII fusion protein having the amino acid sequence of vintrafusp alfa, and a PARP inhibitor selected from the group consisting of olaparib, lucaparib, niraparib, thalazoparib, beriparib, pamiparib, nicotinamide, and theophylline.

[0333] 95. A pharmaceutical composition according to any one of items 91 to 94, for use in treatment, for example, in a method of treating cancer.

[0334] 96. A pharmaceutical composition according to any one of items 91 to 94, for use in treatment, for example, in a method of treating cancer in conjunction with radiation therapy.

[0335] 97. A kit comprising a PD-1 inhibitor and a package insert containing instructions for using the PD-1 inhibitor in combination with a PARP inhibitor, a TGFβ inhibitor, and optionally radiotherapy to treat or slow the progression of cancer in a subject.

[0336] 98. A kit comprising a PARP inhibitor and a package insert containing instructions for use to treat or delay the progression of cancer in a subject using the PARP inhibitor in combination with a PD-1 inhibitor, a TGFβ inhibitor, and optionally radiotherapy.

[0337] 99. A kit comprising a TGFβ inhibitor and a package insert containing instructions for using the TGFβ inhibitor in combination with a PD-1 inhibitor, a PARP inhibitor, and optionally radiotherapy to treat or delay the progression of cancer in a subject.

[0338] 100. A kit comprising a PD-1 inhibitor and a package insert containing instructions for using the PD-1 inhibitor in combination with a PARP inhibitor, a TGFβ inhibitor, and optionally radiotherapy to treat or slow the progression of cancer in a subject, This kit contains a PD-1 inhibitor (an anti-PD(L)1 antibody), a TGFβ inhibitor (TGFβRII or an anti-TGFβ antibody), and a PARP inhibitor (a small molecule).

[0339] 101. A kit comprising a PARP inhibitor and a package insert containing instructions for using the PARP inhibitor in combination with a PD-1 inhibitor, a TGFβ inhibitor, and optionally radiotherapy to treat or slow the progression of cancer in a subject, This kit contains a PD-1 inhibitor (an anti-PD(L)1 antibody), a TGFβ inhibitor (TGFβRII or an anti-TGFβ antibody), and a PARP inhibitor (a small molecule).

[0340] 102. A kit comprising a TGFβ inhibitor and a package insert containing instructions for using the TGFβ inhibitor in combination with a PD-1 inhibitor, a PARP inhibitor, and optionally radiotherapy to treat or slow the progression of cancer in a subject, This kit contains a PD-1 inhibitor (an anti-PD(L)1 antibody), a TGFβ inhibitor (TGFβRII or an anti-TGFβ antibody), and a PARP inhibitor (a small molecule).

[0341] 103. A kit comprising a PD-1 inhibitor, a TGFβ inhibitor, and a package insert containing instructions for using the PD-1 inhibitor and TGFβ inhibitor in combination with a PARP inhibitor and optional radiotherapy, This kit contains a PD-1 inhibitor and a TGFβ inhibitor fused as an anti-PD(L)1:TGFβRII fusion protein, and a PARP inhibitor that is a nicotinamide analog.

[0342] 104. A kit described in any one of items 97-103, the instructions for use state that the medicine is intended for use in treating subjects with cancer who are positive for PD-L1 expression.

[0343] 105. A method for promoting PD-1 inhibitors, TGFβ inhibitors, and PARP inhibitors, comprising encouraging a targeted reader to use the combination of the above selectively in conjunction with radiotherapy to treat a subject having cancer, for example, a cancer selected based on the expression of PD-L1 in a sample taken from the subject.

[0344] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] Table 1-5

Claims

1. 1. A pharmaceutical composition comprising a PD-1 inhibitor, a TGFβ inhibitor, and a PARP inhibitor for use in a method of treating cancer in a subject, the method comprising administering to the subject the PD-1 inhibitor, the TGFβ inhibitor, and the PARP inhibitor.

2. 2. The pharmaceutical composition of claim 1, wherein the PD-1 inhibitor is an anti-PD-L1 antibody or a fragment thereof capable of binding to PD-L1, and the TGFβ inhibitor is a TGFβRII or a fragment thereof capable of binding to TGF-β, or an anti-TGFβ antibody or a fragment thereof capable of binding to TGFβ.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the anti-PD-L1 antibody or fragment thereof has a heavy chain sequence comprising CDRH1 having the sequence of SEQ ID NO: 1, CDRH2 having the sequence of SEQ ID NO: 2, CDRH3 having the sequence of SEQ ID NO: 3, and a light chain sequence comprising CDRL1 having the sequence of SEQ ID NO: 4, CDRL2 having the sequence of SEQ ID NO: 5, and CDRL3 having the sequence of SEQ ID NO: 6, or the anti-anti-PD-L1 antibody or fragment thereof comprises a heavy chain sequence comprising CDRH1 having the sequence of SEQ ID NO: 19, CDRH2 having the sequence of SEQ ID NO: 20, and CDRH3 having the sequence of SEQ ID NO: 21, and a light chain sequence comprising CDRL1 having the sequence of SEQ ID NO: 22, CDRL2 having the sequence of SEQ ID NO: 23, and CDRL3 having the sequence of SEQ ID NO:

24.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the TGFβ inhibitor is the extracellular domain of TGFβRII or a fragment thereof.

5. 5. The pharmaceutical composition of claim 1, wherein the PD-1 inhibitor and the TGFβ inhibitor are fused as an anti-PD(L)1:TGFβRII fusion protein.

6. 6. The pharmaceutical composition of claim 5, wherein the light and heavy chain sequences of the anti-PD(L)1:TGFβRII fusion protein have at least 90% sequence identity to a light and heavy chain sequence selected from the group consisting of: (1) SEQ ID NO:7 and SEQ ID NO:8, (2) SEQ ID NO:15 and SEQ ID NO:17, and (3) SEQ ID NO:15 and SEQ ID NO:

18.

7. 6. The pharmaceutical composition of claim 5, wherein the amino acid sequence of the anti-PD(L)1:TGFβRII fusion protein corresponds to the amino acid sequence of vintrafusp alfa.

8. 8. The pharmaceutical composition of any one of claims 5 to 7, wherein the anti-PD(L)1:TGFβRII fusion protein is administered intravenously at a dose of 1200 mg Q2W or at a dose of 2400 mg Q3W.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the PARP inhibitor is a small molecule.

10. The pharmaceutical composition of claim 9 , wherein the PARP inhibitor is a nicotinamide analog.

11. 10. The pharmaceutical composition of claim 9, wherein the PARP inhibitor is selected from the group consisting of olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, nicotinamide, and theophylline.

12. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein the PARP inhibitor is administered orally QD or BID at a dose of 0.1 to 1000 mg.

13. 13. The pharmaceutical composition of any one of claims 1 to 12, wherein the method further comprises administering the PD-1 inhibitor, TGFβ inhibitor, and PARP inhibitor in combination with radiation therapy.

14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the cancer is selected from the group consisting of squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer, glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, renal cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma, cervical cancer, brain cancer, gastric cancer, bladder cancer, liver cancer, breast cancer, colon cancer, biliary tract cancer, and head and neck cancer.

15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the cancer has a homologous recombination repair deficiency.